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1GENERAL INTRODUCTION 
Optimal clinical management of Parkinson’s disease (PD) requires regular and careful 
evaluation of a long list of symptoms and signs. Medical decisions are based on periodic 
in-clinic evaluations, but such “snapshot” evaluations cannot capture the actual impact 
of the disease on the patient’s functioning in their own environment. This is especially 
true for patients with PD who perform paradoxically well during in-clinic exams. 
Therefore, treatments cannot be tailored to the actual patient in such conditions. 
Lately, thanks to advances in technology, there has been a growing interest in applying 
objective assessments to quantify PD-related symptoms and signs. The use of objective 
assessments, for example, those extracted from wearable sensors, may provide clinicians 
with a longitudinal, detailed, and accurate overview of PD-related symptoms as they 
present over time in daily life in a typical home-based setting. However, the feasibility 
and reliability of such approaches in large populations followed for long periods has 
yet to be determined. This thesis addresses the feasibility of objective measurements for 
quantifying motor symptoms in large PD populations. In the upcoming sections of this 
chapter, I provide a brief overview of PD clinical presentation and clinical management. 
Then, by using wearable sensors as a prime example, I elaborate on the use of objective 
measurements for quantifying the motor symptoms of PD.  I end this chapter with an 
outline of the general aims of this thesis.
Parkinson’s disease
PD is a multifaceted disorder whose aetiology appears to involve a complex interplay 
between multiple genetic and environmental factors [1]. James Parkinson first described 
it 200 years ago as “The Shaking Palsy” [2]. After Alzheimer’s, PD is the most common 
neurodegenerative disease [3]. The prevalence increases with age, affecting 1% of 
individuals older than 60 years, and affecting more men than women (male-to-female 
ratio 3:2) [4, 5]. 
Clinically, PD is characterised by the appearance of a wide range of motor and non-
motor symptoms (Box 1.1.) that result from progressive pathologic changes in the brain. 
It is estimated that 31% of the neurons in the substantia nigra have already been lost by 
the time of diagnosis, when the characteristic bradykinesia, 4-6 Hz resting tremor, and 
rigidity appear [6, 7]. 
Chapter 1
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Box 1.1. | Motor and non-motor symptoms of Parkinson’s disease
Motor symptoms*
• Bradykinesia
Slowness of initiating voluntary movement and sustaining repetitive movement with progressive 
reduction in speed and amplitude
• Resting tremor
Involuntary rhythmic oscillatory movement (4-6 Hz) of a body part
• Rigidity
Increased resistance to passive displacement of a body part
• Postural instability
Poor balance, unsteadiness, and falls
• Gait disturbances
Difficulties in rhythm control, gait asymmetry, diminished step length, freezing of gait
Non-motor symptoms
• Cognitive problems:
- Problems with decision-making
- Impaired planning and goal-directed behaviour
- Dementia
• Psychiatric and behavioural complications:
- Hallucinations
- Depression
- Anxiety
- Impulsive control disorders
- Compulsive behaviours
- Apathy
• Sleep disturbances:
- Problems with sleep initiation and maintenance
- REM sleep behaviour disorder
- Excessive daytime sleepiness
- Restless leg syndrome
- Difficulties turning in bed
• Autonomic dysfunction:
- Orthostatic hypotension
- Constipation
- Urinary dysfunction
- Sexual dysfunction
- Excessive drooling
*In pink: diagnosed criteria for Parkinson’s disease
Braak and colleagues studied how the neuropathological alterations progress during 
the course of the disease. Their work resulted in a six-stage classification scheme that 
emphasises the pathological alterations starting at the lower brainstem and then ascending 
caudo-rostrally through susceptible regions, ultimately reaching the cerebral cortex 
[8, 9]. Although this work was helpful for understanding how pathological changes 
occur in PD, the classification does not fully correlate with the presentation, severity, or 
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1progression of the various symptoms [10, 11]. In fact, patients with PD present a large 
diversity of symptoms that can progress at very variable rates and that can also present 
in a variable following order across patients. In clinical practice, this variation has been 
clustered, and there are now three major accepted PD subtypes: tremor-dominant, 
akinetic-rigid, and mixed type [12]. Among them, the tremor-dominant phenotype is 
considered to be a more benign phenotype, with less disability and a slower progression 
rate [13]. 
Even though three motor symptoms are the hallmarks of the disease [14], many more 
motor and non-motor symptoms exist. These include freezing of gait, falls, executive 
dysfunctions, memory disturbances, constipation, depression, reduced ability to smell, 
and REM sleep behaviour disorders. Interestingly, some of these symptoms can present 
years before the diagnosis [12].
Treatment of PD is based largely on pharmacologic interventions [15]. After the discovery 
of levodopa, a precursor of dopamine that is capable of crossing the brain barrier, 
pharmacological interventions became the first-line treatment for PD [16]. Levodopa-
based medication aims to regain the balance of dopaminergic levels, which is lost due 
to the death of dopaminergic neurons. Though it is effective, long-term levodopa usage 
is related to motor and non-motor fluctuations and development of dyskinesias [17]. 
Many patients are ultimately treated with a combination of levodopa and other drugs 
to combat this side effect. This includes dopamine agonist [18], Monoamine oxidase 
blockers and occasionally acetylcholinergics [19]. In advanced disease stages, when the 
response fluctuations to the oral treatment are progressively more difficult to control, 
neurosurgical interventions such as deep brain stimulation (DBS) or a continuous 
duodenal infusion of liquid levodopa can be used to treat adequately selected patients. 
In addition to pharmacologic treatment, non-pharmacologic interventions play a 
crucial role in the clinical management of PD [20]. A growing evidence of the efficacy 
of physiotherapy [21-23], occupational therapy [20], speech–language therapy [24], 
and cognitive training [25, 26] for PD clinical management has fuelled the acceptability 
of those non-pharmacologic interventions. These interventions mainly aim to combat 
symptoms that do not respond well to dopaminergic drugs, such as mild cognitive 
impairment, depression, impaired balance, and falls. Physiotherapy is a good example of 
the efficacy of non-pharmacologic interventions for patients with PD. Such interventions 
improve activities of daily living by diminishing the burden of motor-related symptoms 
and preventing inactivity, which itself can negatively influence PD functioning [22, 27]. 
Non-pharmacologic interventions are important in helping patients with PD deal with 
the inevitable changes in activities of daily living [22]. 
Chapter 1
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The diagnosis of PD is based on clinical judgement and a set of predefined criteria 
(Box 1.1) [14, 28]. Clinical judgement is used not only for diagnosing, but also for 
assessing the severity of the symptoms, monitoring disease progression, and evaluating 
the efficacy of therapeutic interventions. The Movement Disorders Society provides the 
gold standard scale for evaluating PD-related symptoms and disease progression: The 
Movement Disorders Society – Unified Parkinson’s Disease Rating Scale [29]. This scale, 
comprising four parts, is used to assess the intensity and burden of motor and non-
motor symptoms on an ordinal scale. Many other scales are also used in clinical care to 
assess other symptoms such as cognitive impairment [30], autonomic dysfunction [31], 
freezing of gait [32], falls [33], impact of motor fluctuations, and dyskinesia [34]. 
Two main limitations are associated with using standardised clinical assessments for clinical 
decision-making in PD care [35-37]. First, most scales show high inter-rater variability. 
This variability is partially explained by the ordinal nature of the scales, which makes it 
difficult to capture the non-linear decline of PD. Second, symptom assessment is based 
solely on a standardised clinical assessment during a clinical consultation, which typically 
lasts 10 to 20 minutes. This is a challenging, and perhaps biased, approach to evaluating 
such a complex and highly variable disease as PD. In general, such assessments remain 
a “snapshot” of the patient’s normal behaviour in daily life. Consequently, debilitating 
symptoms such as freezing of gait and falls often do not present well – if at all – during 
these clinical consultations. Attempts to address this limitation have been made, for 
example, by asking patients to maintain diaries reporting the presence and intensity of 
symptoms. However, the compliance and reliability of these diaries is questionable [38], 
especially for those presenting with cognitive impairments. Therefore, the challenge is to 
design a detailed, objective, and reliable home-based assessment that generates knowledge 
about real-life functioning and that can improve care for patients with PD.
Technology for objective assessments in Parkinson’s disease
Technologies for capturing health and disease-related information is a growing field, 
and it presents a number of promising applications (Figure 1.1.) [39]. This is also true 
of high-end, research-grade technologies – nowadays devices on the consumer market, 
such as smartphones, activity trackers, and smartwatches have embedded sensors that 
can capture relevant data. As does The Internet of Things (a digital communication 
infrastructure that enables devices to connect) [40], technology is showing tremendous 
potential to shape our understanding of society, business, and health [41]. Technology 
can support and improve various health-related strategies by collecting, analysing, and 
presenting large amounts of information [42, 43]. In general, wearable sensors contain 
one or more sensors embedded in small devices. Accelerometers and gyroscopes are 
often embedded in these devices; they enable data collection of body acceleration and 
rate of rotation [44]. Wearable sensors are generally worn either attached to the body or 
close to it (e.g. smartphones and smart glasses). 
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1Parkinson’s disease is a prime example of technology being integrated in medical care 
(Figure 1.1.). Wearable sensors can continuously and very frequently (i.e. high frequency) 
collect reliable and fine-grained health-related data that would otherwise be missed [42]. 
This fine-grained information may be helpful in capturing the large variation between 
patients with PD and, perhaps more importantly, between and across days for the same 
patient [42, 45-49]. 
In PD care, wearable sensors collect data for two general scenarios: in standardised 
clinical settings and in a free-living environment (Box 1.2.). In the first scenario, 
wearable sensors are integrated into established standardised tests, such as the Timed Up 
and Go test [74, 75] or the motor examination of the MDS-UPDRS [76]. The main 
goal here is to collect relevant information that the ‘naked eye’ of an assessor might 
miss. Overall, under standardised conditions, wearable sensors can accurately detect or 
monitor PD-specific motor symptoms such as tremor, bradykinesia, and dyskinesia (Box 
1.2.). Compared with gold standard assessments such as the MDS-UPDRS, wearable 
sensors show a moderate to high validity in symptom detection [42, 46]. Additionally, 
when they are used to distinguish groups, for instance PD versus non-PD [56, 77], 
or PD fallers from non-fallers [78, 79], the wearable sensors demonstrated excellent 
specificity and sensitivity: between 96% and 100%. In the second scenario, because 
wearable sensors can be deployed for long periods, they may be useful for collecting 
large amounts of information relating to patient behaviour and/or symptoms over 
time [42, 49]. This long-term evaluation takes places outside research laboratories and 
clinics in a free-living environment. This naturalistic approach has the great advantage 
of revealing information about overall daily functioning [80, 81], which cannot be 
collected with standardised assessments [44, 49]. Wearable sensors can collect data 
outside the clinic; such data are not biased by the improved performance commonly 
seen when patients perform standardised tests. Prime examples of wearable sensors in 
free-living environments can capture physical activity patterns [82-84] or medication 
intake [85, 86] (for more examples, please see Box 1.2.). 
Wearable sensors are also a promising approach for aiding self-management among patients 
with PD [86, 130]. Sensors offer a basis for understanding the therapeutic efficacy of different 
interventions by offering a longitudinal overview of symptoms in context with activities of 
daily living and medication intake. Continuous feedback about daily life patterns, combined 
with gamification to improve compliance with using the new technology [131] may also 
positively influence behaviour and help patients with PD become more active [132, 133]. 
Further, symptom tracking, and medication reports can empower patients. Participants who 
actively collect information about their own health can make better informed decisions 
about health and disease management. Longitudinal monitoring with wearable sensors 
may improve decision-making in PD care by offering clinicians a long-term and often more 
realistic assessment of the disease impairment [134, 135].
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Box 1.2. | Overview of initiatives using wearable sensors to quantify PD-related motor symptoms for two 
scenarios: standardised clinical settings and the free-living environment
Clinical feature Reference numbers of relevant papers
Standardised clinical settings Free-living environment
Bradykinesia [56, 57, 60, 87–95] [90, 96]
Rigidity [97] -
Tremor [58, 59, 62, 63, 92, 95, 98–105] [106]
Motor fluctuations [107–109] [110, 111]
Gait impairment [93, 112–119] [113, 120–122]
Balance [65, 123-126] [125]
Falls - [78, 127-129]
Aim of  this thesis
Many previous initiatives have investigated the use of objective measurements in PD 
in standardised, laboratory settings. Yet, the feasibility of using such a strategy in large 
populations followed for long periods of time in the home environment has to be established. 
Therefore, the aim of this thesis was to provide evidence of the feasibility of using objective 
measurements in a large PD population. I use a two-fold approach to complete two aims:
 1.   To investigate the usability and compliance with wearable sensor use over a 
longer period in a large PD population (Chapters 2 and 3);
 2.  To demonstrate the clinical and research applicability of wearable sensors 
(Chapters 4– 6). 
Thesis outline
In Part I of this thesis, I investigate the compliance of a large PD population using 
multiple sensors in the home environment. Chapter 2 describes a research protocol 
aiming to share with other researchers how our research group has designed this large 
observational study. In Chapter 3, I analyse the feasibility of this large-scale wearable 
sensor deployment, first by examining the compliance of participants with the wearable 
systems, then by describing which design was successful and identifying which areas 
should be explored for further improvement in future research. Next, in Part II of this 
thesis, I seek to offer evidence for the applicability of wearable sensors for research 
and clinical purposes. In Chapter 4, by reviewing the current literature, I highlight 
the promises and pitfalls of the currently available wearable sensors for quantifying 
freezing of gait and falls in PD. Then, I describe the successful application of wearable 
sensors to determine the incidence of falls in a large population of patients with PD 
and matched controls. I do this by analysing wearable sensor data from more than 4000 
elderly patients with PD (Chapter 5). Then I close Part II by evaluating the clinical 
applicability of wearable sensors to quantify the impact of motor fluctuations on activity 
levels in patients with PD. For this purpose, I examine gait-related features of data from 
the wearable sensors of more than 300 patients with PD. The wearable sensors recorded 
the data while the patients were in a free-living environment (Chapter 6). 
Chapter 1
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ABSTRACT
Background: Long-term management of Parkinson’s disease does not reach its full 
potential because we lack knowledge about individual variations in clinical presentation 
and disease progression. Continuous and longitudinal assessments in real-life (i.e., 
within the patients’ own home environment) might fill this knowledge gap.
Objective: The primary aim of the Parkinson@Home study is to evaluate the feasibility 
and compliance of using multiple wearable sensors to collect clinically relevant data. 
Our second aim is to address the usability of these data for answering clinical research 
questions. Finally, we aim to build a database for future validation of novel algorithms 
applied to sensor-derived data from Parkinson’s patients during daily functioning.
Methods: The Parkinson@Home study is a two-phase observational study involving 
1000 Parkinson’s patients and 250 physiotherapists. Disease status is assessed using 
a short version of the Parkinson’s Progression Markers Initiative protocol, performed 
by certified physiotherapists. Additionally, participants will wear a set of sensors 
(smartwatch, smartphone, and fall detector), and use these together with a customized 
smartphone app (Fox Insight), 24/7 for 3 months. The sensors embedded within the 
smartwatch and fall detector may be used to estimate physical activity, tremor, sleep 
quality, and falls. Medication intake and fall incidents will be measured via patients’ 
self-reports in the smartphone app. Phase one will address the feasibility of the study 
protocol. In phase two, mathematicians will distill relevant summary statistics from the 
raw sensor signals, which will be compared against the clinical outcomes.
Results: Recruitment of 300 participants for phase one was concluded in March, 2016, 
and the follow-up period will end in June, 2016. Phase two will include the remaining 
participants, and will commence in September, 2016.
Conclusions: The Parkinson@Home study is expected to generate new insights into 
the feasibility of integrating self-collected information from wearable sensors into both 
daily routines and clinical practices for Parkinson’s patients. This study represents an 
important step towards building a reliable system that translates and integrates real-life 
information into clinical decisions, with the long-term aim of delivering personalized 
disease management support.
Keywords
Parkinson’s disease; Ambulatory monitoring; Signal processing; Computer-assisted; 
Wearable sensors
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INTRODUCTION
Parkinson’s disease (PD) is a progressive and complex neurological disorder. Patients can 
experience a wide range of motor symptoms and signs, including bradykinesia, tremor, 
rigidity, and postural instability. Non-motor symptoms include executive dysfunctions, 
memory disturbances, attention difficulties, and reduced ability to smell [1-3].
The cornerstone of current therapy is based on the replacement of dopamine but can 
also include other drugs that play a role in the activation of dopamine receptors [4]. 
Although these medications initially have good results in disease management, the 
effects remain successful for a limited period of time. Most patients eventually develop 
motor complications, such as the wearing-off effect or dyskinesias [5,6]. Some disease 
symptoms, such as postural instability and voice/speech impairment, are insufficiently 
(or sometimes not at all) responsive to dopaminergic therapy.
Two major problems hamper the delivery of optimal individual treatment. First, 
evaluation of day-to-day variations in a complex disease such as PD is difficult when 
relying solely upon periodic consultations with experts working in a clinical setting 
[7]. Even when health professionals use specific and validated instruments, such as the 
Movement Disorder Society - Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) 
[8], the results represent a subjective and episodic snapshot taken under well-controlled 
conditions, which are usually not representative of the patient’s functioning in daily 
life. More detailed, objective, and reliable knowledge about real-life functioning would 
greatly improve the quality of individual medical management. Second, virtually all 
scientific evidence that is presently available to inform PD management stems from 
biased clinical studies with short follow-up periods in highly selected sub-populations, 
who were studied under carefully controlled trial conditions [9,10]. As such, this evidence 
does not reflect the clinical presentation, treatment response, or disease progression in 
actual daily life.
To overcome these limitations, wearable sensors are emerging as new tools to continuously 
and longitudinally obtain information from patients in real-life. The accuracy of sensor 
data for everyday activity recognition (eg, walking, running) in real-life ranges from 
58% to 97% [11]. These sensors, typically consisting of embedded accelerometers, have 
been used successfully to determine PD-related symptoms [12-16]. However, to date 
these studies have relied upon small sample sizes (n=5 to 43 participants) and short 
follow-up periods (3 days to 6 months; see Multimedia Appendix 2.1.).
The primary aim of the Parkinson@Home study is to evaluate the feasibility and patient 
compliance of using wearable sensors to collect data for at least 3 months in a large 
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patient group. A secondary aim of this study is to address the usability of these data 
for answering clinically relevant research questions (eg, to determine the relationship 
between sensor-derived measures and clinical measures). Finally, the study aims to build 
a database for future development and testing of novel algorithms applied to sensor-
derived data from PD patients during daily functioning.
METHODS 
Study Design
The Parkinson@Home study is an observational study involving 1000 patients (from 
whom data will be recorded) and 250 physiotherapists (who will assist in performing 
the clinical assessments, and who may act as personal coaches during follow-up). Both 
patients and therapists will be recruited throughout the Netherlands. The study consists 
of two phases. Phase one aims to assess the feasibility of deploying wearable sensors in a 
large PD population (n=300). For this purpose, patients will use a number of wearable 
devices (Pebble smartwatch, Android smartphone, and fall detector) in combination 
with a customized app (Fox Insight). Follow-up will occur after 3 months (13 weeks), 
starting from the moment the first data are streamed to the server. In addition to using 
wearable devices, participants will attend a one-time consultation, during which a 
detailed clinical assessment will be performed by an experienced physiotherapist or a 
research team member. This clinical assessment will take place in week 7, or later during 
the follow-up period. Phase two, which will include an additional 700 participants, aims 
to collect raw sensor data in order to investigate the usability of these data for answering 
clinical research questions. This phase will also be used to build a database for future 
validation of novel algorithms applied to sensor-derived data from PD patients during 
daily functioning. Patients involved in phase one can also be included in phase two if 
they wish. Data collection for clinical results and device-based outcomes, as well as the 
follow-up period, will be identical to phase one. To ensure the success of the raw data 
collection during phase two, devices and raw data collection strategies used in this phase 
will be chosen after the evaluation of data collected during phase one.
The study protocol was successfully piloted prior to full study implementation to ensure 
methodological feasibility. In total 20 Dutch PD patients participated in this pilot, 
using a set of wearable devices (one smartphone and one smartwatch) and the Fox 
Insight app. The patients were asked to use these devices for 24 hours, seven days a 
week, and were followed for four weeks. In total, 58% of patients that were approached 
agreed to participate. Some patients were reluctant to manage technology and to deal 
with possible technical problems, which caused them to refrain from participation. All 
participants (except for two) needed at least one support call for device troubleshooting. 
Streaming compliance for the sensor data was 88%.
The Parkinson@Home study protocol
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Inclusion and Exclusion Criteria
Patients
The inclusion and exclusion criteria for patients will be kept purposefully broad, in 
order to represent the full diversity of real-life PD experiences. Inclusion criteria specify 
that patients must be 30 years of age or older and be diagnosed with PD by a physician. 
No exclusion criteria will be applied.
Physiotherapists
Physiotherapists who are members of the Dutch ParkinsonNet [17,18] are eligible to 
participate. ParkinsonNet physiotherapists have received several PD-specific educational 
training programs, and treat a high number of PD patients each year. Physiotherapists 
who want to participate should take the official MDS-UPDRS course (provided online 
by MDS [19], and further in person training provided by the research team) and be able 
to include and/or assess an average of four PD patients for the study.
Patient Recruitment Process
We will apply an incremental recruitment strategy. Initially, we will only include patients 
that already possess a compatible Android/iPhone smartphone. Subsequently, and only 
if needed, we will include patients that do not possess a smartphone; these patients will 
be provided with a loaned smartphone device. The reason for this incremental approach 
is that patients with their own device will likely require less technical support from the 
research team, as was the case in our pilot study. This strategy will increase the feasibility 
of complete data collection in a total of 1000 patients.
Patients will be recruited both in the community and through their treating 
physiotherapists. To reach potential participants in the community, we will use a 
number of communication channels: (1) the ParkinsonConnect community, an online 
community for Parkinson’s patients and healthcare professionals involved in their care 
[18]; (2) the webpage of the Dutch Parkinson Patient Association; (3) an article in the 
magazine of the Dutch Parkinson Patient Association; (4) presentations about the study 
to local patient support groups (Parkinson Cafés); (5) promotional material for patients 
will be sent to all ParkinsonNet physiotherapists (approximately 990 individuals), 
regardless of whether they participate in the study or not, and we will ask them to 
recruit patients within their practice; and (6) via a study website [20] which provides 
information about the study. The study website offers both patients and physiotherapists 
the possibility to sign up for the study online.
After signing up for the study, potential participants will be contacted by phone by a 
member of the research team, who will provide additional information about the study 
and check eligibility. If respondents are eligible and willing to participate, they will 
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receive an informed consent form. After the informed consent form has been signed 
digitally, the research team will provide the participant with all necessary devices and 
user manuals.
Recruitment and Training of  Physiotherapists
All ParkinsonNet physiotherapists will be contacted by email to inquire about study 
participation. Should this email not result in adequate numbers of participating 
physiotherapists, we will personally contact ParkinsonNet physiotherapists by telephone. 
As with the recruitment process for patients, after signing up via the study website, 
physiotherapists will be contacted by email or phone to check eligibility.
Once included, physiotherapists must pass the online MDS-UPDRS training successfully 
[19], as required by the International Parkinson and Movement Disorder Society, 
which allows them to perform the MDS-UPDRS [8]. After successful completion of 
the training, physiotherapists will participate in one face-to-face training session, in 
which they will assess one patient, in order to practice the MDS-UPDRS assessment 
and consolidate their understanding of the assessment process and study procedures.
Ethical Aspects and Trial Registration
This study will be conducted in compliance with the Ethical Principles for Medical 
Research Involving Human Subjects, as defined in the Declaration of Helsinki. The study 
protocol and communication materials have been approved by the local ethics committee 
(Commissie Mensgebonden Onderzoek, Arnhem-Nijmegen; NL53034.091.15).
Consent will be obtained by the research team through an innovative online procedure, 
which includes a compulsory cooling-off period in a digital environment. When the 
patient is deemed eligible (e.g., meets the inclusion criteria specified in the online sign-up 
form), an information letter and consent form will be sent by email. The research team 
and an independent physician can be approached for questions and verbal explanation. 
Next, the potential participant has the possibility to confirm participation digitally, via 
a new URL sent to him/her by email after 48 hours. The URL redirects the patient 
to the study webpage, where he/she can confirm that they have read all information 
and that they agree to participate. As recommended by the ethics committee, this final 
step is blocked for 48 hours after the first email has been sent, to ensure that potential 
participants take time to consider participation. After the agreement to participate, 
the participant will see a confirmation message on the study webpage. No signature or 
scanning of documents will be necessary at this point. The Parkinson@Home study is 
registered in the ClinicalTrials.gov registry (NCT02474329) [21].
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Wearable Sensors Phase One
Pebble Smartwatch
The Pebble is a commercially available smartwatch, with a variety of embedded sensors, 
such as tri-axial accelerometer, light sensor, and magnetometer. Accelerometers are 
able to record acceleration along three orthogonal spatial axes, producing acceleration 
vectors as single data points, and up to 100 acceleration data vectors can be recorded 
per second. The Pebble smartwatch operating software allows access to the unprocessed 
raw accelerometer data vectors, creating the opportunity for subsequent analyses of this 
sensor data. In order to obtain continuous accelerometer data, the Fox Insight app will 
be installed on each smartwatch. The app enables streaming of the accelerometer data 
to the smartphone, with a sampling frequency of 50 data vectors per second, using the 
built-in Bluetooth radios of both the smartwatch and smartphone.
Fox Insight App
The Fox Insight app is an Android/iPhone app created and developed by Intel Corporation 
(Tel Aviv, Israel). This app receives 50 accelerometer data points per second from the 
Pebble smartwatch, and estimates levels of activity, tremor, and sleep movement analyses 
using dedicated algorithms running within the app. The app presents these estimated 
quantities to the user by means of graphs and summary reports of the data collected.
Activity graphs show the level of activity throughout the day (Figure 2.1.). The calculation 
is performed by aggregations (30 second intervals) of the raw data previously collected. 
The graph also highlights the moments in time when medication was taken.
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Figure 2.1. Fox Insight Mobile App activity graph.
Daily tremor graphs show how many minutes the patient has experienced tremor during 
a certain day (a tremor is defined as any movement in the range of 3.5-12Hz). Sleep 
analysis graphs (Figure 2.2.) show the amount of time that the patient has been active 
during the sleep time. These graphs provide an impression of the intensity and duration 
of movements.
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Figure 2.2. Fox Insight Mobile App sleep analysis graph.
These estimated quantities are sent every 10 minutes to a cloud-based data platform 
through an Internet connection on the smartphone. Different mechanisms allow the 
participants to know whether the data are recorded correctly. First, participants can 
check the metric graphs (eg, activity graph, sleep analysis, and tremor); these graphs 
are plotted using the data recorded in the servers and will only appear if the data were 
collected. Second, the main app screen (Figure 2.3.) displays how many hours of data 
the participant has contributed to the study; if this metric does not increase it means 
the data are not being collected. Finally, participants can view the white pill icon in the 
smartphone task bar; if the icon has a crossing line over it, data are not being actively 
recorded.
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Figure 2.3. Fox Insight Mobile app main screen.
Fall Detector
Falls and movement patterns are measured with a pendant device. Patients are given 
the choice to wear either a fall detector (FD), or the Philips Mobility Monitor (PMM) 
[22,23]. Both sensors are CE-marked non-medical devices; the PMM is developed by 
Philips Research. The FD device used in this study is an adapted fall detection device, 
originally intended for seniors living in their own homes, that was designed to detect falls 
from stance. The FD device can be worn 24/7, while the PMM is recharged overnight 
and thus only worn during the day. 
The FD device uses multiple sensors and a proprietary analytical algorithm to detect 
some types of fall events, which are stored in the device. The PMM contains a 3-axial 
accelerometer and a barometric pressure sensor, with a sampling frequency of 50Hz 
and 25Hz, respectively. Data are continuously recorded and stored on a micro SD card 
within the device. Based on these data, information about the daily movements, as well 
as falls detected, are calculated after read-out at the end of each patient’s trial period.
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Wearable Sensors Phase Two
Devices will be chosen after analysis of the study procedure, and data collection is 
complete in phase one.
Technical Support
Patients will have access to extended support, including an installation guide, user 
manual, and information on the study’s webpage. For the duration of the study, a 
helpline will be available during working hours to support the installation and device 
usage, and for troubleshooting.
Clinical and Feasibility Assessment
Certified physiotherapists will perform the short version of the Parkinson Progression 
Marker Initiative (PPMI) in order to assess disease status [24]. This assessment includes: 
the MDS-UPDRS (parts I, III, and IV) for disease rating [8]; the Montreal Cognitive 
Assessment for cognition [25]; and the Modified Schwab and England Activities of 
Daily Living Scale for activities of daily living [26].
Additional questionnaires will be completed by the patients: MDS-UPDRS part II 
for motor experiences of daily living; the Scales for Outcomes in Parkinson’s Disease 
- Autonomic System (SCOPA-AUT) for autonomic dysfunction [27]; the Geriatric 
Depression Scale for depressive symptoms [28]; and the Epworth Sleepiness Scale for 
day sleepiness [29].
To assess feasibility, patients will also complete the System Usability Scale [30] and a 
satisfaction survey created by the research team, to address patients’ impressions on how 
well particular features of the app are functioning, and the burden associated with the 
methodology. An overview of outcomes is provided in Multimedia Appendix 2.2..
Data Collection and Management
Due to privacy issues, patients will receive a personal identification code that does not 
contain any information that relates to the individual. The key-file, connecting personal 
identification codes to personal information, will be stored on a Radboudumc data 
server, and only the research team has access to the key-file. The key-file will be stored 
on a different server from the study data for five years, allowing the research team to 
contact patients after they have finished the study. We anticipate that our efforts to 
obtain additional research funding will allow for additional follow-up assessments. The 
key-file will be destroyed after five years.
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Data for the study will be collected in the following ways:
Data from smartwatch and smartphone: data will be collected continuously in a coded 
manner and will be transferred to Intel’s cloud data storage environment using an 
Internet connection. The cloud environment is based on Amazon Web Services and 
developed and managed by Intel’s Advanced Analytics team. Data from the watch and 
Fox Insight app will be transferred to the Intel platform using a personal identification 
code for each patient. Moreover, no personally identifiable data will be entered into the 
app or sent to this data storage platform.
Data from the PMM and FD: data will be collected during the time that patients are 
not lying in bed. Each FD has a unique identifier, and Philips Research will only receive 
coded data. No personal information is required to use these devices, and no personal 
data from patients will be shared with Philips.
Data from the clinical assessments: data will be collected by means of paper-based forms 
and will be entered manually into an online certified data management system. Forms 
will only contain personal identification codes.
Data from support and logistics: ZenDesk software will be used to support the logistics 
of the recruitment process and provide technical support during the follow-up phase. 
ZenDesk is Internet-based, and data access is authenticated by username and password. 
All communications with ZenDesk servers use industry-standard Secure Sockets Layer 
encryption by default, and the ZenDesk servers are located at a different site than the 
Amazon servers. Therefore, research data is never stored on the same server as patients’ 
identifying codes.
Patients that complete the clinical assessment and stream data for more than seven days 
will have their data included in further analyses.
Data Analyses
Phase One
Feasibility and compliance will be addressed using descriptive analyses. For feasibility, 
the primary outcomes will include the total support time per participant, the number 
and rate of drop-outs, usability of the system, bias within recruitment strategies, and 
the type of problems faced by patients. Regarding compliance, the outcome measures 
include the total hours of sensor data collected per participant, the number of compliant 
days, and the percentage of time that sensor data were streamed during the follow-up 
period.
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Phase Two
The potential for the data to answer clinically relevant research questions will be explored. 
First, we aim to extract a limited set of outcomes, including: the number, diversity, 
and performance of physical activities; specific activities (eg, standing, walking, sitting); 
response fluctuations in relation to drug treatment; and specific motor symptoms (eg, 
tremor, gait freezing, shuffling falls).
Additionally, we aim to explore how these outcomes are related to clinical assessments, 
and to self-monitoring during follow-up (including timing of medication intake and fall 
incidents). Finally, we aim to extract patterns of disease progression, assess the recognition 
of disease profiles based on reported symptoms and progression patterns, and address 
the effect of medication intake on symptoms. In both phases, analyses will be performed 
using specialized algorithms (when necessary) developed within the Matlab platform, 
with additional statistical analyses using the R software package.
RESULTS 
Patient Recruitment Process
Within eight months of recruitment (August, 2015 to March, 2016) the Parkinson@
home study received 1164 applications. Among those invited for phase one (n=342), 
the participation rate was 87.7%, resulting in  300  inclusions.  Recruitment strategies 
through the network of the Dutch Parkinson Association, and a personal approach 
by the research team or health care providers, have been very successful (Table 2.1.). 
Applicants include all respondents that demonstrated interest in the study, while 
participants include all respondents that were actually included in the study (which 
excludes dropouts and those who refused to participate). Phase two will begin in 
September, 2016, and participants will be recruited from the 734 participants placed in 
the study waiting list.
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Table 2.1. Number of applications obtained from each recruitment strategy
Recruitment strategy Applicants 
(n=1164)
Participants 
(n=258)
Online community for patients, called ParkinsonConnect 1% 3%
Website of Dutch Parkinson Association 12% 8%
Article in the magazine of Dutch the Parkinson Associations 39% 39%
Informative presentation at Parkinson Cafés by research team 10% 14%
Personal invitation by Physiotherapist or Neurologist 17% 12%
Others 19% 19%
Not specified 2% 5%
*Applicants = number of participants that have demonstrated interest in join the study. **Participants = 
number of participants included excluding those who refused to participate and drop-outs.
DISCUSSION
 
In this paper we present the rationale and design of the Parkinson@Home study, a large 
(n=1000) observational cohort study that aims to explore the feasibility and usability 
of collecting raw sensor data from wearable sensors in patients with PD. There is a 
pressing need for collection of reliable medical information from PD patients while they 
perform activities of daily living, due to gaps in knowledge as to why different patients 
have variable rates of PD progression and different patterns of symptoms [31,32]. It has 
proven to be extremely difficult to understand such variations, and to capture objective 
data about the patient’s actual functioning in current clinical practice, which typically 
consists of episodic and brief clinical evaluations in hospitals.
Gathering data from wearable sensors has high scientific potential and offers several 
advantages compared to more traditional methods of data collection. Wearable sensors 
offer the possibility to collect data by self-administered tests, and to objectively monitor 
PD symptoms and day-to-day variation both remotely and at home [33-35]. The raw 
sensor data can be analyzed later by specialized algorithms or by algorithms embedded 
in apps themselves, providing scientific insights for researchers and clinicians. Moreover, 
data can be collected continuously over a prolonged period of time. For individual PD 
patients, those data can be used for long-term health monitoring. When applied in a 
group context, the data may offer a better understanding of PD (e.g., by revealing the 
presence of specific phenotypic subtypes, or by predicting disease progression) [36].
Using wearable sensors also brings about challenges. First, data from sensors are a 
potential target for invasions of privacy [37]. For example, Global Positioning System-
based sensor data can be used to identify the physical location of an individual, and 
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their homes [38]. As a remedy, approaches such as restricting access to the data and 
anonymizing files have been suggested [39]. To allow for the collection of sensitive 
data, and to address security issues, the Parkinson@Home project will adopt several 
precautions, including: coding the data; storing the data on secure servers, separately 
from personal data; and restricting data use, by only allowing access to authorized 
researchers within the research team. When making information available to the wider 
research community, data will be anonymized and access will be granted only through a 
secure research database. These actions decrease the risk of identification of the patient 
and inappropriate use of the data.
A second challenge faced in the Parkinson@Home study is the lack of experience that 
elderly people have with technical devices. This lack of experience affects the acceptance 
of, and compliance with, the technology [40]. Overcoming this lack of experience in our 
target population, without introducing a selection bias, will be a challenge. However, 
we believe that the best approach for this issue is to rely on the willingness of patients 
to learn and be engaged in the management of their disease, combined with an efficient 
support model.
In conclusion, this study will generate new insights into the use of wearable sensors in 
daily living by PD patients, and if the data collection shows potential, it will make a 
contribution to the integration of self-collected information into clinical practice for 
PD patients. This study represents the first steps towards building a reliable system that 
integrates real-life information into clinical decisions.
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i-a
xi
al
 a
cc
el
er
at
io
n,
 a
ud
io
 a
nd
 
to
uc
h 
sc
re
en
 ta
pp
in
g 
ev
en
ts
Sm
ar
tp
ho
ne
10
 P
W
P
10
 h
ea
lth
y 
co
nt
ro
ls 
1 
m
on
th
W
ea
ra
bl
e 
se
ns
or
s c
an
 
pr
ov
id
e 
da
ta
 th
at
 e
na
bl
e 
to
 
di
sti
ng
ui
sh
 b
et
w
ee
n 
he
al
th
y 
su
bj
ec
ts 
an
d 
Pa
rk
in
so
n’s
 
pa
tie
nt
s w
ith
 a
 m
ea
n 
se
ns
iti
vi
ty
 o
f  
96
.2
%
 (S
D
 
2%
) a
nd
 m
ea
n 
sp
ec
ifi
ci
ty
 o
f 
96
.9
%
 (S
D
 1
.9
%
). 
Pe
rs
on
al
 
co
m
m
un
ic
at
io
n 
Ts
an
as
, 2
01
2
1:
 C
oh
or
t
2:
 H
om
e
1:
 A
cc
ur
ac
y 
of
 sp
ee
ch
 si
gn
al
s t
o 
es
tim
at
e 
U
PD
R
S 
ra
tin
g.
 
2:
 S
ix
 v
oi
ce
 re
co
rd
in
gs
 o
f t
he
 
su
sta
in
ed
 p
ho
na
tio
ns
 ‘a
aa
ah
’, 
su
sta
in
ed
 a
s l
on
g 
as
 e
ac
h 
pa
tie
nt
 
w
as
 a
bl
e 
to
. V
oi
ce
 re
co
rd
in
gs
 w
er
e 
ca
pt
ur
ed
 b
y 
us
in
g 
a 
m
ic
ro
ph
on
e 
on
 a
 d
ed
ic
at
ed
 m
on
ito
rin
g 
de
vi
ce
, 
on
ce
 a
 w
ee
k,
 fo
r a
 d
ur
at
io
n 
of
 6
 
m
on
th
s.
M
ob
ile
 p
ho
ne
 
42
 P
W
P
6 
m
on
th
s
Vo
ic
e 
re
co
rd
in
gs
 e
sti
m
at
e 
th
e 
U
PD
R
S 
w
ith
in
 3
.5
 p
oi
nt
s o
f 
th
e 
cl
in
ic
ia
ns
’ a
ss
es
sm
en
t. 
Pa
te
l [
20
09
][
13
]
1:
 C
oh
or
t
2:
 L
ab
or
at
or
y
1:
 R
el
ia
bi
lit
y 
of
 u
sin
g 
ac
ce
le
ro
m
et
er
 d
at
a 
to
 e
sti
m
at
e 
th
e 
se
ve
rit
y 
of
 sy
m
pt
om
s a
nd
 m
ot
or
 
co
m
pl
ic
at
io
ns
.
2:
 P
at
ie
nt
s p
er
fo
rm
ed
 th
e 
m
ot
or
 
as
se
ss
m
en
t p
ar
t o
f t
he
 U
PD
R
S,
 
in
 th
e 
O
N
 [o
nc
e]
 a
nd
 O
FF
 [6
 
tim
es
] p
ha
se
s, 
w
ea
rin
g 
un
ia
xi
al
 
ac
ce
le
ro
m
et
er
 se
ns
or
s p
os
iti
on
ed
 
on
 th
e 
up
pe
r a
nd
 lo
w
er
 li
m
bs
.
Ac
ce
le
ro
m
et
er
s
12
 P
W
P
N
ot
 a
pp
lic
ab
le
U
ni
ax
ia
l a
cc
el
er
om
et
er
 
se
ns
or
s a
re
 a
bl
e 
to
 p
ro
vi
de
 
an
 e
sti
m
at
e 
of
 c
lin
ic
al
 sc
or
es
 
fo
r t
re
m
or
, b
ra
dy
ki
ne
sia
 a
nd
 
dy
sk
in
es
ia
 w
ith
 a
n 
av
er
ag
e 
es
tim
at
io
n 
er
ro
r o
f 3
.4
%
, 
2.
2%
, a
nd
 3
.2
%
 re
sp
ec
tiv
el
y. 
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Ch
ap
te
r 
2
Au
th
or
D
es
ig
n 
(1
)
En
vi
ro
nm
en
t (
2)
Ai
m
 (1
) 
In
te
rv
en
tio
n 
(2
)
Ty
pe
 o
f s
en
so
r
N
Fo
llo
w
 u
p 
pe
rio
d
C
on
cl
us
io
ns
Sh
ar
m
a 
[2
01
4]
[1
2]
1:
 C
oh
or
t
2:
 L
ab
or
at
or
y
1:
 T
o 
in
tro
du
ce
 th
e 
SP
AR
K
 
w
ea
ra
bl
e 
sy
ste
m
 fo
r m
ea
su
rin
g 
di
se
as
e 
sy
m
pt
om
s.
2:
 P
at
ie
nt
s w
or
e 
a 
pa
ir 
of
 d
ev
ic
es
 
(s
m
ar
tw
at
ch
 a
nd
 sm
ar
tp
ho
ne
), 
an
d 
pe
rfo
rm
ed
 ta
sk
s t
o 
ev
al
ua
te
 fa
ci
al
 
tre
m
or
s, 
sp
ee
ch
, d
ys
ki
ne
sia
 a
nd
 
fre
ez
in
g 
of
 g
ai
t. 
 Th
ey
 w
er
e 
al
so
 
as
ke
d 
to
 p
er
fo
rm
 ta
sk
s i
nc
lu
de
d 
in
 
a 
di
gi
ta
l v
er
sio
n 
of
 th
e 
U
PD
R
S.
Sm
ar
tp
ho
ne
 a
nd
 
sm
ar
tw
at
ch
5 
PW
P
N
ot
 a
pp
lic
ab
le
Th
e 
sy
ste
m
 w
as
 a
bl
e 
to
 
pr
ov
id
e 
us
ef
ul
 fe
at
ur
es
 fo
r 
m
ea
su
rin
g 
sy
m
pt
om
 se
ve
rit
y 
in
 th
e 
re
al
 w
or
ld
. F
ur
th
er
 
w
or
k 
in
 sy
ste
m
 v
al
id
at
io
n 
is 
sti
ll 
in
 d
ev
el
op
m
en
t. 
Ba
ch
lin
 [2
01
0]
 [1
6]
1:
 C
oh
or
t
2:
 L
ab
or
at
or
y
1:
 S
en
sit
iv
ity
 a
nd
 sp
ec
ifi
ci
ty
 o
f 
de
te
ct
in
g 
fre
ez
in
g 
of
 g
ai
t e
ve
nt
s.
2:
 P
at
ie
nt
s w
or
e 
a 
se
t o
f w
ea
ra
bl
e 
de
vi
ce
s, 
w
hi
ch
 a
re
 a
bl
e 
to
 d
et
ec
t 
fre
ez
in
g 
of
 g
ai
t a
ut
om
at
ic
al
ly
 
an
d 
pr
ov
id
es
 a
 c
ue
in
g 
so
un
d 
w
he
n 
th
is 
ev
en
t i
s d
et
ec
te
d.
 Th
e 
m
ea
su
re
m
en
t w
as
 d
iv
id
ed
 in
to
 
th
re
e 
pa
rt
s, 
an
d 
w
as
 p
er
fo
rm
ed
 o
n 
th
e 
sa
m
e 
da
y 
at
 th
e 
la
bo
ra
to
ry
.
Ac
ce
le
ro
m
et
er
s 
10
 P
W
P
N
ot
 a
pp
lic
ab
le
Se
ns
iti
vi
ty
 o
f 7
3%
 a
nd
 
sp
ec
ifi
ci
ty
 o
f 8
2%
 in
 
id
en
tif
yi
ng
 fr
ee
zin
g 
of
 g
ai
t 
ev
en
ts 
G
riffi
th
s [
20
12
][
14
]
1:
 C
oh
or
t
2:
 H
om
e
1:
 T
o 
te
st 
th
e 
us
e 
of
 th
e 
co
m
m
er
ci
al
 K
in
et
ig
ra
ph
 a
lg
or
ith
m
 
to
 p
ro
vi
de
 a
 c
on
ve
nt
io
na
l c
lin
ic
al
 
ra
tin
g.
2:
 P
at
ie
nt
s w
or
e 
a 
de
vi
ce
 
w
hi
ch
 in
co
rp
or
at
es
 a
 3
-a
xi
s 
ac
ce
le
ro
m
et
er
, f
or
 1
0 
da
ys
.
Pa
rk
in
so
n’s
 
K
in
et
ig
ra
ph
34
 P
W
P 
10
 d
ay
s
Th
e 
K
in
et
ig
ra
ph
 a
lg
or
ith
m
 
pr
ed
ic
te
d 
th
e 
cl
in
ic
al
 
dy
sk
in
es
ia
 ra
tin
g 
sc
al
e 
w
ith
 
a 
95
%
 m
ar
gi
n 
of
 e
rr
or
 
of
 3
.2
 u
ni
ts 
co
m
pa
re
d 
w
ith
 th
e 
in
te
r-
ra
te
r 9
5%
 
lim
its
 o
f a
gr
ee
m
en
t f
ro
m
 3
 
ne
ur
ol
og
ist
s o
f −
3.
4 
to
 +
4.
3 
un
its
.
Chapter 2
52
Au
th
or
D
es
ig
n 
(1
)
En
vi
ro
nm
en
t (
2)
Ai
m
 (1
) 
In
te
rv
en
tio
n 
(2
)
Ty
pe
 o
f s
en
so
r
N
Fo
llo
w
 u
p 
pe
rio
d
C
on
cl
us
io
ns
Pa
te
l [
20
11
][
15
]
1:
 C
oh
or
t
2:
 L
ab
or
at
or
y 
an
d 
ho
m
e
1:
 T
o 
es
tim
at
e 
cl
in
ic
al
 sc
or
es
 
fo
r m
ot
or
 sy
m
pt
om
s u
sin
g 
ac
ce
le
ro
m
et
er
s
2:
 S
ub
je
ct
s p
er
fo
rm
ed
 m
ot
or
 
as
se
ss
m
en
ts 
on
 th
re
e 
da
ys
. Th
e 
fir
st 
tw
o 
da
ys
 o
f m
on
ito
rin
g 
pe
rfo
rm
ed
 
in
 th
e 
cl
in
ic
al
 se
tti
ng
, t
hi
rd
 d
ay
 
of
 m
on
ito
rin
g 
pe
rfo
rm
ed
 in
 th
e 
ho
m
e 
se
tti
ng
. F
ou
r t
es
t s
es
sio
ns
 
ar
e 
pe
rfo
rm
ed
 o
n 
ea
ch
 d
ay
 o
f 
m
on
ito
rin
g.
 D
ur
in
g 
ea
ch
 o
f t
he
se
 
te
sts
, s
ub
je
ct
s p
er
fo
rm
 a
 se
t o
f 
ta
sk
s f
ro
m
 th
e 
U
PD
R
S,
 w
hi
le
 
w
ea
rin
g 
a 
tr
i-a
xi
al
 a
cc
el
er
om
et
er
 
se
ns
or
.
Tr
ia
xi
al
 
ac
ce
le
ro
m
et
er
s 
[S
H
IM
M
ER
® 
pl
at
fo
rm
]. 
5 
PW
P
3 
da
ys
 w
ith
 4
 
m
on
th
s c
oo
lin
g 
off
 p
er
io
d 
be
tw
ee
n 
ea
ch
 
da
y 
Th
e 
se
ns
or
s a
nd
 a
lg
or
ith
m
 
ar
e 
ab
le
 to
 tr
ac
k 
lo
ng
itu
di
na
l 
ch
an
ge
s i
n 
m
ot
or
 sy
m
pt
om
s, 
by
 a
na
ly
zin
g 
 U
PD
R
S 
sc
or
es
 u
sin
g 
ra
nd
om
 fo
re
st 
re
gr
es
sio
n,
 w
ith
in
 0
.5
 p
oi
nt
s 
on
 a
 sc
al
e 
of
 0
-4
.
Ts
ip
ou
ra
s [
20
12
] 
[4
2]
1:
 C
oh
or
t
2:
 L
ab
or
at
or
y
1:
 A
cc
ur
ac
y 
of
 a
n 
el
et
ro
ni
c/
au
to
m
at
ed
 m
et
ho
do
lo
gy
 fo
r 
m
ea
su
rin
g 
le
vo
do
pa
 in
du
ce
d 
dy
sk
in
es
ia
.
2:
 Th
e 
m
et
ho
do
lo
gy
 is
 b
as
ed
 o
n 
th
e 
an
al
ys
is 
of
 si
gn
al
s r
ec
or
de
d 
du
rin
g 
th
re
e 
m
aj
or
 ta
sk
s: 
1-
 ly
in
g 
on
 th
e 
be
d;
 2
- r
isi
ng
 fr
om
 th
e 
be
d 
an
d 
sit
tin
g 
on
 a
 c
ha
ir 
lo
ca
te
d 
ne
ar
 
th
e 
be
d;
 3
- s
ta
nd
in
g 
up
 fr
om
 th
e 
ch
ai
r a
nd
 p
er
fo
rm
in
g 
a 
se
rie
s o
f 
ta
sk
s.
Ac
ce
le
ro
m
et
er
s, 
gy
ro
sc
op
es
 a
nd
 
a 
po
rt
ab
le
 d
at
a 
re
co
rd
er
. 
11
 P
W
P
5 
he
al
th
y 
co
nt
ro
ls
N
ot
 a
pp
lic
ab
le
Th
e 
re
su
lts
 o
bt
ai
ne
d 
in
di
ca
te
 th
at
 th
e 
pr
op
os
ed
 
m
et
ho
d 
is 
effi
ci
en
t (
97
.3
6%
 
cl
as
sifi
ca
tio
n 
ac
cu
ra
cy
) f
or
 
de
te
ct
in
g 
le
vo
do
pa
 in
du
ce
d 
dy
sk
in
es
ia
. 
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Ch
ap
te
r 
2
Au
th
or
D
es
ig
n 
(1
)
En
vi
ro
nm
en
t (
2)
Ai
m
 (1
) 
In
te
rv
en
tio
n 
(2
)
Ty
pe
 o
f s
en
so
r
N
Fo
llo
w
 u
p 
pe
rio
d
C
on
cl
us
io
ns
C
an
ce
la
 [2
01
3]
 [4
3]
1:
 C
oh
or
t
2:
 L
ab
or
at
or
y 
an
d 
ho
m
e
1:
 T
o 
in
ve
sti
ga
te
 th
e 
te
ch
ni
ca
l 
pe
rfo
rm
an
ce
 o
f t
he
 P
ER
FO
R
M
 
w
ea
ra
bl
e 
sy
ste
m
, a
 m
on
ito
rin
g 
an
d 
he
al
th
 c
ar
e 
pl
at
fo
rm
 fo
r P
D
 
pa
tie
nt
s. 
2:
 P
ha
se
 1
 a
nd
 2
: r
ec
or
di
ng
s w
he
n 
w
ea
rin
g 
th
e 
PE
R
FO
R
M
 sy
ste
m
, i
n 
a 
ho
sp
ita
l e
nv
iro
nm
en
t. 
Ph
as
e 
3:
 2
 re
co
rd
s o
f 
ap
pr
ox
im
at
el
y 
4 
ho
ur
s w
ea
rin
g 
th
e 
PE
R
FO
R
M
 sy
ste
m
, f
or
 fi
ve
 
co
ns
ec
ut
iv
e 
da
ys
, i
n 
th
e 
pa
tie
nt
’s 
ho
m
e.
Ac
ce
le
ro
m
et
er
s 
an
d 
gy
ro
sc
op
es
20
 h
ea
lth
y 
[p
ha
se
 1
] 
36
 P
W
P 
[p
ha
se
 2
]
44
 P
D
P 
an
d 
12
 
he
al
th
y 
co
nt
ro
ls 
[p
ha
se
 3
]
5 
da
ys
Th
e 
PE
R
FO
R
M
 sy
ste
m
, 
sh
ow
ed
 a
n 
ac
cu
ra
cy
 o
f 
93
.7
3%
 fo
r t
he
 c
la
ss
ifi
ca
tio
n 
of
 le
vo
do
pa
 in
du
ce
d 
dy
sk
in
es
ia
 se
ve
rit
y, 
 8
6%
 
br
ad
yk
in
es
ia
 se
ve
rit
y, 
an
d 
87
 %
 fo
r t
re
m
or
. R
eg
ar
di
ng
 
us
ab
ili
ty
, 8
 o
ut
 o
f 2
4 
pa
tie
nt
s r
ep
or
te
d 
ex
tre
m
e 
di
sc
om
fo
rt
/p
ai
n 
w
he
n 
w
ea
rin
g 
th
e 
sy
ste
m
. 
La
ks
hm
in
ar
ay
an
a 
[2
01
4]
 [3
5]
1:
 S
tu
dy
 p
ro
to
co
l o
f  
N
RT
 
2:
 H
om
e
1:
 T
o 
ev
al
ua
te
 th
e 
im
pa
ct
 o
f u
sin
g 
a 
sm
ar
tp
ho
ne
 a
nd
 w
eb
 a
pp
s t
o 
pr
om
ot
e 
pa
tie
nt
 se
lf-
m
an
ag
em
en
t 
as
 a
 to
ol
 to
 in
cr
ea
se
 tr
ea
tm
en
t 
ad
he
re
nc
e 
an
d 
en
ha
nc
e 
th
e 
qu
al
ity
 
of
 c
lin
ic
al
 c
on
su
lta
tio
n.
2:
 G
ro
up
 1
: s
m
ar
tp
ho
ne
 a
nd
 
in
te
rn
et
-e
na
bl
ed
 P
D
 tr
ac
ke
r 
sm
ar
tp
ho
ne
 a
pp
G
ro
up
 2
: u
su
al
 m
an
ag
em
en
t 
[tr
ea
tm
en
t] 
fo
r P
D
P 
an
d 
th
ei
r 
ca
re
rs
.
Sm
ar
tp
ho
ne
22
2 
PW
P
4 
m
on
th
s
St
ud
y 
is 
cu
rr
en
tly
 ru
nn
in
g.
 
N
RT
 - 
N
on
-r
an
do
m
ize
d 
tr
ia
l; 
U
PD
R
S 
- U
ni
fie
d 
Pa
rk
in
so
n’s
 D
ise
as
e R
at
in
g 
Sc
al
e;
 S
PA
R
K
 –
 S
m
ar
tp
ho
ne
/S
m
ar
tw
at
ch
 sy
ste
m
 fo
r P
ar
ki
ns
on
 d
ise
as
e;
 P
ER
FO
R
M
 - 
A 
so
Ph
ist
ic
at
Ed
 m
ul
ti-
pa
rR
am
et
ric
 sy
ste
m
 F
O
R
 th
e c
on
tin
uo
us
 eff
ec
tiv
e a
ss
es
sm
en
t a
nd
 M
on
ito
rin
g 
of
 m
ot
or
 st
at
us
 in
 P
ar
ki
ns
on
’s 
di
se
as
e a
nd
 o
th
er
 n
eu
ro
de
ge
ne
ra
tiv
e 
di
se
as
es
; U
PD
R
S 
- U
ni
fie
d 
Pa
rk
in
so
n’s
 D
ise
as
e 
R
at
in
g 
Sc
al
e;
 P
D
- P
ar
ki
ns
on
’s 
D
ise
as
e;
 P
W
P-
 P
eo
pl
e 
w
ith
 P
ar
ki
ns
on
’s 
D
ise
as
e;
 P
ER
FO
R
M
 - 
A 
so
Ph
ist
ic
at
Ed
 m
ul
ti-
pa
rR
am
et
ric
 sy
ste
m
 F
O
R
 th
e 
co
nt
in
uo
us
 e
ffe
ct
iv
e 
as
se
ss
m
en
t a
nd
 M
on
ito
rin
g 
of
 m
ot
or
 st
at
us
 in
 P
ar
ki
ns
on
’s 
di
se
as
e 
an
d 
ot
he
r n
eu
ro
de
ge
ne
ra
tiv
e 
di
se
as
es
.
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M
ul
ti
m
ed
ia
 A
pp
en
di
x 
2.
2:
 P
ar
ki
ns
on
@
H
om
e 
stu
dy
 d
at
a
St
ud
y 
In
st
ru
m
en
t
O
ut
co
m
e 
m
ea
su
re
T
yp
e
F
re
qu
en
cy
D
em
o
gr
ap
h
ic
	p
ro
fi
le
A
ge
 a
t d
is
ea
se
 o
ns
et
Pa
tie
nt
 s
el
f-
re
po
rt
O
nc
e
E
th
ni
ci
ty
Pa
tie
nt
 s
el
f-
 re
po
rt
O
nc
e
Le
ve
l o
f 
ed
uc
at
io
n
Pa
tie
nt
 s
el
f-
 re
po
rt
O
nc
e
T
im
e 
si
nc
e 
di
ag
no
se
s 
Pa
tie
nt
 s
el
f 
- r
ep
or
t
O
nc
e
PP
M
I: 
M
D
S-
U
PD
R
S 
[8
]
N
on
-m
ot
or
 e
xp
er
ie
nc
es
 o
f 
da
ily
 li
vi
ng
Ph
ys
io
th
er
ap
is
t r
ep
or
t
O
nc
e
M
ot
or
 e
xp
er
ie
nc
es
 o
f 
da
ily
 li
vi
ng
Ph
ys
io
th
er
ap
is
t r
ep
or
t
O
nc
e
M
ot
or
 e
xa
m
in
at
io
n
Ph
ys
io
th
er
ap
is
t r
ep
or
t
O
nc
e
M
ot
or
 c
om
pl
ic
at
io
ns
Ph
ys
io
th
er
ap
is
t r
ep
or
t
O
nc
e
PP
M
I: 
E
pw
or
th
 s
le
ep
in
es
s 
sc
al
e 
[2
9]
Sl
ee
p 
qu
al
ity
Pa
tie
nt
 s
el
f-
re
po
rt
O
nc
e
PP
M
I: 
G
er
ia
tr
ic
 D
ep
re
ss
io
n 
Sc
al
e 
[2
8]
D
ep
re
ss
iv
e 
be
ha
vi
or
 
Pa
tie
nt
 s
el
f-
re
po
rt
O
nc
e
PP
M
I: 
M
oC
A
 [2
5]
C
og
ni
tiv
e 
im
pa
ir
m
en
t
Ph
ys
io
th
er
ap
is
t r
ep
or
t
O
nc
e
PP
M
I: 
Sc
hw
ab
 a
nd
 E
ng
la
nd
 a
ct
iv
iti
es
 
of
 d
ai
ly
 li
vi
ng
 [2
6]
Fu
nc
tio
na
l l
ev
el
 a
t a
ct
iv
iti
es
 o
f 
da
ily
 li
vi
ng
Ph
ys
io
th
er
ap
is
t r
ep
or
t
O
nc
e
PP
M
I: 
SC
O
PA
-A
U
T
 [2
7]
A
ut
on
om
ic
 d
ys
fu
nc
tio
ns
Pa
tie
nt
 s
el
f-
re
po
rt
O
nc
e
Fo
x 
In
si
gh
t a
pp
M
ed
ic
at
io
n 
in
ta
ke
 [c
om
pl
ia
nc
e]
Pa
tie
nt
 s
el
f-
re
po
rt
M
ul
tip
le
 ti
m
e 
po
in
ts
Fa
lls
 
Pa
tie
nt
 s
el
f-
re
po
rt
M
ul
tip
le
 ti
m
e 
po
in
ts
Pe
rc
en
ta
ge
 o
f 
se
ns
or
 d
at
a 
st
re
am
in
g 
in
 3
 m
on
th
s 
[c
om
pl
ia
nc
e]
Pr
oc
es
se
d 
A
cc
el
er
om
et
er
M
ul
tip
le
 ti
m
e 
po
in
ts
Sm
ar
tw
at
ch
 (P
eb
bl
e)
T
im
e 
th
at
 th
e 
pa
tie
nt
 is
 a
ct
iv
e 
du
rin
g 
th
e 
da
y
Pr
oc
es
se
d 
A
cc
el
er
om
et
er
0.
2H
z
Le
ve
l o
f 
ph
ys
ic
al
 a
ct
iv
ity
 d
ur
in
g 
th
e 
da
y
Pr
oc
es
se
d 
A
cc
el
er
om
et
er
0.
2 
H
z
H
ou
rs
 d
ur
in
g 
th
e 
da
y 
w
he
re
 th
e 
pa
tie
nt
 h
ad
 tr
em
or
Pr
oc
es
se
d 
A
cc
el
er
om
et
er
0.
03
 H
z
A
m
ou
nt
 o
f 
m
ov
em
en
ts
 d
ur
in
g 
sl
ee
p 
tim
e
Pr
oc
es
se
d 
A
cc
el
er
om
et
er
0.
00
3 
H
z
R
aw
 s
en
so
r d
at
a
R
aw
 a
cc
el
er
om
et
er
50
 H
z
PM
M
/F
D
 
N
um
be
r o
f 
fa
ll 
ev
en
ts
Pr
oc
es
se
d 
A
cc
el
er
om
et
er
D
ep
en
di
ng
 o
n 
th
e 
nu
m
be
r 
of
 d
et
ec
te
d 
fa
ll 
ev
en
ts
The Parkinson@Home study protocol
55
Ch
ap
te
r 
2
St
ud
y 
In
st
ru
m
en
t
O
ut
co
m
e 
m
ea
su
re
T
yp
e
F
re
qu
en
cy
Z
en
de
sk
 
T
im
e 
sp
en
t p
ro
vi
di
ng
 tr
ou
bl
es
ho
ot
in
g 
te
le
ph
on
e 
su
pp
or
t p
er
 p
at
ie
nt
 [f
ea
si
bi
lit
y]
St
ud
y 
su
pp
or
t t
ea
m
 
in
di
ca
to
rs
M
ul
tip
le
 ti
m
e 
po
in
ts
In
cl
us
io
n 
ra
te
 [f
ea
si
bi
lit
y]
St
ud
y 
su
pp
or
t t
ea
m
 
in
di
ca
to
rs
O
nc
e
D
ro
p-
ou
t r
at
e 
[f
ea
si
bi
lit
y]
St
ud
y 
su
pp
or
t t
ea
m
 
in
di
ca
to
rs
O
nc
e
Ty
pe
 o
f 
te
ch
ni
ca
l a
nd
/o
r s
tu
dy
 p
ro
ce
du
re
 p
ro
bl
em
 
en
co
un
te
re
d 
by
 p
at
ie
nt
s 
[f
ea
si
bi
lit
y]
Pa
tie
nt
 s
el
f-
re
po
rt
N
/A
Pa
tie
nt
s’ 
so
ci
oe
co
no
m
ic
 s
ta
tu
s(
SE
S)
 [p
os
si
bl
e 
bi
as
es
 in
 
th
e 
po
pu
la
tio
n]
Pa
tie
nt
 s
el
f-
re
po
rt
O
nc
e
Sy
st
em
 U
sa
bi
lit
y 
Sc
al
e 
[2
8]
U
sa
bi
lit
y 
an
d 
le
ar
na
bi
lit
y 
of
 th
e 
Fo
x 
In
si
gh
t a
pp
Pa
tie
nt
 s
el
f-
re
po
rt
O
nc
e
Sa
tis
fa
ct
io
n 
su
rv
ey
U
se
r’s
 s
at
is
fa
ct
io
n 
w
ith
 th
e 
sy
st
em
 (s
m
ar
tw
at
ch
 a
nd
 
ap
p)
Pa
tie
nt
 s
el
f-
re
po
rt
O
nc
e
Pa
tie
nt
s’ 
so
ci
od
em
og
ra
ph
ic
 d
et
ai
ls
 (e
.g
. g
en
de
r, 
di
se
as
e 
du
ra
tio
n,
 a
ge
 a
nd
 p
re
vi
ou
s 
ex
pe
rie
nc
e 
w
ith
 
sm
ar
tp
ho
ne
s)
 [p
os
si
bl
e 
bi
as
es
 in
 th
e 
po
pu
la
tio
n]
Pa
tie
nt
 s
el
f-
re
po
rt
O
nc
e
PP
M
I 
- 
Pa
rk
in
so
n 
Pr
og
re
ss
io
n 
M
ar
ke
r 
In
iti
at
iv
e;
 M
D
S-
U
PD
R
S 
- 
M
ov
em
en
t 
D
iso
rd
er
 S
oc
ie
ty
 -
 U
ni
fie
d 
Pa
rk
in
so
n’s
 D
ise
as
e 
R
at
in
g 
Sc
al
e;
 M
oC
A 
- 
M
on
tre
al
 
C
og
ni
tiv
e 
As
se
ss
m
en
t f
or
 c
og
ni
tio
n;
 S
C
O
PA
-A
U
T-
 S
ca
le
s f
or
 O
ut
co
m
es
 in
 P
ar
ki
ns
on
’s 
D
ise
as
e 
– 
Au
to
no
m
ic
 S
ys
te
m
 fo
r a
ut
on
om
ic
 d
ys
fu
nc
tio
n 

Chapter 3
Feasibility of  large-scale deployment 
of  multiple wearable sensors in 
Parkinson’s disease
PLoS One. 2017;12(12):e0189161
Chapter 3
58
ABSTRACT
Introduction: Wearable devices can capture objective day-to-day data about Parkinson’s 
Disease (PD). This study aims to assess the feasibility of implementing wearable 
technology to collect data from multiple sensors during the daily lives of PD patients. 
The Parkinson@home study is an observational, two-cohort (North America, NAM; 
The Netherlands, NL) study.
Methodology: To recruit participants, different strategies were used between sites. Main 
enrolment criteria were self-reported diagnosis of PD, possession of a smartphone and 
age ≥ 18 years. Participants used the Fox Wearable Companion app on a smartwatch 
and smartphone for a minimum of 6 weeks (NAM) or 13 weeks (NL). Sensor-derived 
measures estimated information about movement. Additionally, medication intake and 
symptoms were collected via self-reports in the app.
Results: A total of 953 participants were included (NL: 304, NAM: 649). Enrolment 
rate was 88% in the NL (n = 304) and 51% (n = 649) in NAM. Overall, 84% (n = 805) of 
participants contributed sensor data. Participants were compliant for 68% (16.3 hours/
participant/day) of the study period in NL and for 62% (14.8 hours/participant/day) 
in NAM. Daily accelerometer data collection decreased 23% in the NL after 13 weeks, 
and 27% in NAM after 6 weeks. Data contribution was not affected by demographics, 
clinical characteristics or attitude towards technology, but was by the platform usability 
score in the NL (χ2 (2) = 32.014, p<0.001), and self-reported depression in NAM 
(χ2(2) = 6.397, p = .04).
Conclusion: The Parkinson@home study shows that it is feasible to collect objective 
data using multiple wearable sensors in PD during daily life in a large cohort.
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INTRODUCTION 
Parkinson’s Disease (PD) is a common neurodegenerative disease in which patients 
experience both motor and non-motor symptoms [1]. Treatment is primarily based on the 
management of symptoms by increasing dopamine levels through pharmacological therapy 
or surgery [2, 3]. Additionally, non-pharmacological therapies, such as physiotherapy, 
occupational therapy or speech therapy, are available to support patients [4].
Although good results in the management of motor symptoms have been achieved, 
particularly in the early stages of the disease [5, 6], two major problems hamper long-
term treatment. First, current pharmacological therapy is successful for a limited period. 
In the long term, most patients develop unmanageable motor complications that can 
lead to worsening of quality of life [7]. Second, evaluation of day-to-day variations in 
PD symptoms is difficult when relying solely upon periodic consultations by clinicians 
[8]. Therefore, more detailed, objective and reliable measures during daily living could 
potentially improve the management of PD.
Wearable sensors have been used to assess PD-related symptoms continuously and 
longitudinally during daily living [9–12]. Wearables may provide greater insight into 
a patient’s disease status, allowing patients to self-manage their symptoms and monitor 
medication responses [13–18]. Furthermore, wearable sensor data may improve our 
scientific understanding of disease progression by showing changes in motor and non-
motor symptoms over time, furthering the development of digital biomarkers for disease 
progression [19].
While the potential value of wearable sensors for disease management and research are 
increasingly becoming clear, various critical aspects of feasibility remain to be determined. 
Only a few studies have rigorously investigated the feasibility and acceptability of using a 
wearable platform comprising a smartphone in combination to a smartwatch. Moreover, 
these prior findings remained limited by the small sample sizes (biggest sample thus far: 
40 PD patients) [9, 13, 17, 18]. Therefore, we aimed to investigate the feasibility of 
using a wearable platform in a much larger sample of PD patients, with a focus on 
recruitment success, attrition rates, user compliance and system usability.
METHODS
Between August/2015 and November/2016, a total of 953 PD patients from two 
cohorts (n = 304 in The Netherlands (NL) and n = 649 PD in North America (Unites 
States and Canada - NAM) participated in the Parkinson@Home feasibility study. To 
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investigate the feasibility of the technology in different contexts, both cohorts used the 
same wearable platform, but had distinct strategies for recruitment, retention and study 
period. These topics are described separately (overview in Table 3.1.).
Table 3.1. Study design and procedure overview at the two cohorts.
The  
Netherlands
North  
America
Recruitment strategies Through Internet communities ✓ ✓
Through support groups ✓ -
Through physiotherapists ✓ -
Enrolment criteria ≥30 years old ✓ -
Dutch resident ✓ -
Smartphone using Android OS version 4.2 or higher ✓ ✓
Self-reported PD ✓ ✓
≥18 years old - ✓
Registered for Fox Insight study - ✓
English-speaking Canadian or United States resident - ✓
Exclusion criteria None ✓ ✓
Consent process Informative email ✓ ✓
Online digital consent form ✓ ✓
Study kit Pebble smartwatch ✓ ✓
Installation guide ✓ ✓
User manuals ✓ ✓
Clinical evaluations Assessment by physical therapist ✓ -
Fox Insight online self-assessment surveys - ✓
Study duration Minimum of 6 weeks - ✓
Minimum of 13 weeks ✓ -
Instruction for device  
usage
Minimum of 5 hours a day - ✓
24 hours, 7 days a week ✓ -
Support model Call-center during working hours ✓ ✓
Technical support calls for non-data contributors ✓ -
Support emails for non-contributors - ✓
Usability questionnaire - ✓ -
Study design and population
The NL cohort
The population and study design applied in the NL are described in detail elsewhere 
[20]. In short, participants were recruited from support groups, internet communities 
and through physiotherapists specialized in treating PD patients. Enrolment criteria 
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were: (1) ≥30 years of age, (2) possession of a smartphone using an Android OS version 
≥4.2 and (3) self-reported diagnosis of PD. No exclusion criteria were applied beyond 
enrolment criteria.
All enrolled participants received a single medical examination, based on the “Parkinson’s 
Progression Markers Initiative” (PPMI) [21]. This included the full MDS-UPDRS 
[22], the Montreal Cognitive Assessment (MoCA) [23], and the Modified Schwab and 
England Activities of Daily Living Scale [24]. The medical examination was performed 
by specially trained physiotherapists who are members of ParkinsonNet [25], a Dutch 
network of health professionals specialized in PD management. At the end of the 
13-weeks study period, all enrolled participants evaluated the usability of the system 
through the System Usability Scale (SUS) [26, 27], and were enquired about ability to 
use a smartphone (see APPENDIX). Finally, participants had the option to continue 
using the platform or return the Pebble smartwatch.
The NAM cohort 
Study recruitment for the NAM cohort was entirely virtual through direct emails to 
subjects participating in the “Fox Insight online study”, Facebook advertisements to 
targeted populations, and advertisements on Fox Trial Finder, a clinical trial matching 
tool for people with PD [28]. Additional to the NL, the following enrolment criteria 
were applied: (1) ≥18 years of age and (2) participation in the Fox Insight Online Study 
[29]. In order to enroll, interested participants had to first register in the Fox Insight 
study (if they had not done so already). Through Fox Insight, each participant completed 
online surveys about demographics, medical history, cognition, physical activity, 
symptoms and PD related medications and surgeries. Once enrolled in the Fox Insight, 
participants were eligible to register for the NAM cohort of the Parkinson@Home study 
on a separate webpage. These users completed an online enrolment form which was 
reviewed by the study team to determine eligibility. All study registrants received an 
email confirming their eligibility or non-eligibility. After finishing the 6-weeks study 
period, participants had the option to continue using the platform.
Wearable platform
The Intel® Pharma Analytics Platform used has been described in detail elsewhere [20, 
30].	Briefly,	it	consists	of 	the	Fox	Wearable	Companion	app,	used	on	both	a	smartwatch	
and smartphone, and a cloud environment. In this study, a Pebble smartwatch, was used 
together with the patients’ Android phones. 50 Hz accelerometer data were collected 
continuously from the smartwatch and streamed to the smartphone.
Sensor analysis algorithms are applied to the aggregated (30 second interval) 
smartwatch accelerometer data in the app to estimate outcomes (i.e. levels of
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activity, tremor and movement during sleep). These estimated quantities are 
transmitted, via Wi-Fi or mobile data, to a cloud environment. They are also 
presented to the user by graphs and summary reports within the app. Additionally, 
users are able to set medication reminders, report actual medication intake 
and rate their symptoms (e.g. tremor, dyskinesia, rigidity, bradykinesia) within 
the mobile app (Figure 3.1.). Both estimated outcomes and patients reported 
outcomes (PROs) are stored in the cloud environment.
Study procedures at both cohorts
Participants from both cohorts provided electronic consent and received a research 
kit containing a Pebble smartwatch, an installation guide and user manuals. Next, 
participants installed the Fox Wearable Companion App on their devices and were asked 
to wear the smartwatch and keep their smartphone with them as much as possible on 
either a 24/7 basis for 13-weeks study period (NL) or for a minimum of 5 hours a day, 
7 days a week, for a 6-weeks study period (NAM). Additionally, participants reported 
their medication intake (i.e medication name and doses) and PD symptom severity 
using the app. A helpline was available during the study period for technical support. 
Support calls or emails were sent to participants from whom data were not collected for 
more than seven consecutive days.
Outcome definitions and statistical analysis
Feasibility assessment included recruitment, attrition, compliance and system usability. 
Recruitment success was analysed by (1) the total number of enrolled participants and 
(2) the number of eligible registrants that did not complete the informed consent. 
Compliance, similar to previous studies [31, 32], was calculated as the median 
percentage of the study period where accelerometer data were collected. Attrition rate 
based upon Eysenbach et al. [33], were measured by (1) decrease in the daily percentage 
of collected accelerometer data during each study period and (2) decrease in the number 
of participants contributing accelerometer data. Finally, system usability was measured 
by the median total score on the System Usability Scale.
We investigated the relationship between self-reported demographics, clinical data, ability 
to use a smartphone System Usability score and the percentage of accelerometer data 
collected to identify factors that influence compliance levels. Participant demographic 
and clinical characteristics were grouped into categories either following previously 
described literature (presence of depression [34]; presence of cognitive impairment 
[23]) or by convenience (age; educational level: a measure of the last completed level 
of education where low education was equal to high school or lower levels, middle 
education was equal to bachelor, and high education was equal to master or higher levels; 
Hoehn & Yahr stage and Modified Schwab and England scale). Because compliance was 
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not normally distributed, the median and quartiles were used to divide participants into 
three compliance groups (low, middle and high). The first quartile was the cut-off for the 
low compliant group and third quartile for the high compliant group. Depending on 
the distribution of other variables in the analysis, either Chi-square, Fisher’s Exact Test 
or Kruskal-Wallis were used to investigate significant differences between compliance 
groups considering demographics, clinical characteristics, ability to use a smartphone 
and System Usability score.
Ethics standards
This study was conducted in compliance with the Ethical Principles for Medical Research 
Involving Human Subjects, as defined in the Declaration of Helsinki. The study protocol 
and communication materials were approved by the local ethics committee (NL: CMO 
Arnhem- Nijmegen; NL53034.091.15; NAM: New England IRB: 15–046).
RESULTS
Recruitment and sample characteristics
In the NL cohort, 347 eligible PD patients were invited to participate. Among 
those invited, 43 refused to participate. The main refusal reasons were “Study 
protocol seems too burdensome” (44%, n = 19), followed by “Personal 
circumstances” (33%, n = 14). A total of  304 patients (enrolment rate = 88%) 
were enrolled.
In the NAM cohort, from the 866 participants of  the Fox Insight study who 
received a direct invitation to participate, 306 were enrolled (6% were ineligible). 
344 additional participants were included from the remaining recruitment 
channels, with varied ineligibility rates. A total of  649 registrants (enrolment rate 
= 51%) were enrolled.
In both cohorts, 953 participants were enrolled. From them, 805 were data 
contributors (participants that contributed at least one accelerometer data point 
during study period). Analysis of  the demographic characteristics of  both 
cohorts showed that, in comparison to NA, the NL cohort presented more men 
(χ2 (1) = 9.5146, p<0.01); older (χ2 (2) = 16.435, p = 0.001) and higher educated 
(χ2 (2) = 25.270, p<0.001) PD included participants. The characteristics of  all 
participants are presented in Table 3.2..
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Technical support to participantsIn both cohorts, the helpdesk consisted of two 
research assistants, available for 20 hours (NL) and 40 hours (NAM) per week. Th e actual 
workload was dependent on: (1) the number of participants simultaneously enrolled 
in the trial; and (2) the occurrence of bugs in the app or server downtime. Th e most 
frequent and time-consuming problems were: (1) Bluetooth disconnection between the 
smartwatch and the smartphone and (2) questions regarding the medication report, 
especially in the fi rst weeks of participation.
Compliance
Among both cohorts, 85% (n = 805 of 953 enrolled) of participants were data 
contributors. In the NL, 291 data-contributors collected data for a median of 1,478 
hours each in the 13-weeks, with quartile ranges (1st and 3rd QR) of 888 to 1,827 
hours. In NAM, 514 data contributors collected a median of 621 hours (1st QR: 286 
and 3rd QR: 828 hours) each during the 6-weeks. Compliance rates for each cohort 
were 68% (1st and 3rd QR: 41%-83%) equal to 16.3 hours/ participant/day in the NL 
and 62% (1st and 3rd QR: 28%-82%) equal to 14.8 hours/participant/day in NAM 
(Figure 3.2.).
Figure 3.2. Distribution of compliance among all enrolled participants in the NL (n=304-black) and 
NAM (n=649-white) study cohorts.
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Attrition
In the NL, 13 participants (4% of all NL enrolled participants) did not contribute any 
data dur- ing the study period and were thus non-compliant. In NAM, this number was 
135 (21% of all NAM enrolled participants). Additionally, 82 (27% of all enrolled) data-
contributors in the NL became non-compliant during the study period. Th e primary 
known reasons (n = 47) were “Personal circumstances” (38%, n = 18) and “System too 
complex/System related issues” (34%, n = 16). For the NAM cohort, although reasons 
were unknown, this number was 89 (17% of all enrolled).
Th e attrition in the median percentage of sensor data collected daily varied between 
cohorts. In the NL, the attrition rate was 23% after 13-weeks’ study period. In the 
NAM, attrition was 27% after 6-weeks’ study period (Figure 3.3.).
Figure 3.3. Attrition in compliance per day for NL (n = 291, black) and NAM participants (n = 514, 
gray) during the follow up period.
Attrition in participation was tracked during and beyond the compulsory study period 
for each cohort. Th e number of participants decreased rapidly after the end of the study 
period in the NL cohort. A more gradual attrition in participation occurred in the NAM 
cohort (Figure 3.4.).
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Figure 3.4. Number of participants actively collecting sensor data at the NL (gray) and NAM (black) 
cohorts during and after the follow- up period (total initial n = 805).
Ninety-six percent (n = 280) of data-contributors in the NL reported their medication 
through the app, while 78% (n = 404) did so in NAM. On average, data-contributors 
who used medication reports reported 351±217 medication intakes during the 13-week 
study period in the NL and 127±113 over 6-week study period in NAM. Both cohorts 
showed a low and non-exponential attrition in medication report, similar to the attrition 
showed in compliance with the accelerometer data (data not shown).
System usability
In the NL cohort, 256 participants completed the System Usability Scale 
(response rate = 71.4%). The median score was 62.5 (1st and 3rd QT 47.5–72.5), 
which	classifi	es	the	wearable	platform	in	a	c	ategory	between	“Ok”	and	“Good”	
(Figure 3.5.).
Figure 3.5. SUS scoring of the Fox Wearable Companion platform (smartwatch with smartphone app) as 
rated by participants.
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Factors related to compliance
After grouping all NL data-contributors into compliance groups, analysis reveals no 
significant differences in the distribution of demographics, clinical characteristics and 
ability to use a smartphone between these groups. However, Kruskal-Wallis analysis 
demonstrates that the System Usability score reported is significantly different between 
the groups (χ2 (2) = 32.014, p<0.001). The mean rank score is 84.8 for the low compliant 
group, 130.8 for the middle compliant group and 160.0 for the high compliant group, 
which indicates that participants in the high compliant group provided a higher usability 
score to the system.
For the NAM cohort, analysis shows that demographics and clinical characteristics 
between the three compliance groups was comparable, except for a trend regarding self-
reported depression (χ2(2) = 6.397, p = .04). This result indicates that a slightly higher 
number of self-reported depressed patients are in the low compliant group (Table 3.3.).
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DISCUSSION
This study assessed the feasibility of using a wearable platform for long-term data 
collection in a large sample of PD patients. We focused on: recruitment success, attrition 
rates, compliance and system usability. Enrolment rate was 88% (n = 304) in the NL 
and 51% (n = 649) in NAM. Nearly 85% of all enrolled participants contributed 
sensor data during the study period. Median compliance rate was 68% (16.3 hours/
participant/day) in the NL, and 62% (14.8 hours/participant/day) in NAM. The rate 
of accelerometer data collected each day declined 23% in the NL after 13-weeks of 
study period, and 27% in NAM after 6-weeks of study period. The distribution of 
demographics, clinical characteristics and ability to use a smartphone did not differ 
across compliance groups in the NL, but System Usability score did differ. For the NAM, 
the distribution of demographics and clinical characteristics between the compliance 
groups was comparable, except for self-reported depression status.
The high compliance in this study shows that it is feasible for people with PD to use 
this wearable platform in a real-world environment for many months. Although the 
feasibility of using consumer wearable sensors to monitor PD symptoms has been 
previous reported [9, 13,  17, 18, 31, 35], this is the first rigorous observational study 
to investigate the feasibility of a wearable platform comprising a smartwatch combined 
with a smartphone in such a large patient group (the largest prior study included only 
40 patients). Additionally, the small differences in study protocols across cohorts allowed 
us to observe the impact of varying usage instructions on compliance. Comparing the 
feasibility results obtained in this study to other studies, where either mobile apps were 
used in large cohorts [36] or e-health technologies were used [37, 38], we achieved a 
high compliance together with small and non-exponentially decreasing attrition rate, 
even though exponential decrease in compliance is the norm in these sort of studies 
[33].
This unusually high compliance rate may be attributed to the “passive” data collection. In 
this case, little or no interaction with the technology is required in order to collect sensor 
data. Participants using the Parkinson@Home wearable platform, other than reporting 
their medication intake when reminded by the alarm (which was widely perceived as 
a service, instead of a burden), did not need to interact actively with the smartphone 
or smartwatch. In another similar smartphone-based study where “active”, “task-based” 
monitoring was used (that is, where participants needed to perform certain specific 
tasks, at regular intervals prompted by the platform) [36], a more typical high and 
exponential attrition rate was observed. While it is difficult to draw firm conclusions 
from this comparison (because the two platforms are somewhat different), we suspect 
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that periodic and long interaction by users may increase attrition, leading to attrition 
rates seen in paper-based diaries [39]. The low and non-exponential attrition seen in the 
medication reports, a quick and less burdensome task, strengthened this conclusion. 
Thus, passive monitoring, where little to no interaction with the technology is required, 
may lead to better overall compliance rates.
Despite the potential influence of age, gender and PD-related impairment (i.e. 
physical or cognitive) on compliance, our results showed that overall disease severity, 
MDS-UPDRS scores, independency level or cognitive impairment, did not influence 
compliance, which suggests that this platform could be used by most PD patients. 
The unique design of the Parkinson@home study can partially explain this result. 
The presence of a personalized support centre, which was previously described as an 
effective strategy to improve retention of participants [33], may have increased patients’ 
confidence in using the system and have compensated for any disease-related difficulties.
Moreover, the “pro-active” support model, with scheduled calls to participants who 
showed signs of low compliance, may have boosted compliance by providing a quick 
resolution of technical interruptions, and addressed any apathy towards participation 
caused by technology difficulties. This support is even more important because 
compliance is compromised in participants that reported low System Usability scores. 
Therefore, in order to achieve high compliance while using smartphone/smartwatch 
wearable platforms to measure PD related symptoms at home, it is beneficial to: (1) 
improve the platform’s usability, (2) reduce the number of technical issues, and (3) run a 
personalized support center that can provide guidance to deal with possible technology 
related issues that participants may encounter.
LIMITATIONS
The Parkinson@Home study did have a few limitations. First, this is one of the first large-
scale cohort studies using consumer wearable sensors in PD, with a long study period 
duration (i.e. up to 13 weeks). However, the study sample consisted only of PD patients 
that possessed a smartphone, thus introducing a possible selection bias, e.g. towards 
more highly educated subjects. Although smartphone penetration in the NL and NAM 
is high [40, 41], participants may not reflect the majority of PD patients living in the 
Netherlands, North America, or elsewhere in the world. Furthermore, when compared 
to the general PD population [42], participants were mainly young with a mild disease 
impairment and with some degree of cognitive impaired. Even though these variables 
showed no obvious influence on compliance, a more impaired population may need 
more personal support in order to maintain compliance.
Future studies should aim for a more stratified population in order to further confirm 
the lack of influence across the full range of disease severity in the compliance with 
wearable sensors among PD patients. Second, the present results only apply to the use 
of two specific consumer grade devices (i.e. smartphone and smartwatch). Although 
consumer grade devices bring potential advantage over the use of dedicated medical 
devices, it is unknown whether our promising feasibility results would generalize to 
dedicated medical devices which are often more expensive and less user-friendly.
CONCLUSION
In conclusion, the Parkinson@home trial showed that it is feasible to deploy a technology 
plat- form consisting of consumer-grade wearable and mobile devices for long-term 
data collection in a large and geographically diverse PD population. Importantly, 
compliance was comparable for patients with a range of backgrounds, including men 
and women, different ages, and some variations in disease severity. These findings 
suggest that wearables may offer a promising approach to overcome the limitations in 
monitoring disease status and progression of mildly impaired PD patients in a real-life 
environment. The platform here used is a promising and practical approach to capturing 
large amounts of sensor data from many participants by passive means, without much 
need for interaction with the technology. In the future, these properties may position 
sensor technologies as effective tools for monitoring PD and the “lived experience” of 
PD patients.
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Applicability of  objective 
measurements for answering clinical 
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wearable sensors for quantifying 
gait and falls
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ABSTRACT
Introduction: Despite the large number of studies that have investigated the use of 
wearable sensors to detect gait disturbances such as Freezing of gait (FOG) and falls, 
there is little consensus regarding appropriate methodologies for how to optimally apply 
such devices. Here, an overview of the use of wearable systems to assess FOG and falls 
in Parkinson’s disease (PD) and validation performance is presented.
Methodology: A systematic search in the PubMed and Web of Science databases was 
performed using a group of concept key words. The final search was performed in 
January 2017, and articles were selected based upon a set of eligibility criteria.
Results: In total, 27 articles were selected. Of those, 23 related to FOG and 4 to falls. 
FOG studies were per- formed in either laboratory or home settings, with sample sizes 
ranging from 1 PD up to 48 PD presenting Hoehn and Yahr stage from 2 to 4. The shin 
was the most common sensor location and accelerometer was the most frequently used 
sensor type. Validity measures ranged from 73–100% for sensitivity and 67–100% for 
specificity. Falls and fall risk studies were all home-based, including samples sizes of 1 
PD up to 107 PD, mostly using one sensor containing accelerometers, worn at various 
body locations.
Conclusion:  Despite the promising validation initiatives reported in these studies, they 
were all performed in relatively small sample sizes, and there was a significant variability 
in outcomes measured and results reported. Given these limitations, the validation of 
sensor-derived assessments of PD features would benefit from more focused research 
efforts, increased collaboration among researchers, aligning data collection protocols, 
and sharing data sets.
Keywords
Parkinson’s disease
Ambulatory monitoring; Wearable sensors; Validation studies
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INTRODUCTION
Parkinson’s disease (PD) is a progressive neurodegenerative disease characterized by 
four major motor signs: rest tremor, rigidity, bradykinesia, and postural instability [1]. 
Non-motor impairments, including executive dysfunctions, memory disturbances, and 
reduced ability to smell, are also seen in the disease [2–4]. Gait difficulties and balance 
issues are a disabling problem in many patients with PD, with different contributing 
factors, such as freezing of gait (FOG), festination, shuffling steps, and a progressive loss 
of postural reflexes. Its importance is underlined by a high prevalence of fall incidents in 
PD, especially in the later stages of the disease [5–7].
FOG is defined as a sudden and brief episode of inability to produce effective forward 
stepping [8]. The phenomenon is closely related to falls, appearing mainly during gait 
initiation, turning while performing a concomitant concurrent activity (i.e.,  dual  tasks), 
or  approaching narrow spaces [9–13]. Similar to FOG, fall episodes occur mainly during 
a half-turn or while dual tasking [6]. With disease progression, the increase of FOG and 
falling episodes, as well as the decrease in effectiveness of dopaminergic therapy amplify 
the burden related to these symptoms [6, 12, 14].
The management of gait disturbances, such as FOG and falls, often includes 
pharmacological interventions [12]. However, there is a growing interest in non-
pharmacological interventions, such as physiotherapy [15], deep brain stimulation [16], 
or cueing devices [17, 18]. In all cases, reliable tools are required to determine the 
severity of gait disorders and evaluate the efficacy of interventions [5].
A number of subjective rating scales are used to evaluate motor symptoms, but most of 
them have limited validity and reliability [19]. To overcome these limitations, wearable 
sensors are emerging as new tools to objectively and continuously obtain information 
about patients’ motor symptoms [20–22]. These sensors, typically consisting of 
embedded accelerometers, gyroscopes and other, have been used to determine PD-
related symptoms, including gait disorders [17, 18, 23–28]. They can act as an 
extension of health-professionals’ evaluation of PD symptoms, improving treatment, 
and augmenting self-management [29, 30].
Despite a large number of studies that investigated the use of wearable sensors to detect 
gait disturbances, such as FOG and falls, there is little agreement regarding the most 
effective system design, e.g., type of sensors, number of sensors, location of the sensors 
on the body, and signal processing algorithms. Here, we provide an overview of the use 
of wearable systems to assess FOG and falls in PD, with emphasis on device setup and 
results from validation procedures.
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REVIEW METHODOLOGY
A systematic search in the PubMed and Web of Science databases was performed in 
accordance with the PRISMA statement [31]. These databases were chosen to allow 
both medical and engineering journals to be included in the search process.
The search query, based on the PICO strategy [31], included Parkinson’s disease 
representing the Population, wearable, sensors, device representing the Intervention and 
falls or freezing of gait representing the Comparison. Outcome was not included as a 
key word to keep the query broad. The truncation symbol (*) and title/abstract filter 
were used to both broaden the search and provide more specificity. The final search 
query is shown in Table 4.1..
Table 4.1. Search queries used for each database
Database Query Hits
Web of  Science (((TI=(sensor*) OR TS=(sensor*) OR TI=(device*) OR 
TS=(device*) OR TS=(wearable*) OR TI=(wearable*)) AND 
(TS=(freezing*) OR TI=(freezing*) OR TI=(fall*) OR TS=(fall*)) 
AND (TI=(Parkinson’s*) OR TS=(Parkinson’s*))))
272
PubMed ((“Freezing of  gait” [tiab] OR Freezing* [tiab] OR fall* [tiab]) 
AND (wearable* [tiab] OR sensor* [tiab] OR device* [tiab]) AND 
Parkinson* [tiab]) 
280
The final search was performed in January 2017. In addition to the database search, a 
search in the references of review articles and book chapters that appeared during the 
search was performed. The goal was to identify potentially eligible articles absent in the 
database search.
Articles were selected based upon a set of eligibility criteria. As the objective of this 
review was to provide an overview of articles published on the topic, selection criteria 
were kept broad. Therefore, studies were included if they (1) present original research on 
the validation of wearable sensors (i.e., a single or combination of body worn computer/
sensor [32, 33]) to detect, measure or monitor FOG, falls, or fall risk and (2) were 
performed in Parkinson’s disease patients. Studies were excluded if they (1) only used 
wearables to deliver cueing for FOG, (2) were published in languages other than English, 
or (3) did not provide sufficient information about study design and results.
Data extraction was performed using a predefined table. Variables extracted included: 
author, sample size, device usage (i.e., type of sensor, number of sensors, and location of 
the device), data collection procedures, and validation results. Validity was considered 
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as the extent to which an instrument is measuring a concept that it is supposed to 
measure. It can be further divided into different types of validity, such as criterion-
referenced validity, construct validity and content validity. In the case of wearable 
sensors, researchers are often interested in criterion-referenced validity, which can be 
assessed by the correlation between the sensor-derived outcome and the outcome of a 
reference instrument that has already been validated [34, 35]. Construct validity, also 
known as discriminant validity, is commonly used by assessing the extent to which 
groups that are supposed to produce different outcomes, indeed do so, for example, by 
comparing PD with non-PD, or DBS ON with DBS OFF.
RESULTS
Selection process
In total, 552 articles were retrieved by the query. The selection process led to the final 
inclusion of 27 articles. Of those, 23 articles related to FOG, and 4 to falls. A complete 
overview of the selection process is presented in Figure 4.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1 Selection process for eligible articles 
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Figure 4.1. Selection process for eligible articles
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Methodologies
FOG detection
A total of  23 articles investigated the use of  wearable sensors to assess FOG in 
PD [18, 28, 36–56] (Table 4.2.). 
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The sample sizes varied from 1 [28] to 48 PD [51] per study, with a non-PD 
group being included  in  a  few  studies [28, 40, 48, 51, 53, 56]. Disease severity, 
when reported, ranged from 2 to 4 according to the Hoehn and Yahr scale. Data 
were collected according to three types of  protocols: (1) a set of  structured 
tasks performed in a laboratory environment (n = 18); (2) a protocol performed 
in a laboratory environment in which at least a part of  which was designed to 
capture naturalistic behaviour (n = 2); and (3) natural or naturalistic behaviour in 
a home environment (n = 3).
The types of  sensors embedded in the devices worn by the participants varied. 
Tri-axial accelerometers were used in 22 articles, either as a single sensor (48%, 
n = 11), or combined with gyroscopes (35%, n = 8), or magnetometers (13%, 
n = 3). One study used electroencephalogram to measure changes in the brain 
activity from pre-determined areas during FOG episodes. Regarding the number 
of  body locations, 56% (n = 13) of  the studies utilized one location, while the 
other 44% (n = 10) used a combination of  two or more locations. The shin (66% 
of  studies, n = 16; 4 times used as the single location) and waist (33% of  studies, 
n = 8; 3 times as the single location) were the most common body locations for 
the devices, although nine other locations were also explored (Figure 4.2.).
 
Fig. 2 Distribution of device body location for FOG measurement 
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Figure 4.2. Distribution of device body location for FOG measurement
Falls: detection and fall risk analysis
Four articles on falls were retrieved: one article on fall detection and three articles 
presented the use of  wearable sensors for analyzing fall risk. All protocols were 
performed in a home-based setting (Table 4.3.) [57–60], and the sample size 
varied from one patient in a case report [57] up to 107 PD in a cross-sectional 
Chapter 4
98
study [59]. One study reported disease severity and had an average Hoehn and 
Yahr score of  2.6 ± 0.7 [59]. All studies used tri-axial accelerometers. One 
study combined this sensor with force and bending sensors [58]; another with 
gyroscopes [60]. Sensor body locations included chest, insole (i.e., under the arch 
of  the foot), and lower back.
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Validation
FOG detection
Among the 23 articles investigating FOG detection, 18 reported measures of validation 
performance (e.g., sensitivity, specificity, or accuracy) [17, 36–45, 47–49, 52–55], three 
studies used correlation measures, correlating the wearable-derived measure with the 
period of freezing or number of FOG events [50, 51, 56], and two studies did not report 
validity measures [28, 46].
Overall, validity values ranged from 73 to 100% for sensitivity, and from 67 to 100% for 
specificity, and accuracy ranged from 68% up to 96%. Validity measures are summarized 
and compared across protocol setups in Figures. 4.3 and 4.4.
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Figure 4.3. Instrument performance (sensitivity) in FOG detection
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Fig. 4 Instrument performance (specificity) in FOG detection 
* Not reported. 
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Figure 4.4. Instrument performance (specificity) in FOG detection
* Not reported.
Fall detection and fall risk analysis
One article investigated the use of  wearable sensors to detect falls, by comparing the 
data from a self-reported diary to the sensor data. The sensor captured 19 fall events 
from a total of  22 self-reported events [57].
Three articles presented the use of  wearable sensors for analyzing fall risk. All of  them 
reported discriminant validity by comparing sensor-derived outcomes between different 
groups, such as fallers and non-fallers or PD versus non-PD (see Table 4.3. for details). 
Weiss et al. [59] reported an illustrative approach, whereby the 107 participating PD 
patients wore one sensor in the lower back and made diary annotations about fall events. 
The sensor data, collected remotely in the patient’s home, were subsequently used to 
calculate a fall risk index. The time until variable gait pattern (log rank test: p = 0.0018, 
Wilcoxon test: p = 0.0014).
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DISCUSSION
This review included 27 articles, 23 on FOG, and four on falls. FOG studies were 
performed either in a laboratory or at home, with different types of protocols (structured 
versus free-movement). The shin (16/28 studies) was the most common device location 
and tri-axial accelerometers (26/28 studies) the most common sensor type. Sensitivity 
ranged from 73% to 100% and specificity ranged from 67% to 100% for the detection 
of FOG. Fall and fall risk studies were all home-based, using mostly one device (3/4 
studies) containing tri-axial accelerometers. Sensors were positioned on the chest, insole, 
and lower back. The systems detected falls or quantified fall risk by various approaches 
and with varying degrees of validity.
FOG detection
The results in this review support the potential for wearable devices. In the laboratory, 
systems showed a moderate to high specificity and sensitivity, which are in line with 
other evidence that wearable systems detecting FOG are already well validated in a 
laboratory setting [30]. Moreover, promising results were also achieved in studies 
performed in the home environment. Interestingly, the comparison of validity measures 
in terms of sensitivity and specificity (Figs. 3,  4)  suggests  that  wearable sensors are able 
to accurately detect FOG, independent of study protocol (e.g., home versus laboratory 
environment; structured versus unstructured protocols) and system design (e.g., one 
sensor only versus multiple sensors, and one device versus a set of combined devices in 
different body locations). However, one should be cautious when directly comparing 
reported performance between studies, for a number of reasons: in particular, one 
should consider additional factors, such as algorithm used, outcome definitions, data 
analysis methods, and the intended application of the system.
First, even though FOG is a well-defined symptom [8], what objectively constitutes 
FOG is unclear. The challenge lies in rigorously defining, from an algorithmic point 
of view, such a complex event, which can appear in different forms and intensities. 
Furthermore, the definition of the measured outcome has an important impact upon 
instrument validity assessment. In this review, some studies only included long-duration 
FOG episodes. Omitting small FOG episodes may lead to inaccurate estimates of FOG 
detection rates. A comprehensive definition such as that used by Djuric–Jovici and 
colleagues [47], differentiating between FOG with trembling and FOG with complete 
motor blocks prior to video labeling and test properties, seems to address the problem 
by incorporating different types of FOG events. However, this definition was not used 
in other studies. A clear and comprehensive definition would improve the comparability 
of instrument performance.
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Second, the intended application of the instrument is another aspect to be considered 
in FOG detection. It is attractive to aim for rates of 100% specificity and sensitivity. 
However, this may result in signal processing operations which require substantial 
computational resources. As illustrated by Ahlrichs [37], the detection of FOG episodes 
was achieved with high sensitivity and specificity, but the data processing was time-
consuming with delays of up to 60s. Similarly, algorithms with high accuracy may 
require substantial computational resources which may have an adverse effect on power 
consumption and hence battery life for non-intrusive, portable devices. This fact may 
prevent the use of such systems for real-time detection and cueing. Therefore, it is 
reasonable to conclude that at this point, the acceptability of instrument performance 
in detection of FOG relate to its application, and many of these algorithms will require 
substantial mathematical and engineering efforts in order to reduce computational delays 
to an acceptable level. Furthermore, some algorithms required individual calibration 
and others did not, which also has practical consequences for applications in clinical 
and research practice.
Finally, although there exists the potential for these instruments being applied to long-
term monitoring in free living conditions, only a few systems were actually validated 
in the home environment. Therefore, the majority of the technology available lacks 
‘‘ecological’’ validation. Thus, further research using larger sample sizes, longer follow-
up periods under more realistic home environments is necessary.
Fall detection and fall risk calculation
Del Din and colleagues described that real-world detection of falls is a substantial 
challenge from a technical perspective, and almost all evidence in their review was limited 
to controlled settings and young healthy adults [30]. This finding is confirmed in this 
review, most clearly illustrated by the fact that we only found one article reporting on 
fall detection accuracy in PD. However, it is possible that this small number of articles 
is not only a result of the complexity of capturing falls in PD under realistic, free-living 
conditions. It certainly highlights an area where the validity of wearable sensors still 
needs to be examined. In addition, fall risk calculation has the potential to provide 
objective information before the fall event happens, which may be more valuable than 
simply counting the number of events and dealing with the consequences.
Fall risk estimation has a clear relevance for clinical practice [58]. Falls are common 
and disabling, even in early PD [61]. In addition, falls are also related to physical injury 
[61], high hospitalization cost [62], and social/psychological impact [63], either on their 
own or due to the anticipatory fear of falling [64]. Even though the number of retrieved 
articles investigating fall risk calculation was not high, the results seem to confirm the 
potential for wearable sensors to accurately calculate fall risk for PD.
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CONCLUSION
This systematic review presents an overview of studies investigating the use of wearable 
sensors for FOG and falls in Parkinson’s disease. Despite promising validation initiatives, 
study sample sizes are relatively small, participants are mainly in early stages of the 
disease, protocols are largely laboratory-based, and there is little consensus on algorithms 
analysis. Further work in ecological validation, in free-living situations, is necessary. 
There also is a lack of consistency in outcomes measured, methods of assessing validity, 
and reported results. Given these limitations, the validation of sensor-derived assessments 
of PD features would benefit from increased collaboration among researchers, aligning 
data collection protocols, and sharing data sets.
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ABSTRACT
Importance: Falling is among the most serious clinical problems in Parkinson’s disease 
(PD). 
Objective: We used body-worn sensors (falls detector worn as a necklace, with embedded 
tri-axial accelerometer and barometer) to quantify the hazard ratio of falls in PD patients 
in real life. 
Design: We analyzed prospectively collected data from a commercial dataset on a 
cohort of home-dwelling elderly subjects. Fall events were collected either automatically 
using the wearable falls detector or registered by a button push on the same device. We 
extracted fall events from a 2.5-year window, with average follow-up of 1.1 years. All 
falls included were confirmed immediately by a subsequent telephone call. 
Setting: Elderly subscribers to an emergency response program including automatic fall 
detection.
Participants: We matched 2,063 individuals with self-reported PD to 2,063 individuals 
without PD matched for age, gender, comorbidity, and domestic conditions.
Main outcomes: (1) Incidence rate of any fall, (2) incidence rate of a new fall after 
enrollment (i.e. hazard ratio), and (3) one-year cumulative incidence of falling.
Results: Incidence rate of any fall was higher among PD patients than matched elderly 
(2.1 versus 0.7 falls/person, respectively; p<.0001). The incidence rate of a new fall 
after enrollment (i.e. hazard ratio) was 1.8 times higher for PD patients than matched 
elderly (95% confidence interval: 1.6-2.0). A higher percentage of PD patients (49%) 
than matched elderly (29%) experienced at least one fall during one year of follow-
up (p<.0001). Among PD patients, 30% (n=610) registered more than two falls after 
enrollment against 15% (n=300) in matched elderly (p<.0001). The number of falls 
resulting in emergency transport was higher for PD patients (n=292) compared to 
matched elderly (n=183). 
Conclusion and Relevance: Having PD nearly doubles the incidence of falling in 
real life. These findings highlight PD as a prime “falling disease” and emphasize the 
importance of dedicated strategies to prevent falls. The results also point to the feasibility 
of using body-worn sensors to monitor falls in daily life.
Keywords
Falls incidence; Parkinson’s disease
Wearable sensor; home-based monitoring
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INTRODUCTION
Falling is among the most serious clinical problems faced by older adults, occurring 
in 19-49% of the elderly population [1]. Falls can have major consequences, such as 
fractures and other injuries [2], hospitalization, and a negative impact on social and 
psychological wellbeing [3]. Moreover, mortality is increased in subjects with falls [4]. 
Parkinson’s disease (PD) is a prime example of a progressive neurological condition 
where falls are very common, presumably because many risk factors coincide in this 
disorder. Specifically, persons with PD have both balance and gait deficits (including 
freezing episodes), and commonly also cognitive deficits [5]. Additional risk factors 
include – among others – visual impairments [6], benzodiazepine intake [2], and 
postural hypotension [7]. 
Epidemiological studies and evaluations of novel interventions are difficult to design 
because fall detection in daily life remains difficult. The typical methodology for capturing 
real-life fall events is using diaries [8-12]. However, these diaries have a poor reliability 
and compliance is suboptimal. Consequently, the outcomes usually correlate poorly 
with real-life behavior [11, 13]. Modern technology offers new possibilities to overcome 
those limitations, e.g. by using body-worn wearable sensors [14-17]. Such sensors can 
potentially detect falls automatically, quantitatively and, importantly, continuously 
in the patient’s own environment, thus providing an attractive alternative to the self-
reported burdensome and unreliable diaries. Some promising examples of using wearable 
sensors to quantify fall events in controlled settings and free-living environments were 
reported in PD [18, 19]. Using a single sensor to automatically register fall events, one 
study automatically detected 19 out of 22 true events [19]. Moreover, sensors can also 
be used together with a personal emergency response system built into the sensor box, 
thus providing patients with rapid access to emergency assistance if needed, e.g. when 
they experience difficulty rising after the fall [20]. 
In this study, we analyzed data from such a personal emergency response system in 
a large cohort of elderly subjects who used a single wearable fall detector, worn as a 
necklace, to collect fall events in their own home environment. Using these real-life 
data, collected for up to 2.5 years follow-up, we aimed to determine the hazard ratio of 
falling among participants with PD compared to matched-elderly.
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METHODOLOGY
Study design and participants
In this prospective cohort study, we analyzed an existing dataset composed of data 
from subscribers to a personal emergency response system (Philips  Lifeline® service). 
No personal, customer, or proprietary data were shared by Philips. This service can 
provide immediate access to appropriate help. The personal emergency response system 
consists of a device worn as a necklace with multiple sensors embedded (i.e. tri-axial 
accelerometer and barometer) and is designed to automatically detect fall events in 
elderly. It also enables users to press a button to report emergency situations, such as 
a fall event, and contact a central response center for help. [20] Either way, when a 
fall is automatically detected or self-reported, a call is generated to a central response 
center and support is provided as needed. In addition to support, the central response 
center confirms whether or not a fall event took place. The fall detector can be worn 
continuously and contains a battery that lasts for more than 18 months. 
Among all participants, we selected a convenience sample including all self-reported 
PD participants (n=2,063). Using sample characteristics – age, gender, number of self-
reported medical conditions, and domestic conditions (i.e. living alone or not) – we 
extracted a matched elderly group from those elderly reporting not to have PD, but 
who were also prone to falling and had therefore subscribed to the same falls program. 
No selection based on type of medical condition was applied to the control group. 
Therefore, participants included in the matched group consisted of elderly subscribers 
living with a diversity of chronic conditions. For the matching procedure we used the 
Propensity Score Matching technique, matching cases with a nearest neighbor approach 
guided by logit scores [21].
The analysis was conducted on a pseudonymized pre-existing data set, and was approved 
by the Philips internal board of ethics. Therefore, approval from an external Medical 
Ethical Committee was not required for this analysis. 
Data collection and outcomes
Fall events were reported either by a button-push or collected automatically using a fall 
detector worn as a necklace with multiple sensors embedded (i.e. tri-axial accelerometer 
and barometer – figure 5.1.). The pendant device uses data from the embedded sensors 
(i.e. tri-axial accelerometer and barometric pressure) to identify falls from changes in 
height, orientation, and impact, as experienced during a fall episode. The fall detection 
algorithm was developed and validated by Philips, based on recorded sensor data from 
approximately 600 simulated falls of n=31 healthy volunteers for typical falls (standing, 
forward, backward, sideward, sitting), from falls using crash dummies for high risk 
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situations (e.g. stairs) and approximately 30000 hours of daily-life activity collected 
from elderly people [20]. The results from the white paper on device performance 
showed that validity was good, with a detection rate >95% [20]. All falls incidents 
that are reported in the present study were confirmed and annotated by a call center; 
false-positive findings (automatically detected falls that were not confirmed during the 
follow-up call) were excluded from the analyses.
Figure 5.1. GoSafe service
The dataset was created between January 2012 and June 2014. From this dataset, we 
extracted data from a window of data of up to 2.5 years after service enrollment. Fall 
events were collected until the participant was lost to follow-up or reached the end of the 
2.5-year observational window. We analyzed all fall events that were confirmed as “fall” 
during the call between the central response center and the participant. Calls to the 
central response center were initiated either by an automatic fall detection algorithm or 
a button push by the subject immediately after the fall. False alarms, accidental button 
presses or near-falls were not labeled as a fall event in the dataset. The database included 
loggings of all contacts between the participant and the central response center from 
which the number of falls was determined. Information on demographics and self-
reported medical history was collected during a welcome call at service enrollment.
The following outcomes were calculated: (1) incidence rate of any fall: ratio between 
any fall event registered and the observed follow-up time (falls per person-year), (2) 
incidence rate of a new fall after enrollment: additional hazard ratio of experiencing 
a new fall event after enrollment for patients having PD in comparison to matched-
elderly, and (3) one-year cumulative incidence of falling: percentage of participants in 
both groups that presented at least one fall one-year after enrolment. For all outcomes, 
we assessed the difference between PD patients and matched-elderly.
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Statistical analysis
Descriptive analysis was used to report the incidence rate of any fall for both PD patients 
and matched-elderly. Between-group differences were determined by t-tests (continuous 
variables) or chi-squared tests (categorical variables). We assessed the association of 
PD with the incidence rate of any fall using ANOVA models, with PD status, age, 
gender, and number of medical conditions as independent predictors and number of 
falls as dependent variable (significance at p<.05). Using this model as base, we added 
two-way and three-way interaction terms of age, gender, or age*gender with PD in 
separate sensitivity analyses. We subsequently stratified analyses by age, in which we 
dichotomized at the mean value (78.6 years) to create a young (<mean age) and an old 
(>mean age) groups of participants.
We investigated the association of PD with the incidence rate of a new fall after 
enrollment using Cox regression models, with PD status, age, gender, and number of 
medical conditions as independent predictors and new fall after enrollment (yes/no) as 
the dependent variable. The proportional hazards assumption was verified by plotting 
the residuals over time (supplementary figure). In separate sensitivity analyses, we added 
two-way and three-way interaction terms of age, gender, or age*gender with PD to the 
main model to assess possible interaction. Finally, a Kaplan-Meier survival analysis was 
applied to assess the cumulative incidence of new falls after enrollment during one-year 
follow-up for both PD and matched-elderly. 
For all analyses, a p-value ≤.05 was regarded as statistically significant. All analyses were 
performed using R statistical software, version 3.3.2. 
RESULTS
Participants characteristics
All 2,063 subscribers to the personal emergency response system with self-reported PD 
were included. A matched group of 2,063 subscribers not reporting PD was considered 
as matched-elderly. Table 5.1. presents the subjects’ characteristics. Data were extracted 
from a 2.5-year window, and average follow-up was 1.1 years (because not all participants 
used the personal emergency response system throughout this period).
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Table 5.1. Characteristics of PD and matched-elderly
Variable PD (n=2063)* Matched-elderly (n=2063)*
Follow-up (mean±SD) 1.1±0.6 1.1±0.6
Age in years (mean±SD) 78.6±8.4 78.4±8.9
Gender (% of men) 48.3 48.1
Number of medical conditions (mean±SD) 2.6±2.3 2.5±2.2
Living condition (% living alone) 92.1 92.6
*Due to matching procedure, the groups did not differ in any characteristics (p>.05). 
Fall events
A total of 6,436 falls events were detected in both groups. PD participants had a 
higher incidence rate of any fall compared to controls (2.1 versus 0.7 falls/person-
year, respectively; p<0.0001). The difference in incidence rate of any fall between PD 
participants and matched elderly was more distinct among older individuals (table 5.2.). 
Among PD patients, 30% (n=610) registered more than two falls during their follow-
up of 1.1 year and were thus classified as recurrent fallers. This was 15% (n=300) in 
matched elderly (p<.0001). The absolute number of fall events resulting in emergency 
transport, but not the proportion, was higher among PD patients (n= 292; 6% of all 
falls among PD) in contrast to matched elderly (n=183; 12% of all falls among elderly-
matched). When only recurrent fallers where analyzed, the number of events resulting 
in emergency transport among PD patients (n=45, 2%) was almost double that of the 
matched elderly group (n=28, 1%).
Table 5.2. Fall incidence for patients with Parkinson’s disease and a matched control group
PD
(n=2063)
Matched
(n=2063)
p-value
Incidence rate of any fall
(falls per person-year)
All subjects 2.1 0.7 <.00011
Younger* 
(<78.6 years)
1.7 0.6 <.00012
Older* 
(>78.6 years)
2.7 0.8
Type of faller (%) Non-faller 1080 (52.4%) 1425 (69.1%) <.00013
Single faller 
(1 fall/year)
373 (18.1%) 338 (16.4%)
Recurrent faller 
(≥2 falls/year)
610 (29.6%) 129 (14.5%)
*Groups were dichotomized at the mean value (78.6 years). 1-Poisson regression, 2- ANOVA Two-way 
interaction analysis; 3-Chi-square test.
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One-year conversion to fallers rate
The incidence rate of a new fall after enrollment (i.e. hazard ratio for falling or time 
to a new fall) was 1.8 (95% CI=1.6-2.0) for a participant having PD compared to a 
matched-elderly participant. The hazard ratio of falling was not influenced by two-way 
interaction of age and PD (p=.6), gender and PD (p=.2), or three-way interaction of 
age, gender and PD (p=.9). A higher percentage of PD participants had at least one fall 
after a one-year follow-up, with 48.8% of PD participants, compared to 29.5% in the 
matched-elderly group (p<.001) (figure 5.2.).
Figure 5.2. Probability of falling after enrolment for PD group (black) and matched-elderly (gray).
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DISCUSSION
This is the first large-scale study that determines the real-life incidence of falls using a 
wearable system, with all reported falls being confirmed by the faller during a telephone 
contact immediately after the fall. This enabled us to robustly quantify the hazard ratio 
of falling of PD patients in daily life. The large cohort size allowed us to create both a 
PD group and a matched elderly control group, leading to an accurate estimation of 
the additional relative hazard ratio that PD brings. Results from 4,126 participants, 
followed on average for 1.1 years, showed that PD patients have a much higher incidence 
rate of any fall compared to controls. Fall rates were highest for older PD patients, 
who sustained on average 2.7 falls per person-year (three times as often as controls). 
Finally, PD patients had a 1.8 times higher incidence rate of a new fall after enrollment 
compared to controls. This hazard ratio was not influenced by the interaction between 
PD and age or gender.
A high number of fallers among PD patients has been described previously [22,23]. A 
similar prospective cohort study followed 100 PD patients and 55 matched controls 
[23]. After one year, 54% of PD patients and 18% of controls were fallers. Our present 
results (48% fallers among PD patients versus 31% in matched elderly controls after one-
year follow-up) are in accordance with this. Additionally, we show that the interaction 
of age and PD leads to higher incidence rate of any fall. Specifically, in our cohort, older 
PD patients fell almost three times as often as controls. The effect of age on fall rates 
was inconsistent in previous reports [24], but the ageing process may affect the clinical 
presentation of PD, leading to a worse phenotype [25]. Additionally, older PD patients 
are likely to show a higher disease duration and greater severity, thus being more prone 
to falling [26]. 
We also show that PD nearly doubles the hazard ratio of a new fall after enrollment. In 
previous studies [10,26,27], the criteria used to select matched individuals may have 
substantially affected the fall incidence rate, as well as the observed hazard ratio for falling 
associated with PD. For example, Mak [10] reported a much higher fall risk rate of 4.2 
after following 72 PD patients and 47 controls. However, their control group involved 
healthy subjects recruited from local community health centers, who usually have fewer 
falls. This bias is not present in our study: our PD participants were not selected or 
excluded based on any medical condition or living style. Additionally, the large sample 
size allowed us to produce a more representative control group than seen previously, 
avoiding the non-realistic increase or decrease of fall risks. Thus, we believe that the 
hazard ratio of falling presented here is the most accurate hazard ratio – incidence rate 
of a new fall after enrollment – for home-dwelling PD patients subscribers to a personal 
emergency system. Importantly, this finding confirms that PD is associated with a high 
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incidence rate of fall in daily life, emphasizing the need for fall-prevention programs 
tailored to this specific population.
The results of this study are an encouraging example of the feasibility of wearable sensors 
to monitor falls in real life. In the past years, several initiatives applied wearable sensors 
for fall detection, with good results [28]. Although more work is needed to refine 
algorithms, especially for PD patients in real life [29], those studies highlighted the 
utility of sensors not only to detect falls, but also to predict falls and quantify the risk 
of falling. In fact, an accurate and unobtrusive wearable falls monitoring system could 
improve data collection for trials and support daily care, by overcoming the high attrition 
rates and incorrect data completion seen with paper diaries [30]. Moreover, wearable 
sensors have potential to identify patients with a high risk of falling [31]. Consequently, 
monitoring with sensors may increase timely referral to falls prevention programs, 
aiming to decrease the impact of falls in the daily life and increase independency [32]. 
This potential of sensors becomes more important when considering the higher number 
of falls in PD patients resulting in emergency transport that was observed in the present 
study. Future research focusing on refining algorithms for fall detection, fall prediction, 
and fall risk analysis would assist the field by providing a more robust body of evidence 
to introduce wearable sensors as instruments for falls management.   
Strengths and drawbacks 
Beyond the large and well-matched groups of PD patients and controls, three further 
points strengthen this study. First, this is the first large study to objectively monitor 
fall episodes during a long follow-up in a home environment using a wearable sensor. 
Other smaller initiatives successfully used wearable sensors to collect falls-related data 
in the elderly [33]. However, initiatives to monitor falls for long periods in daily life 
remain scarce. Our study supports the merits of using wearable sensors as an option 
to objectively and reliably monitor falls in a patient’s home environment over a longer 
period. Second, many prior studies adopted tight in- and exclusion criteria [34], thus 
creating a selected population that may not mirror the real population with PD and thus 
bias the results. Our study did not apply such tight exclusion criteria, producing a more 
representative sample of PD patients in real-life. Finally, this is the first study to analyze 
a total of 6,436 fall events that were all confirmed immediately after the incident by a 
telephone call. This large dataset of confirmed falls ensures that the results presented 
here reflects the burden faced by PD patients in real-life.
Our study also had several limitations. First, all variables, except for the fall episodes, 
were self-reported by patients. This limitation was partially addressed by the matching 
procedure and the large sample size. However, we could not verify the diagnosis of PD, 
as this also depended on self-report. We consider it unlikely that many participants 
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reported having PD, whereas in fact they suffered from very different conditions. 
However, we cannot exclude that some patients had a form of atypical parkinsonism 
or that some participants in the control group are fallers who have not yet been 
diagnosed with PD. In any scenario, these limitations would lead to even higher fall 
rates. Additionally, the dataset used in this study did not included detailed information 
on competing risk for falls, such as type of medication in use. This limitation hampered 
the application of additional survival analysis methods during data analysis. Although 
it does not invalid the conclusions presented here, this limitation should be addressed 
in future studies. Second, although all fall episodes were confirmed by an immediate 
call, the confirmation procedure was only triggered by either algorithm detection or a 
button press. Therefore, during this process, some fall events may have been missed if 
the algorithm detection failed and, at the same time, patients also did not use the button 
press (i.e. we do not know the false negative rate of falls). However, this could only imply 
that actual fall rates in daily life are even higher than what we observed here, and we 
have no reason to assume that this false-negative rate would be different for PD patients 
and matched controls. Third, it was not possible to verify the ratio of falls reported by 
button-push versus those detected by algorithm detection, which also precluded the 
analysis of system performance among PD patients. However, this information does 
not influence the hazard ratio of falling here reported. Finally, our conclusions apply 
only to a population composed of elderly people prone to falling and subscribers to a 
personal emergency response system. Whether this high rate of falling is also present in 
the general PD population remains to be investigated. 
CONCLUSION
In conclusion, by collecting fall events using wearable sensors, this study demonstrated 
that having PD nearly doubles the incidence of falling in real life. This confirms PD as a 
prime falling disease. Additionally, the collection of fall events in over 4,000 participants, 
using a wearable sensor connected to a personal emergency response system, highlights 
the potential of using body-worn sensors for long-term home monitoring. 
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ABSTRACT
Introduction: People with PD (PWP) have an increased risk of becoming inactive. 
Wearable sensors can provide insights into daily physical activity and walking patterns.
Research questions: (1) Is the severity of motor ﬂuctuations associated with sensor-
derived average daily walking quantity? (2) Is the severity of motor ﬂuctuations associated 
with the amount of change in sensor-derived walking quantity after levodopa intake?
Methods: 304 Dutch PWP from the Parkinson@Home study were included. At baseline, 
all participants received a clinical examination. During the follow-up period (median: 
97 days; 25-Interquartile range-IQR: 91 days, 75-IQR: 188 days), participants used the 
Fox Wearable Companion app and streamed smartwatch accelerometer data to a cloud 
platform. The ﬁrst research question was assessed by linear regression on the sensor-
derived mean time spent walking/day with the severity of ﬂuctuations (MDS-UPDRS 
item 4.4) as independent variable, controlled for age and MDS-UPDRS part-III score. 
The second research question was assessed by linear regression on the sensor-derived 
mean post-levodopa walking quantity, with the sensor-derived mean pre-levodopa 
walking quantity and severity of ﬂuctuations as independent variables, controlled for 
mean time spent walking per day, age and MDS-UPDRS part-III score.
Results: PWP spent most time walking between 8am and 1pm, summing up to 72 ± 39 
(mean ± standard deviation) minutes of walking/day. The severity of motor ﬂuctuations 
did not inﬂuence the mean time spent walking (B = 2.4 ± 1.9, p = 0.20), but higher age 
(B = −1.3 ± 0.3, p = < 0.001) and greater severity of motor symptoms (B = −0.6 ± 0.2, 
p < 0.001) was associated with less time spent walking (F(3216) = 14.6, p < .001, R2 = 
.17). The severity of ﬂuctuations was not associated with the amount of change in time 
spent walking in relation to levodopa intake in any part of the day.
Conclusion: Analysis of sensor-derived gait quantity suggests that the severity of motor 
ﬂuctuations is not associated with changes in real-life walking patterns in mildly to 
moderate affected PWP.
Keywords
Parkinson’s disease; Motor ﬂuctuations
Ambulatory monitoring; Gait quantity; Wearable devices
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INTRODUCTION
People with Parkinson’s disease (PWP) are at risk of  developing an inactive lifestyle 
[1]. The reason for this is multifactorial, with involvement of  both physical and 
psychological	 factors.	 Some	of 	 these	 risk	 factors	 are	non-specific,	 such	 as	older	 age	
and	 fear	of 	 falling	 [2,3],	while	others	 are	more	 specific	 to	Parkinson’s	disease	 (PD),	
such as reduced physical capacity or gait and balance problems [4,5]. Being physically 
inactive is generally undesirable, particularly for PWP. Traditionally, self-reported diaries 
and questionnaires are used to assess daily physical activity. These instruments have 
dubious reliability and validity, in particular for people with cognitive impairments [6]. 
To overcome limitations related to self-reported activity, wearable sensors may provide 
more objective and continuous measurements, with the potential to generate novel 
insights into real-life activity patterns in PWP. Early studies that used wearable sensors 
to quantify physical activity in PD showed that greater disease severity correlates with 
less ambulatory activity [2,7,8]. These studies typically had small sample sizes, with the 
exception of  one (n = 586) [2] and had short follow-up periods (maximum 7 days).
In addition to assessing the overall amount of  ambulatory activity, wearable sensors 
oﬀer the possibility to study activity patterns throughout the day in detail. This is 
particularly	 relevant	 for	 PWP	 who	 experience	 motor	 fluctuations,	 i.e.	 periods	 with	
either a good levodopa therapy response (“ON” state) or periods when the medication 
eﬀects wear oﬀ and motor symptoms re-emerge (“OFF” state) [9]. The presence of  
OFF periods has a large limiting impact on mobility and quality of  life in PD [10,11]. It 
is known that gait patterns change in response to levodopa intake in PWP with motor 
fluctuations	[12]	and	small-scale	studies	demonstrated	that	wearable	sensors	can	capture	
the eﬀects of  levodopa on gait quality [13–15]. However, the impact of  levodopa intake 
on gait quantity, as a measure of  physical activity, is largely unknown and has never been 
studied in a large population followed for a long period of  time.
Therefore, the aim of this study is to investigate whether the severity of motor ﬂuctuations 
is associated with changes in physical activity patterns in a large cohort of PWP, who 
used wearable sensors for a prolonged period of time (up to 665 days). As walking is 
the most common activity for older adults, the meant time spent walking in minutes 
per day – labeled as “gait quantity” in this study – is used as a proxy measure of physical 
activity. 
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METHODOLOGY
Participants
PWP included in this study participated in the Dutch cohort of  the Parkinson@
Home study. The Parkinson@Home study was an observational, two-cohort (North 
America and The Netherlands) study aiming to investigate the feasibility of  large-scale 
deployment and the compliance with wearable sensor usage over a long follow-up 
time. The recruitment process and study design were previously described in detail 
[16]. In summary, in the Dutch cohort, 304 participants were recruited from support 
groups, internet communities, and through physiotherapists specialized in treating 
PWP. Inclusion criteria were: 30 years of  age or older; possession of  a smartphone with 
Android	OS	version	≥	4.2;	and	self-reported	diagnosis	of 	PD.	No	exclusion	criteria	
were applied. Participants used the Fox Wearable Companion app de- veloped by Intel® 
Pharma Analytics Platform team [17]. The application was installed on the participants 
own Android smartphone and on a Pebble smartwatch provided by the research team. 
Participants were asked to wear the smartwatch and keep their smartphone with them 
as much as possible on a 24/7 basis for 13-weeks. At the end of  the 13- weeks study 
period, participants had the option to continue using the system, if  they wished. The 
Parkinson@Home study showed that compliance of  PWP with the wearable system 
was high [16].
This study was conducted in compliance with the Ethical Principles for Medical 
Research	 Involving	Human	Subjects,	 as	defined	 in	 the	Declaration	of 	Helsinki.	The	
study protocol was approved by the local ethics committee (CMO Arnhem-Nijmegen; 
NL53034.091.15).
Data used in this study were collected during the Parkinson@Home study and 
obtained from a database curated by the Michael J. Fox Foundation. The Fox Wearable 
Companion app platform used in that study enables raw smartwatch accelerometer data 
capture (average 50 Hz sampling rate) streaming via Bluetooth radio to a complementary 
smartphone Android app. Next, the smartphone app transfers data via Wi-Fi or mobile 
data to the Intel Pharma Analytics cloud platform  which uses machine learning to 
estimate objective measures of  participants behavior. Among these objective measures 
is a gait detection algorithm, which estimates whether or not a person was walking 
during	 a	 specific	 time	 interval.	For	 the	detection	of 	gait	 episodes,	 an	 algorithm	was	
trained on 10 h of  walking and non-walking episodes collected from PWP (N = 19) 
and non PWP (N = 12) wearing a smartwatch. Raw accelerometer data were segmented 
into 5 s interval and transformed into aggregate features in the time and frequency 
domains. Then, a decision tree model was used to classify every 5-s interval as either 
walking or non-walking. The algorithm accuracy was 98.5% (precision 98.9%, recall 
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96%) on the training data [17] (see Appendix A for algorithm details). The objective 
measures are presented to participants using graphs and summary reports within the 
app. In addition to using the smartwatch and smartphone app, users were asked to set 
medication reminders and report their daily actual medication intake within the app 
(Figure 6.1.). Finally, all enrolled participants received a single medical examination, 
based on the “Parkinson’s Progression Markers Initiative”   (PPMI)   protocol.   The 
medical   examination   collected information such as time since diagnosis and the 
full MDS-UPDRS [18]. The medical examination was performed in the ON state by 
specially trained physiotherapists who are members of  ParkinsonNet, a Dutch network 
of  health professionals specialized in PD management.
Figure 6.1. screenshots of the Fox Wearable Companion app: (A) main screen; (B) activity graph; (C) 
movement during sleep graph; (D) medication reminder. Reprinted from [Intel and Michael J Fox 
Foundation] under a CC BY license, with permission from [INTEL®], original copyright [2017]
Outcomes and statistical analysis
Two statistical analyses were performed. Th e ﬁrst analysis aimed to assess whether 
a higher severity of motor ﬂuctuations is associated with a smaller mean time spent 
walking per day. Only participants that contributed at least 7 days of accelerometer data 
during the follow-up period were included. Th e mean time spent walking per day was 
calculated by ﬁrst dividing the total number of minutes identiﬁed as walking by the 
total number of minutes of accelerometer data. Next, this ratio was multiplied by 1440, 
i.e. the number of minutes in a day, to obtain the daily mean expressed in minutes. Th e 
severity of ﬂuctuations was determined by the score of item 4.4 of the MDS-UPDRS 
Part IV (question: “4.4 Functional impact of ﬂuctuations”) and the severity of motor 
symptoms was expressed as the sum score of the MDS- UPDRS Part III. Both outcomes 
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were treated as scale variables in the analyses. Linear regression analysis was performed 
on the mean time spent walking per day, with the severity of ﬂuctuations as independent 
variable. To control for potential confounders, age and MDS-UPDRS part III scores 
were included in the model using a backward stepwise input selection (criterion of 
removal: probability of F > 0.10).
The second	analysis	aimed	to	investigate	whether	a	higher	severity	of 	motor	fluctuations	
is associated with a higher change in time spent walking after levodopa intake. Only 
levodopa intakes were considered because this drug has the strongest association with 
occurrence	of 	fluctuations	[19].	The	analysis	was	performed	separately	for	the	morning	
(between  6:00  and  12:00),  afternoon  (between  12:00  and 18:00), evening (between 
18:00 and 0:00) and night (between 0:00 and 6:00), because both the amount of  walking 
[20] and the responsiveness to levodopa may vary across the day [21]. To account for 
possible participants errors while reporting medication intake, e.g. reporting the same 
medication	intake	time	point	multiple	times,	only	the	first	report	within	a	certain	hour	
was considered as the actual time of  medication intake.
To assess the change in time spent walking, we calculated both the mean time spent 
walking in the second hour after levodopa intake (post-levodopa activity) and the mean 
time spent walking in the last hour before levodopa intake (pre-levodopa activity) 
per individual (Figure 6.2.). Only pairs of  pre-levodopa and post-levodopa activity 
consisting of  at least 115 min of  data, out of  a possible total of  120 min during those 
two hours, were included. Moreover, participants needed to have at least a total of  10 
unique levodopa reports in the part of  the day being analyzed. Linear regression was 
performed on the mean post-levodopa activity, with the mean pre-levodopa activity 
and	 the	 severity	 of 	 fluctuations	 as	 independent	 variables.	 To	 control	 for	 potential	
confounders, the mean time spent walking per day, age and MDS-UPDRS part III 
score were included as inputs to the model using backward stepwise selection (criterion 
of  removal: probability of  F > 0.10).
For	the	coefficients,	a	critical	p-value	of 	0.05	was	applied.	All	analyses	were	performed	
using the Statistical Package for the Social Sciences (SPSS®) Version 22.
Impact of  motor fluctuations on real-life gait
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Figure 6.2. Data reduction and pre/post-levodopa activity calculation per participant
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RESULTS
The cohort consisted of 304 mostly mildly to moderately affected PWP (Table 6.1.).
Table 6.1. Demographic and clinical characteristic of the study participants (n=304).
n (%) Mean±SD
Gender Men 163 (66%) -
Age (years) - 63.1±8.5
Time since diagnose (years)  - 6.1±4.3
Disease stage1
 
 
0 6 (3%) -
1 68 (28%) -
2 127 (53%) -
3 34 (14%) -
4 5 (2%) -
5 1 (0.4%) -
Cognitive impairment2  - 25.4±3.0
Severity of motor symptoms3 - 28±14.5
Independency level4 ≤70 36 (15%)  -
71-80 51 (21%)  -
81-90 110 (46%)  -
≥91 41 (17%)  -
Severity of fluctuations5 None 120 (50%) -
Slight 42 (17%) -
Mild 21 (9%) -
Moderate 47 (20%) -
Severe 11 (5%) -
*Number of missing values differed across variables; only valid percentages are reported. 1-Disease stage: 
Hoehn and Yahr stage (0-5 point scale); 2-Cognitive impairment: Montreal Cognitive Assessment (0-30); 
3- Severity of motor symptoms: sum of Movement Disorders Society – Unified Parkinson’s Disease Rating 
Scale (MDS-UPDRS) part III (0-132); 4-Independency level: Schwab and England scale (0-100), 5-Impact 
of motor fluctuations: item 4.4 from MDS-UPDRS part IV (0-4 point scale).
Impact of  motor ﬂuctuations on daily time spent walking
220 participants were included in analysis 1. They contributed a median of 78 complete 
days of usable accelerometer data (25 Interquartile range-IQR: 60 days, 75 Interquartile 
range-IQR: 110 days), during a median of 97 days of follow-up period (25-IQR of 91 
days and 75-IQR of 188 days). On average, participants walked 72 ± 39 min per day, 
with the largest number of minutes walked occurring between 8 am and 1 pm (Figure 
6.3.). The severity of motor ﬂuctuations did not inﬂuence the mean time spent walking 
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(B = 2.4 ± 1.9, p = 0.20), whereas higher age (B = −1.3 ± 0.3, p = < 0.001) and higher 
se- verity of motor symptoms (B = −0.6 ± 0.2, p < 0.001) was associated with less time 
spent walking (model F(3216) = 14.6, p < .001, R2 = .17).
Figure 6.3. Mean time spent walking during each hour of the day (n=220). Error bars indicate standard 
error of the mean.
Impact of  ﬂuctuations on the change in time spent walking after levodopa intake
Th e post-levodopa activity was on average higher than the pre-levodopa activity in the 
morning and night, while in the afternoon and evening the post-levodopa activity was 
lower. Th e pattern of post-levodopa activity did not diff er between week or weekend 
days (Figure. 6.4. a and b). Th e severity of ﬂuctuations was not signiﬁcantly associated 
with the diff erence between pre- and post-levodopa activity (i.e. the amount of change 
in walking quantity) in any part of the day (Table 6.2.).
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Figure 6.4. 4A - Mean time spent walking per hour before (black) and after levodopa intake (white) 
on week days, presented separately for the morning (n=182, number of levodopa reports per person 
ranging from 11 to 429), afternoon (n=175, number of levodopa reports ranging from 11 to 323), 
evening (n=140, number of levodopa reports ranging from 11 to 467) and night (n=99, number of 
levodopa reports ranging from 11 to 197). 4B - Mean time spent walking per hour before (black) and 
after levodopa intake (white) on weekend days, presented separately for the morning (n=134, number 
of levodopa reports per person ranging from 11 to 170), afternoon (n=129, number of levodopa reports 
ranging from 11 to 129), evening (n=100, number of levodopa reports ranging from 11 to 180) and 
night (n=61, number of levodopa reports ranging from 11 to 72). Error bars indicate standard error of the 
mean.
Table 6.2. Adjusted impact of the severity of motor fl uctuations on post-levodopa activity (in minutes).
n B ± SE β p-value ∆R2
Morning 166 .004 ± .104 .002 .97 <.001
Afternoon 162 .156 ± .082 .074 .06 .005
Evening 134 .082 ± .044 .122 .07 .015
Night 95 .124 ± .203 .044 .54 .002
Confounders and R2 per model:
Morning: pre-levodopa activity (p = .43), mean time spent walking (p < .001); R2 = .72.
Afternoon: pre-levodopa activity (p < .001), mean time spent walking (p < .001); R2 = .77.
Evening: pre-levodopa activity (p < .001); R2 = .44.
Night: pre-levodopa activity (p = .002), mean time spent walking (p < .001), age (p=.03); R2 = .54.
DISCUSSION
Th is study presents data from the ﬁrst large-scale cohort study using wrist-worn 
accelerometry in which sensor-based passive monitoring was combined with daily 
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reports of levodopa intake. The much longer follow-up time here (up to 665 days, with 
a median follow-up of 97 days) contrasts markedly with previous studies using wearable 
sensors, where follow-up was typically limited to one week [8,13,22,23]. Our sample 
size was also large. Using this sizeable dataset, we demonstrated that the severity of motor 
ﬂuctuations did not lead to a smaller mean amount of daily walking quantity. Also, 
higher severity of motor ﬂuctuations did not cause a higher mean change in walking 
quantity in relation to levodopa intake. These ﬁndings contradict our hypothesis that 
PWP with more severe motor ﬂuctuations would be more inactive before intake of 
levodopa, as a result of wearing off. Studies in controlled settings showed that motor 
performance, which includes gait and postural transitions, is worse during off periods 
[12]. Thus, it seems reasonable that this could affect the amount of real-life walking 
quantity, both through physical limitations and through a patient’s conﬁdence in being 
active. Therefore, a careful interpretation of possible explanations for our present results 
is needed.
Our ﬁndings highlight the complexity of studying physical activity in a free-living 
environment, where little or no contextual information about participants behavior is 
known. As a reﬂection of this, large variation in the amount of activity is present both 
between patients and within patients on different days. Our study showed that the 
severity of potential ﬂuctuations around the time of levodopa intake does not explain 
a substantial proportion of this already large variation in walking quantity. On the 
one hand, this may be explained by the fact that a patient’s activity pattern is highly 
inﬂuenced by behavioral factors that are not related to the severity of symptoms. For 
example, the inﬂuence of participants’ behavior most likely explains the large increase 
in the time spent walking after levodopa intake during the night presented in Fig. 4. As 
the majority of the levodopa reports at night took place around 5 a.m., the comparison 
includes a part of the morning, with a higher number of minutes walked. On the other 
hand, our results indicate that the severity of ﬂuctuations does not have a detectable or 
consistent inﬂuence on activities around the time of levodopa intake. This is supported 
by the fact that patients in our study were on average still active before levodopa 
administration, regardless of the severity of their ﬂuctuations. It should be emphasized 
that we investigated a relatively mildly to moderately affected PD population, hence the 
generalizability to later stage PWP, who typically have more disabling ﬂuctuations [24], 
remains to be addressed.
Some limitations of this approach need to be discussed. First, the severity of ﬂuctuations 
was based on item 4.4 from the MDS-UPDRS part IV, which may be susceptible to 
inter-rater variability. However, it is a valid scale [25] and all assessors involved in this 
study received additional training for conducting the MDS-UPDRS. Using alternative 
approaches to evaluate motor ﬂuctuations, such as the Hauser dairy [26], might allow 
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for a more accurate comparison of the amount of activity between OFF and ON periods, 
particularly if ﬂuctuations are characterized by unpredictable OFF periods, dose failures 
or delayed ON periods. However, it is unlikely that these phenomena were important 
in our study sample, as these typically occur in people with more advanced PD [27]. 
Second, limitations related to compliance may have inﬂuenced the results. Because data 
related to actual wear time were not available, we cannot guarantee that all sensor data 
were collected while the participants were in fact wearing the smartwatch. To minimize 
this risk and ﬁlter out highly non-compliant participants, we have only including 
participants with a minimum amount of streamed data. In addition, we have no reason 
to believe that the proportion of non-wear data correlates with our main variable of 
interest, namely the severity of ﬂuctuations. Although the gait detection algorithm 
was only validated in a lab-based setting [17], the outcomes of both the mean walking 
quantity and the daily pattern are similar to what has been reported earlier [2,20,28]. 
Moreover, we were also able to reproduce earlier ﬁndings that age and MDS-UPDRS 
part III are determinants for the amount of activity [1,8]. These ﬁndings give us some 
conﬁdence that the gait measurements from the smartwatch data are reasonably reliable. 
Lastly, although we have no data on the accuracy or compliance with medication reports 
through the app, we believe that the medication reminders and the high compliance 
with the system usage increased the accuracy of medication reports. Despite the fact 
that our ﬁndings contradict those of a small study with a short follow-up [29], we 
posit that limitations in their data analysis (e.g. only comparing post- and pre-levodopa 
activity without assessing the inﬂuence of the severity/presence of ﬂuctuations on this 
difference, producing a result that is highly inﬂuenced by general behavioral factors) 
explain the divergence in conclusions.
A clinically relevant conclusion of our ﬁndings is that gait quantity is not a suitable 
way to capture wearing off in mild to moderately affected PWP. Instead, the use of 
gait quality features that are more responsive to levodopa [9], reﬂect changes over time 
[30], and are likely less affected by behavior, appears as a more adequate approach to 
monitor changes in gait due to motor ﬂuctuations in a real-life environment. Together 
with the role of gait quality analysis, determining optimal sensor type, sensor location 
and feature extraction for home- based monitoring still remains to be addressed. Lastly, 
in addition to exploring the role of gait quality to capture the inﬂuence of ﬂuctuations 
on walking patterns, future research into activity patterns of PWP would beneﬁt from 
a more heterogeneous PWP group and age-matched healthy controls, to be able to 
better discriminate between PD-speciﬁc and behavioral inﬂuences in activity patterns. 
Hopefully, this will lead to a better understanding of the underlying factors that have 
an impact on physical activity in PD and generate useful knowledge that can further 
contribute to the promotion of an active life-style among PWP.
Impact of  motor fluctuations on real-life gait
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In conclusion, this study showed that the severity of motor ﬂuctuations was not 
associated with the mean amount of walking quantity in PWP. Similarly, the severity 
of motor ﬂuctuations was not associated with the mean change in walking quantity 
in relation to levodopa intake. Finally, our study does not support the assessment of 
gait quantity as a suitable method to investigate the inﬂuence of motor ﬂuctuations on 
walking activity in real-life.
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SUMMARY
 
Care in Parkinson’s disease (PD) is largely based on clinical judgment of standardized 
assessments of symptom severity, disease progression, and efficacy of therapeutic 
interventions. However, high inter-rate variability and the “snapshot” nature of 
standardized clinical assessments make it difficult to capture the large variability and 
non-linear decline in PD. Therefore, the current challenge is to design a detailed, 
objective, and reliable assessment that generates knowledge about real-life functioning. 
Wearable sensors have the potential to continuously collect objective, and fine-grained 
health-related data at high frequency, which would otherwise be missed. This summary 
describes the studies in this thesis, which consider the feasibility and applicability of 
objective measurements in PD for clinical and research purposes. 
Part I. Feasibility of  large-scale deployment of  wearable sensors in large Parkin-
son’s disease cohorts
Chapter 2 describes the structured observational study protocol of  the Parkinson@
Home study, which evaluates the feasibility of  large-scale sensor deployment. We 
analysed the feasibility by investigating the system usability and compliance. For 
this purpose, the participants used a set of  sensors (smartwatch, smartphone, and 
fall detector) and a customized smartphone app (Fox Wearable Companion). We 
evaluated the disease severity with the short version of  the Parkinson’s Progression 
Markers Initiative protocol. We aimed to recruit 1000 participants with PD and 250 
physiotherapists in the Netherlands (NL) via internet communities, support groups, 
and treating therapists. We purposefully kept the enrolment criteria broad in order 
to capture the whole diversity of  PD. Thus, potential participants only had to have a 
self-reported diagnosis of  PD, possess a smartphone, and be older than 18 years. To 
optimize inclusion, we arranged for potential participants to give informed consent 
online in an easy “click-to-accept” procedure. After inclusion, the participants used 
the wearable system 24/7 for 13 weeks and self-reported their medication intake and 
symptoms via the app. A second cohort of  PD participants living in North America 
(NAM) was included so that we could investigate the feasibility in different contexts. 
The NAM cohort used the same wearable sensors, but for a minimum of  5 hours 
a day for 6 weeks. The feasibility outcomes for both cohorts included recruitment, 
attrition, compliance, and system usability. Depending on the distribution of  variables, 
the	Chi-square,	Fisher’s	exact,	or	Kruskal-Wallis	test	was	used	to	investigate	significant	
differences between the compliance groups (i.e. groups with low, middle, and high 
compliance). For this purpose, we considered the demographics, clinical characteristics, 
ability to use a smartphone, and the system usability score. In total, 953 participants 
with PD were included (NL: 304 and NAM: 649). The results of  this study, described in 
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Chapter 3, showed an enrolment rate of  88% (304 NL participants) and 51% (649 NAM 
participants). Overall, 84% (805 participants) contributed sensor data. Compliance with 
technology usage was high: 68% (16.3 hours/participant per day) of  the study period in 
NL and 62% (14.8 hours/participant per day) in NAM. Participation attrition rates were 
low, with a loss of  82 data contributors in the NL cohort (27% of  all enrolled) and 89 in 
the NAM cohort (17% of  all enrolled). Further, 13 participants (4% of  all NL enrolled 
participants) and 135 (21% of  all NAM enrolled participants) did not contribute any 
data during the study period. The attrition rates for daily accelerometer data collection 
were 23% in the NL cohort after 13 weeks, and 27% in the NAM cohort after 6 weeks. 
The feasibility scores were not affected by demographics, clinical characteristics, or 
attitude towards technology. However, the Dutch participants, who rated the system 
usability higher, were more likely to be in the group with greater compliance (χ2(2) = 
32,014, p < 0.001). In the NAM cohort, self-reported depressed patients were more 
likely to show low compliance with system usage (χ2(2) = 6397, p = 0.04).
Take-home messages: 
1.  It is feasible to deploy multiple wearable sensors across large PD populations.
2.  Neither demographic nor clinical characteristics hamper wearable sensor 
usage
Part II. Applicability of  objective measurements for answering clinical and rese-
arch-relevant questions: wearable sensors for quantifying gait and falls
Validity of  wearable sensors for quantifying freezing of  gait and falls 
In Chapter 4, I address the lack of consensus about the appropriate methodologies 
for freezing of gait (FOG) and fall detection with a systematic review of the use of 
wearable systems for assessing FOG and falls in PD. We searched the PubMed and Web 
of Science databases using a list of relevant key words and MeSH terms. The final search 
was completed in January 2017, and we selected articles with a set of eligibility criteria. 
Of the total of 27 articles selected, 23 related to FOG and 4 to falls. The FOG studies 
took place either in laboratory (total of 20) or home settings (total of 3), with sample 
sizes ranging from 1 to 48 patients with PD; the Hoehn and Yahr stages ranged from 
2 to 4. The shin was the most common sensor location, and an accelerometer was the 
most frequently used sensor type. Validity measurements ranged from 73 to 100% for 
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sensitivity and 67 to100% for specificity. All the fall and fall-risk-related studies were 
home based. The samples sizes were 1 to 107 patients with PD, and most used one 
sensor containing accelerometers, worn at various body locations. 
Take-home messages:
1.  Sensor-based FOG assessments performed in standardized settings are well 
validated.
2.  Sensor-based fall risk assessments are a promising application of objective 
measurements for fall monitoring.
3.  Despite the promising validation initiatives currently reported, the studies 
retrieved had relatively small sample sizes, with significant variability in 
outcomes measured and results reported.
4.  The field of wearable sensors for Parkinson’s disease would benefit from 
more focused research efforts, increased collaboration among researchers, 
aligned data-collection protocols, and shared data sets.
The applicability of  objective measurements for answering research questions
In Chapter 5, I approach falls, one of the most serious clinical PD problems, by using 
wearable sensors to quantify the hazard ratio of falls of patients with PD in daily life. In 
this study, we analysed prospective data from a cohort of elderly people who subscribed 
to an emergency response program with automatic fall detection in a device worn 
as a necklace. First, we selected all 2,063 participants with self-reported PD. Using 
demographic characteristics, we randomly extracted a matched control group of 2,063 
people who did not report PD. Fall events were either collected automatically by the fall 
detector necklace or registered by a button push on the same device. We extracted fall 
events from a 2.5-year window with an average follow-up of 1.1 years. All falls included 
were confirmed immediately by a subsequent telephone call. The main outcomes in this 
study were: (1) the incidence rate of any fall, (2) the incidence rate of a new fall after 
enrolment (i.e. hazard ratio), and (3) one-year cumulative incidence of falling. We used 
descriptive analysis to report the incidence rate of falling for both participants with 
PD and controls. We used t-tests (continuous variables) or chi-square tests (categorical 
variables) to determine between-group differences. We assessed the association of PD 
with the incidence rate of any fall using ANOVA model, with PD status, age, gender, 
and the number of medical conditions as independent predictors and the number of 
falls as the dependent variable (significance at p < 0.05). Using the previously built 
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model, we added two-way and three-way interaction terms for age, gender, or age x 
gender with PD in separate sensitivity analyses. We investigated the association of PD 
with the incidence rate of a new fall after enrolment using Cox regression models, with 
PD status, age, gender, and the number of medical conditions as independent predictors 
and first fall (yes/no) was entered as the dependent variable. Then we used Kaplan-
Meier survival analysis to assess the cumulative incidence of a new fall after enrollment 
during a 1-year follow-up for both PD and controls. The results revealed that 29.6% 
(610 patients with PD) were recurrent fallers versus 14.5% (300 controls; p < 0.0001). 
Recurrent fallers with PD also showed a higher rate of falls resulting in emergency 
transport (2.2% or 45 participants with PD and 1.4%, 28 people in the control group). 
The incidence rate of any fall was greater among the patients with PD (2.1 falls/person-
years) than controls (0.7 falls/person-years; p < 0.0001). Moreover, the incidence rate 
of a new fall after enrolment (i.e. hazard ratio) was 1.8 times greater for patients with 
PD than for controls (95% confidence interval: 1.6–2.0). The hazard ratio was not 
influenced by the two-way interaction of age and PD (p = 0.6), gender, or PD (p = 0.2), 
or the three-way interaction of age, gender, and PD (p = 0.9).  More patients with PD 
(48.8%) than controls (29.5%) became fallers during 1 year of follow-up (p < 0.0001). 
Take-home messages:
1.  PD is a “falling disease”, so dedicated strategies for preventing falls are 
extremely important. 
2. Wearable sensors are feasible for monitoring falls in daily life. 
3.  Data from wearable sensors are feasible for answering research-related 
questions.
The applicability of  objective measurements for answering clinically relevant questions
Chapter 6 investigates whether the severity of motor ﬂuctuations was associated with 
sensor-derived average time spent walking per day. Here I also examine whether the 
severity of motor ﬂuctuations was associated with a change in sensor-derived time 
spent walking after levodopa intake. The 304 Dutch participants with PD from the 
Parkinson@Home study were included in this study. At baseline, all participants were 
clinically examined. During the follow-up period (median: 97 days; 25-interquartile 
range: 91 days, 75-interquartile range: 188 days), the participants used the Fox Wearable 
Companion app and streamed smartwatch accelerometer data to a cloud platform. We 
assessed the first research question with linear regression on the sensor-derived mean time 
spent walking per day with the severity of motor ﬂuctuations (item 4.4 of the Movement 
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Disorder Society - Unified Parkinson’s Disease Rating Scale) as an independent variable, 
controlled for age and motor performance (MDS-UPDRS part III score). We assessed 
the second research question with linear regression on the sensor-derived mean post-
levodopa time spent walking, with the sensor-derived mean pre-levodopa time spent 
walking and severity of ﬂuctuations as independent variables, controlled for mean time 
spent walking per day, age, and motor performance (MDS-UPDRS part III score). The 
results showed that participants with PD spent most of their walking time between 8 
am and 1pm, totalling 72 ± 39 (mean ± standard deviation) minutes of walking per day. 
The severity of motor ﬂuctuations did not inﬂuence the mean time spent walking (B 
= 2.4 ± 1.9, p = 0.20), but greater age (B = −1.3 ± 0.3, p = 0.001) and greater severity 
of motor symptoms (B = −0.6 ± 0.2, p < 0.001) were associated with less time spent 
walking (F(3216) = 14.6, p < 0.001, R2 = 0.17). The severity of ﬂuctuations was not 
associated with the change in time spent walking in relation to levodopa intake in any 
part of the day. Analysis of sensor-derived gait quantity suggested that the severity of 
motor ﬂuctuations was not associated with changes in daily-life walking patterns of 
people who are mildly to moderately affected by PD.
Take-home messages:
1.  Wearable sensors are a useful tool for answering clinical relevant research 
questions.
2.  Gait quality, instead of gait quantity, may be a better outcome to investigate 
gait-related impairment and motor fluctuations in Parkinson’s disease.
Conclusion
Taken together, the results of the studies included in this thesis emphasise the feasibility 
of using wearable sensors to monitor PD-related symptoms in daily life. Data collected 
with wearable sensors over long-term follow-up can improve the care provided to 
patients with PD and accelerate research.
Chapter 7
150
Samenvatting
151
Ch
ap
te
r 
7
SAMENVATTING
Zorg voor de ziekte van Parkinson (ZvP) is grotendeels gebaseerd op klinische beoordeling 
van gestandaardiseerde metingen van de ernst van symptomen, ziekteprogressie en 
werkzaamheid van therapeutische interventies. Hoge interbeoordelaar-variabiliteit en 
het feit dat gestandaardiseerde klinische beoordelingen een momentopname zijn van 
de werkelijkheid maken het echter moeilijk om de grote variabiliteit en niet-lineaire 
achteruitgang bij de ZvP vast te leggen. Om deze reden is de huidige uitdaging om een 
gedetailleerde, objectieve en betrouwbare methode te ontwerpen die kennis genereert 
over het dagelijkse functioneren. Draagbare sensoren hebben de potentie om continu 
objectieve en nauwkeurige gezondheidsgerelateerde gegevens te verzamelen met een hoge 
frequentie, die anders zouden worden gemist. Deze samenvatting beschrijft de studies 
in dit proefschrift, waarin de haalbaarheid en toepasbaarheid van objectieve metingen 
bij de ZvP voor klinische- en onderzoeksdoeleinden in beschouwing worden genomen. 
Deel I. Haalbaarheid van grootschalige inzet van draagbare sensoren in grote 
cohorten van mensen met de ziekte van Parkinson
Hoofdstuk 2 beschrijft het gestructureerde observationele studieprotocol van 
de ParkinsonThuis studie, die de haalbaarheid evalueert van grootschalige 
sensorimplementatie. We hebben de haalbaarheid geanalyseerd door het onderzoeken 
van de gebruiksvriendelijkheid en de compliance met het gebruik van de sensoren. Voor 
dit doel hebben de deelnemers een reeks sensoren gebruikt (smartwatch, smartphone en 
valdetector) en een op maat gemaakte smartphone app (Fox Wearable Companion). We 
hebben de ernst van de ziekte beoordeeld met behulp van de korte versie van het protocol 
van het ‘Parkinson’s Progression Markers Initiative’. Ons doel was om 1000 patiënten met 
de ZvP en 250 fysiotherapeuten in Nederland te werven via internetgemeenschappen, 
steungroepen en behandelende therapeuten. We hebben de inclusiecriteria bewust 
breed gehouden om de volledige diversiteit van de ZvP te vangen. Hiervoor hoefden 
potentiële deelnemers enkel een zelfgerapporteerde diagnose van de ZvP te hebben, 
in het bezit te zijn van een smartphone en ouder te zijn dan 18 jaar. Om de inclusie te 
optimaliseren, hebben we ervoor gezorgd dat potentiële deelnemers online informed 
consent konden geven met behulp van een eenvoudige “click-to-accept” procedure. 
Na inclusie hebben de deelnemers het draagbare system 24 uur per dag gedurende 
13 weken gebruikt en zelf  hun medicatie-inname en symptomen gerapporteerd via 
de app. Een tweede cohort van deelnemers met de ZvP wonend in Noord-Amerika 
(NAM) werd geïncludeerd zodat we de haalbaarheid in verschillende contexten konden 
onderzoeken. Het NAM-cohort gebruikte dezelfde draagbare sensoren, maar voor een 
minimum van 5 uur per dag gedurende 6 weken. De haalbaarheidsuitkomsten voor 
beide cohorten waren werving, uitvalspercentages, compliance met het gebruik van de 
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sensoren en gebruiksvriendelijkheid van het systeem. Ook hebben wij gekeken in welke 
mate	compliance	wordt	beïnvloed	door	demografische	gegevens,	klinische	kenmerken,	
het vermogen om een smartphone te gebruiken en de gebruiksvriendelijkheidsscore 
van het systeem. Afhankelijk van de verdeling van variabelen werd de Chi-kwadraat, 
Fisher’s	exact	of 	Kruskal-Wallis	test	gebruikt	om	significante	verschillen	te	onderzoeken	
tussen drie groepen: deelnemers met een lage, gemiddelde compliance, uitgedrukt in 
het percentage van de tijd dat sensorgegevens werden verzameld. In totaal zijn er 953 
patiënten met de ZvP geïncludeerd (Nederland: 304 en NAM: 649). De resultaten 
van deze studie, beschreven in Hoofdstuk 3, laten een inclusiepercentage van 88% 
(304 Nederlandse deelnemers) en 51% (649 Amerikaanse deelnemers) zien. In totaal 
heeft 84% (805 deelnemers) sensorgegevens bijgedragen. De compliance met het 
gebruik van de sensoren was hoog: 68% (16.3 uur per deelnemer per dag) tijdens de 
onderzoeksperiode in Nederland en 62% (14.8 uur per deelnemer per dag) in NAM. 
Uitvalspercentages waren laag, met uitval van 82 deelnemers in het Nederlandse cohort 
(27% van alle deelnemers die sensorgegevens hebben bijgedragen) en 89 in het NAM 
cohort (17% van alle deelnemers die sensorgegevens hebben bijgedragen). Verder 
hebben 13 deelnemers (4% van alle Nederlandse geïncludeerde deelnemers) en 135 
deelnemers (21% van alle geïncludeerde deelnemers uit NAM) geen enkele gegevens 
bijgedragen tijdens de studieperiode. Het percentage van de tijd dat sensorgegevens 
werden verzameld nam af  met 23% in het Nederlandse cohort na 13 weken en 27% in 
het	NAM	cohort	na	6	weken.	De	compliance	werd	niet	beïnvloed	door	demografische	
gegevens, klinische kenmerken of  houding ten aanzien van technologie. De Nederlandse 
deelnemers, die de gebruiksvriendelijkheid van het systeem hoger beoordeelden, hadden 
echter meer kans om deel uit te maken van de groep met hogere compliance (χ2 (2) = 
32,014, p < 0.001). In het NAM cohort hadden mensen met een zelfgerapporteerde 
depressie meer kans om deel uit te maken van de groep met een lagere compliance (χ2 
(2) = 6397, p = 0.04).
Take-home messages:
1.  Het is haalbaar om meerdere draagbare sensoren in te zetten in grote 
populaties van mensen met de ziekte van Parkinson.
2.  Noch demografische, noch klinische kenmerken belemmeren het gebruik 
van draagbare sensoren. 
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Deel II. Toepasbaarheid van objectieve metingen voor het beantwoorden van 
klinische en onderzoeks-relevante vragen: draagbare sensoren voor het kwantifi-
ceren van lopen en vallen.
Validiteit van draagbare sensoren voor het kwantificeren van freezing of  gait en vallen
In hoofdstuk 4 behandel ik het gebrek aan consensus over geschikte methoden voor 
freezing of gait (FOG) en valdetectie met een systematische review over het gebruik van 
draagbare systemen voor het beoordelen van FOG en vallen bij de ZvP. We hebben de 
PubMed- en Web of Science databases doorzocht met behulp van een lijst met relevante 
trefwoorden en MeSH termen. De laatste zoekopdracht werd in januari 2017 voltooid 
en we hebben artikelen geselecteerd aan de hand van een aantal criteria. Van de in 
totaal 27 geselecteerde artikelen waren er 23 gerelateerd aan FOG en 4 aan vallen. De 
FOG studies vonden plaats in het laboratorium (in totaal 20) of thuis (in totaal 3), met 
steekproefgroottes variërend van 1 tot 48 patiënten met de ZvP; de Hoehn en Yahr 
stadia varieerden van 2 tot 4. Het scheenbeen was de meest voorkomende sensorlocatie 
en de accelerometer was het meest gebruikte sensortype. Validiteitsmetingen varieerden 
van 73 tot 100 procent voor sensitiviteit en van 67 tot 100 procent voor specificiteit. 
Alle val- en valrisico gerelateerde studies werden thuis uitgevoerd. De steekproeven 
waren 1 tot 107 patiënten met de ZvP en de meeste studies gebruikten één sensor met 
accelerometers, gedragen op verschillende lichaamslocaties. 
  
Take-home messages:
1.  Op sensoren gebaseerde FOG beoordelingen uitgevoerd in 
gestandaardiseerde omgevingen zijn goed gevalideerd.
2.  Op sensoren gebaseerde valrisicobeoordelingen zijn een veelbelovende 
toepassing met objectieve metingen voor het monitoren van vallen. 
3.  Ondanks de veelbelovende validatie-initiatieven die momenteel 
zijn gerapporteerd, hadden de geïncludeerde studies relatief kleine 
steekproefgrootten met significante variabiliteit in gemeten uitkomstmaten 
en gerapporteerde resultaten.
4.  Het werkveld van draagbare sensoren voor de ziekte van Parkinson 
zou baat hebben bij meer gerichte onderzoeksinspanningen, meer 
samenwerking tussen onderzoekers, onderling afgestemde protocollen voor 
dataverzameling en gedeelde datasets.
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De toepasbaarheid van objectieve metingen voor het beantwoorden van onderzoeksvragen
In hoofdstuk 5 behandel ik vallen, één van de ernstigste klinische problemen gerelateerd 
aan de ZvP, door gebruik te maken van draagbare sensoren om het valrisico van 
patiënten met de ZvP in het dagelijks leven te kwantificeren. In deze studie hebben 
we prospectieve gegevens geanalyseerd van een cohort van ouderen die zich hadden 
ingeschreven voor een noodresponsprogramma met automatische valdetectie in een 
apparaat dat werd gedragen als ketting. Eerst hebben we alle 2063 deelnemers geselecteerd 
met zelfgerapporteerde ZvP. Gebruik makend van demografische kenmerken hebben we 
willekeurig een gematchte controlegroep van 2063 mensen geëxtraheerd die geen ZvP 
rapporteerden. Valgebeurtenissen werden of automatisch verzameld door de valdetector 
in de ketting of geregistreerd door een druk op de knop op hetzelfde apparaat. We 
hebben valgebeurtenissen geëxtraheerd uit een periode van 2,5 jaar met een gemiddelde 
follow-up van 1,1 jaar. Alle valgebeurtenissen werden onmiddellijk bevestigd door 
middel van een hierop volgend telefoongesprek. De belangrijkste uitkomstmaten in 
deze studie waren: (1) de incidentie van valincidenten, (2) de incidentie van nieuw 
valincidenten na de inclusie (hazard ratio), en (3) de cumulatieve incidentie van vallen 
een jaar na de inclusie. We hebben beschrijvende statistiek gebruikt om de valincidentie 
te rapporteren voor zowel deelnemers met de ZvP als controle deelnemers. We hebben 
t-tests (continue variabelen) of Chikwadraattests (categorische variabelen) gebruikt 
om de verschillen tussen groepen te bepalen. We beoordeelden de associatie tussen de 
ZvP en de valincidentie met behulp van het ANOVA-model, met ZvP-status, leeftijd, 
geslacht en het aantal medische aandoeningen als onafhankelijke voorspellers en het 
aantal valgebeurtenissen als de afhankelijke variabele (significantie bij p < 0.05). Met 
behulp van het eerder gebouwde model hebben we aan de aanwezigheid van de ZvP 
tweezijdige en driezijdige interactietermen toegevoegd voor leeftijd, geslacht of leeftijd x 
geslacht in afzonderlijke sensitiviteitsanalyses. We onderzochten de associatie tussen de 
ZvP en nieuw valincidenten na het inclusie met behulp van Cox-regressiemodellen, met 
de ZvP-status, leeftijd, geslacht en het aantal medische aandoeningen als onafhankelijke 
voorspellers en de eerste val (ja/nee) werd ingevoerd als de afhankelijke variabele. 
Vervolgens hebben we Kaplan-Meier survivalanalyse gebruikt om de cumulatieve 
incidentie een nieuw  valincidenten na het inclusie te beoordelen gedurende een follow-
up van 1 jaar voor zowel mensen met de ZvP als controles. De resultaten lieten zien dat 
29.6% (610 patiënten met de ZvP) herhaaldelijk vielen versus 14.5% (300 controles; 
p < 0.0001).  Mensen met de ZvP die herhaaldelijk vielen vertoonden ook vaker 
valgebeurtenissen die resulteerden in spoedeisend transport (2.2% van 45 deelnemers 
met de ZvP en 1.4%, 28 mensen in de controlegroep). De valincidentie was groter bij de 
patiënten met de ZvP (2.1 valgebeurtenissen per jaar per persoon) dan bij de controles 
(0.7 valgebeurtenissen per jaar per persoon; p < 0.0001). Bovendien was de incidentie 
van nieuw  valincidenten  na het inclusie1.8 keer groter voor patiënten met de ZvP dan 
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voor controles (95% betrouwbaarheidsinterval: 1.6-2.0). De hazard ratio voor vallen 
werd niet beïnvloed door de tweezijdige interactie van leeftijd en de ZvP (p = 0.6), 
geslacht of de ZvP (p = 0.2), of de driezijdige interactie van leeftijd, geslacht en de ZvP 
(p = 0.9). Meer patiënten met de ZvP (48.8%) dan controles (29.5%) gingen vallen 
gedurende 1 jaar follow-up (p < 0.0001).
Take-home messages:
1.  De ZvP is een “valziekte”, dus speciale strategieën om valpartijen te 
voorkoen zijn uiterst belangrijk.
2.  Draagbare sensoren zijn haalbaar voor het monitoren van vallen in het 
dagelijks leven. 
3.  Gegevens van draagbare sensoren zijn haalbaar voor het beantwoorden van 
onderzoeksgerelateerde vragen.
De toepasbaarheid van objectieve metingen voor het beantwoorden van klinisch rele-
vante vragen 
Hoofdstuk 6 onderzoekt of de ernst van motorische fluctuaties geassocieerd is met de 
tijd die mensen lopen per dag, gemeten met een draagbare sensor. Ook onderzoek ik 
hier of de ernst van motorische fluctuaties geassocieerd was met de verandering in de 
tijd die mensen lopen na inname van levodopa. De 304 Nederlandse deelnemers met 
de ZvP van de ParkinsonThuis studie werden geïncludeerd in deze studie. Bij de start 
van de studie werden alle deelnemers klinisch onderzocht. Tijdens de follow-up periode 
(mediaan: 97 dagen, interkwartielbereik: 91-188 dagen), gebruikten de deelnemers 
de Fox Wearable Companion-app en streamden ze de accelerometergegevens van de 
smartwatch naar een cloudplatform. We beoordeelden de eerste onderzoeksvraag met 
lineaire regressie op de gemiddelde tijd besteed aan lopen per dag, gemeten met de 
sensor, met de ernst van motorische fluctuaties (item 4.4 van de Movement Disorder 
Society - Unified Parkinson’s Disease Rating Scale) als een onafhankelijke variabele, 
gecontroleerd voor leeftijd en motorische symptomen (MDS-UPDRS deel III score). 
We beoordeelden de tweede onderzoeksvraag met lineaire regressie op de gemiddelde 
tijd besteed aan lopen na levodopa inname, met de gemiddelde tijd besteed aan lopen 
voor levodopa inname en de ernst van de fluctuaties als onafhankelijke variabelen, 
gecontroleerd voor de gemiddelde tijd besteed aan lopen per dag, leeftijd en motorische 
symptomen (MDS-UPDRS deel III score). Uit de resultaten bleek dat deelnemers 
Chapter 7
156
met de ZvP in totaal 72 ± 39 (gemiddelde ± standaardafwijking) minuten lopen per 
dag, waarvan het grootste deel tussen 8:00 uur en 13:00 uur. De ernst van motorische 
fluctuaties had geen invloed op de gemiddelde looptijd (B = 2,4 ± 1,9, p = 0,20), maar 
een hogere leeftijd (B = -1,3 ± 0,3, p = 0,001) en ernstigere motorische symptomen (B = 
-0,6 ± 0,2, p <0,001) waren geassocieerd met minder tijd die werd besteed aan lopen (F 
(3216) = 14,6, p <0,001, R2 = 0,17). De ernst van fluctuaties was niet geassocieerd met 
de verandering in tijd die werd besteed aan lopen na levodopa-inname op enig moment 
van de dag. Analyse van de sensor afkomstige loopkwantiteit suggereerde dat de ernst 
van motorische fluctuaties niet geassocieerd was met veranderingen in tijd besteed aan 
lopen in het dagelijks leven van mensen die licht tot matig zijn aangedaan door de ZvP.
Take-home messages:
1.  Draagbare sensoren zijn een bruikbaar hulpmiddel voor het beantwoorden 
van klinisch relevante onderzoeksvragen.
2.  Loopkwaliteit, in plaats van loopkwantiteit, kan een betere uitkomst zijn 
om aan lopen gerelateerde stoornissen en motorische fluctuaties bij de 
ziekte van Parkinson te onderzoeken
Conclusie
Samenvattend benadrukken de resultaten van de studies in dit proefschrift de 
haalbaarheid van het gebruik van draagbare sensoren om symptomen gerelateerd aan de 
ZvP in het dagelijks leven te monitoren. Gegevens verzameld met draagbare sensoren 
over langdurige perioden van follow-up kunnen de zorg voor mensen met de ZvP 
verbeteren en onderzoek versnellen.
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RESUMO 
O tratamento clínico utilizado na doença de Parkinson (DP) é amplamente baseado 
no uso de escalas clínicas com o intúito de avaliar a intensidade dos sintomas e sua a 
progressão,	bem	como	a	eficácia	de	intervenções	terapêuticas. No	entanto,	limitações	
no	 nível	 de	 confiança	 entre	 avaliadores	 e	 a	 natureza	 “momentânea”	 das	 avaliações	
tornam difícil capturar a grande variabilidade dos sintomas e o declínio não-linear visto 
na DP. Portanto,	o	desafio	atualmente	é	criar	uma	forma	de	avaliação	que	seja	detalhada,	
objetiva	e	confiável,	permitindo	um	mapeamento	detalhado	dos	sintomas	e	atividades	
funcionais	das	pessoas	com	DP	no	dia-a-dia.	Sensores	vestíveis	e	portáties	(do	inglês:	
wearable sensors) têm o potencial de coletar informação de uma maneira continua 
e detalhada, que, de outra forma, não seria observada fora da clínica médica. Neste 
capítulo,	um	resumo	dos	estudos	discutidos	nesta	tese	será	apresentado.	Estes	estudos	
tiveram como objetivo investigar a viabilidade e aplicabilidade de sensores vestíveis e 
portáteis	na	coleta	dados	sobre	sintomas	e	funcionamento	motor	de	pessoas	com	DP	
fora da clínica médica. 
Parte I. Viabilidade da implantação em larga escala de sensores vestíveis e 
portáteis para coletar dados clínicos na doença de Parkinson 
 
O Capítulo 2 descreve o protocolo do estudo observacional entitulado: Parkinson@
Home. Este estudo teve como objetivo avaliar a viabilidade do uso de sensores 
vestíveis e portateis em um grupo de pessoas com DP (i.e. larga escala). Para isso, 
os participantes incluídos no estudo utilizaram um conjunto de sensores vestíveis 
e	 portáties	 (smartwatch, smartphone e sensor de quedas) e um aplicativo para 
smartphone (Fox Wearable Companion). Todos os participantes se submeteram a uma 
avaliação	clínica	usando	uma	versão	 simplificada	do	protocolo	usado	no	Parkinson’s	
Progression Markers Initiative. O projeto de pesquisa teve como meta recrutar 1000 
participantes	com	DP	e	250	fisioterapeutas	vivendo	na	Holanda	(NL).	O	recrutamento	
foi feito através de comunidades na Internet, grupos de apoio à pessoas com DP e 
através	dos	fisioterapeutas	da	rede	ParkinsonNET.	Poucos	critérios	de	inclusão	foram	
usados,	afim	de	capturar	toda	a	diversidade	presente	na	DP. Estes foram: diagnóstico 
de	DP	(confirmado	pelo	participante),	possuir	um smartphone e ter mais de 18 anos. 
Para otimizar a inclusão, o termo de consentimento livre e esclarecido foi assinado 
digitalmente.	Após	a	inclusão,	os	participantes	usaram	os	sensores	vestíveis	e	portáteis	
por 24 horas, sete dias por semana, por 13 semanas, bem como registraram digitalmente 
a medicação e sintomas vivenciados nestas 13 semanas através do aplicativo  Fox 
Wearable Companion. Uma segunda coorte de participantes com DP vivendo na 
América do Norte  (NAM) foi incluída para que pudéssemos investigar a viabilidade 
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do	uso	do	sensores	vestíveis	e	portáties	em	diferentes	contextos	(i.e.	diferente	cultura	
e sistema de saúde). A	coorte	NAM	usou	 os	mesmos	 sensores	 vestíveis	 e	 portáteis	
descritos anteriormente, mas por um mínimo de 5 horas por dia durante 6 semanas. 
Para	medir	a	viabilidade	da	implementação	dos	sensores	vestívies	portáties	em	ambos	
os grupos utilizamos os seguintes indicadores: porcentagem de participantes incluídos, 
porcentagem de dados perdidos durante a coleta, e a pontuação na escala de usabilidade. 
Dependendo	 da	 distribuição	 das	 variáveis	 (i.e	 parametrica	 ou	 não-paramétrica),	 os	
testes estatísticos Qui-quadrado, exato de Fisher ou de Kruskal- Wallis foram usados 
para	investigar	diferenças	significativas	em:	1-	caracteristicas	demográficas,	2-	clínicas,	
3- capacidade de usar um smartphone, e 3- pontuação na escala de usabilidade entre 
os 3 grupos de adesão ao uso dos sensores (i.e. baixa, média e alta adesão). Um total 
de 953 participantes com DP foram incluídos (NL: 304 e NAM: 649) neste estudo. 
Os resultados, descritos no Capítulo 3, mostram uma taxa de inclusão de 88% (304 
participantes NL) e 51% (649 participantes NAM) dos participantes abordados para o 
estudo. A adesão ao uso do sistema foi alta: 68% (16,3 horas / participante por dia) do 
período de estudo em NL e 62% (14,8 horas / participante por dia) em NAM. As taxas 
de atrito na participação foram baixas, com uma perda de 82 participantes na coorte de 
NL (27% de todos os inscritos) e 89 na coorte de NAM (17% de todos os inscritos). 
Além disso, 13 participantes (4% de todos os participantes inscritos no NL) e 135 
(21% de todos os participantes inscritos no NAM) nunca usaram o sistema durante o 
período do estudo. As taxas de atrito na quantitade de dados coletados pelos sensores 
foram baixas, com 23% na coorte NL após 13 semanas e 27% na coorte NAM após 6 
semanas. A adesão	ao	uso	do	sistema	não	foi	afetada	por	características	demograficas,	
clínicas ou atitude em relação à tecnologia, mas pela pontuação dada pelos participantes 
ao sistema na escala de usabilidade. Os participantes holandeses que avaliaram o sistema 
com notas mais alta, foram mais propensos a estar no grupo com alta adesão ao uso 
do sistema (χ2 (2) = 32,014, p <0,001). Na	coorte	NAM,	pacientes	que	se	classificaram	
como deprimidos foram mais propensos a estar no grupo com baixa adesão ao uso do 
sistema (χ2 (2) = 6397, p = 0,04). 
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Conclusões: 
1.  É viável o uso de sensores vestíveis e portáteis em grandes grupos de pessoas 
com DP. 
2.  O uso de sensores vestíveis e portáteis por pessoas com DP não é prejudicado 
por diferença socioeconomicas ou nível dos sintomas da DP.
Parte II. Aplicabilidade de medidas objetivas para responder questões clínicas 
e relevantes para pesquisa: sensores vestíveis e portáties para avaliações da 
marcha e quedas 
 
Validade de sensores vestíveis e portáteis para avaliar freezing e quedas 
O	Capítulo	 4	 aborda	 com	 uma	 revisão	 sistemática	 a	 falta	 de	 consenso	 sobre	 quais	
metodologias	são	apropriadas	quando	se	utiliza	sensores	vestíveis	e	portáties	para	avaliar	
freezing (FOG) e detectar quedas em pessoas com DP. Nós pesquisamos os bancos de 
dados PubMed e Web of  Science usando uma lista de palavras-chaves e termos MeSH. 
A	busca	final	foi	concluída	em	janeiro	de	2017	e	os	artigos	foram	selicionados	de	acordo	
com um conjunto de critérios de inclusão. Do total de 27 artigos selecionados, 23 eram 
relacionados	ao	uso	de	sensores	vestíveis	e	portáties	para	avaliar	FOG	e	4	para	detectar	
quedas. Os estudos voltados para avaliação de FOG foram conduzidos em ambientes 
controlados (i.e. laboratório ou hospital) (total de 20) ou no domicílio da pessoa com 
DP (total de 3). Tamanhos amostrais variaram de 1 a 48 pessoas com DP; enquanto 
que os estágios	de Hoehn e Yahr das pessoas com DP variavam de 2 a 4. A perna foi a 
localização mais comum para a colocação dos sensores, enquanto que o acelerômetro 
foi o tipo de sensor mais usado. A validade dos algoritimos para avaliar FOG variaram 
de	73	a	100%	para	 sensibilidade	e	67	a	100%	para	especificidade. Todos os estudos 
relacionados a queda e risco de queda foram realizados no domicílio da pessoa com DP. 
Os tamanhos amostrais variaram de 1 a 107 pessoas com DP, e a maioria utilizou um 
sensor contendo acelerômetros colocados  em diversas partes do corpo dos participantes. 
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Conclusões:
1.  O uso de sensores vestíveis portáties para avaliar FOG em ambientes 
controlados está validado.
2.  Avaliar risco de quedas é uma aplicação promissora para o uso de sensores 
vestíveis portáties por pessoas com DP. 
3.  Apesar das iniciativas promissoras, os estudos em que sensores vestíveis 
portáteis foram utilizados ainda precisam de amostras maiores e 
uniformidade nos parametros utilizados para avaliar o uso destes sensores.
4.  Pesquisas com sensores vestíveis portáteis para avaliar FOG e quedas seriam 
beneficiadas se um consenso no uso dos sensores e nos protocolos de 
pesquisa fosse alcançado. Colaboração entre diferentes grupos de pesquisa 
também beneficiaria e acelararia pesquisas involvendo sensores.
Utilidade dos dados coletados com sensores vestíveis e portáties para pesquisa clínica 
No Capítulo 5, um dos problemas clínicos mais sérios enfrentado por pessoas com DP 
é abordado. Nesse capítulo eu descrevo os resultados do uso de sensores vestíveis e 
portáties	para	quantificar	o	risco	de	quedas	de	pacientes	com	DP	na	vida	diária. Neste 
estudo, nós analisamos dados prospectivos de idosos que eram clientes de um programa 
pago	de	resposta	a	emergências	no	qual	detecção	de	quedas	é	automática	realizada	por	
um sensor vestível no formato de um colar. Primeiramente, selecionamos todos os 2063 
participantes que relataram ter a DP. Usando	características	demográficas,	 extraímos	
aleatoriamente um grupo controle no qual 2063 outras pessoas que participam do 
programa mas não relataram PD foram incluídas. Cada episódio de queda foi coletado 
automaticamente pelo detector de quedas ou registrados por meio da ativação de um 
botão	incluído	no	sensor	vestível	portátil	e	gravado	num	banco	de	dados.	O	número	de	
quedas for extraído de uma janela de 2,5 anos no banco de dados, no qual o tempo médio 
de acompanhamento foi de 1,1 anos. Todas	 as	 quedas	 incluídas	 foram	 confirmadas	
imediatamente por uma ligação telefônica. Os principais resultados deste estudo 
incluíram:	(1)	incidência	de	qualquer	queda	durante	o	estudo,	(2)	incidência	da	primeira	
queda	após	a	inclusão	no	estudo	e	(3)	incidência	cumulativa	de	quedas	no	primeiro	ano	
de estudo. A	incidência	de	qualquer	queda	para	o	grupo	controle	e	o	grupo	com	DP	foi	
analisada usando estatística descritiva. Utilizamos testes-t (para	variáveis	 contínuas) ou 
testes	qui-quadrado	(para	variáveis	 categóricas) para investigar possíveis diferenças entre 
os grupos. Avaliamos	a	associação	da	DP	com	a	taxa	de	incidência	de	queda	usando	o	
modelo	ANOVA,	com	a	presença	da	DP,	idade,	gênero	e	número	de	condições	médicas	
como	 preditores	 independentes	 e	 o	 número	 de	 quedas	 como	 variável	 dependente	
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(significância	em p <0,05). Adicionamos ao modelo construído anteriormente termos 
de	interação	bidirecionais	(idade	versus	gênero)	e	tridirecionais	(	 idade	versus	gênero	
versus	presença	da	PD	)	para	análises	subsequentes.	Investigamos	a	associação	da	DP	
com	a	taxa	de	incidência	de	uma	nova	queda	após	a	inclusão	no	estudo	usando	modelos	
de	 regressão	de	Cox,	 com	presença	da	DP,	 idade,	 gênero	 e	o	número	de	 condições	
médicas	como	preditores	independentes	e	queda	(sim/não)	foi	inserida	como	variável	
dependente. Em	seguida,	utilizamos	a	análise	de	sobrevida	de	Kaplan-Meier	para	avaliar	
a	 incidência	 cumulativa	de	uma	nova	queda	após	a	 inclusão	no	estudo,	 tanto	para	o	
grupo de pessoas com DP quanto para os controles. Os resultados revelaram que 29,6% 
(610 pessoas com DP) sofriam de quedas recorrentes versus 14,5% (300 controles; p 
<0,0001). Pessoas com DP que sofriam com quedas recorrentes mostraram uma taxa 
maior	de	quedas	que	resultaram	em	transporte	de	emergência	(2,2%	ou	45	pessoas	com	
DP e 1,4%, 28 pessoas no grupo controle). A	taxa	de	incidência	de	qualquer	queda	foi	
maior entre pessoas com DP (2,1 quedas/ano por pessoa) do que os controles (0,7 
quedas/ano por pessoa; p <0,0001). Além	disso,	a	taxa	de	incidência	da	uma	nova	queda	
após inclusão no estudo foi 1,8 vezes maior entre pessoa com DP do que entre pessoas 
do	grupo	controle	(intervalo	de	confiança	de	95%:	1,6	a	2,0). A incidencia de uma nova 
queda	após	inclusão	no	estudo	não	foi	influenciada	pela	interação	entre	idade	e	DP	( 
p =	0,6),	gênero	e	DP	( p =	0,2),	ou	a	interação	entre	idade,	gênero	e	DP	( p = 0,9). 
Um número maior de pacientes com DP (48,8%) que controles (29,5%) apresentaram 
quedas	no	final	do	primeiro	ano	de	acompanhamento	( p <0,0001). 
Conclusões:
1.  Quedas são um problema importante em DP. Portanto, estratégias 
dedicadas à prevenção de quedas são extremamente importantes.  
2. Sensores vestíveis portáteis são viáveis para monitorar quedas. 
3.  Dados coletados usando sensores vestíveis portáties são útéis para pesquisa. 
Utilidade dos dados coletados com sensores vestíveis e portáties para prátíca clínica 
O Capítulo 6 investiga se a gravidade das flutuações motoras está	associada	a	quantidade	
diária	de	mínutos,	derivada	de	um	sensor	vestível	portátil,	que	uma	pessoa	com	DP	
caminha. Neste capítulo também se examina a gravidade das flutuações motoras estava 
associada	à	uma	mudança	na	quantidade	diária	de	minutos	que	uma	pessoa	com	DP	
caminha após a ingestão de levodopa. Dados de 304 pessoas com a DP que participaram 
do estudo Parkinson@Home foram incluídos neste estudo. No início do estudo, todos os 
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participantes foram examinados clinicamente. Durante o período de acompanhamento 
(mediana: 97 dias; intervalo de 25 interquartis: 91 dias, intervalo de 75 interquartis: 
188 dias), os participantes usaram o aplicativo Fox Wearable Companion enquanto os 
dados coletados com o acelerômetro embutido no relógio foram transmitidos para uma 
plataforma na nuvem. Para responder a primeira pergunta, nos utilizamos um modelo 
de regressão linear usado o  tempo médio gasto com caminhada por dia, derivado do 
acelerômetro,	usando	como	variável	independente	a	gravidade	das flutuações motoras 
(item 4.4 da Sociedade de Distúrbio do Movimento - Escala de Doença de Parkinson 
Unificada ), controlando para idade e desempenho motor (pontuação MDS-UPDRS 
parte III). Para a segunda pergunta nos usamos um modelo de regressão linear tendo 
como	 variável	 dependente	 a	 quantidade	média	 de	minutos	 caminhados	 pela	 pessoa	
com	DP	 depois	 de	 tomar	 levodopa,	 e	 variávies	 independentes	 a	 quantidade	 media	
de minutos caminhados pela pessoa com DP antes de tomar levodopa e a gravidade 
das flutuações,	 controlando	 para	 a	 quantidade	média	 diária	 de	minutos	 caminhados	
pela pessoa com DP, idade e desempenho motor (pontuação MDS-UPDRS parte 
III). Os resultados mostraram que os participantes com DP caminharam 72 ± 39 
(média ± desvio padrão) minutos por dia, sendo a maior parte dos minutos entre 8h 
e 13h. A gravidade das ﬂutuações motoras não influenciou quantidade	média	diária	de	
minutos caminhados (B = 2,4 ± 1,9, p = 0,20), mas pessoas mais velhas (B = −1,3 ± 
0,3, p = 0,001) e maior gravidade dos sintomas motores (B = −0,6 ± 0,2, p <0,001) 
foram associados com menor tempo de caminhada (F (3216) = 14,6, p <0,001, R2 
= 0,17). A gravidade das flutuações não foi associada com uma mudança no tempo 
gasto	 caminhando	 em	 relação	 à	 ingestão	 de	 levodopa	 em	 qualquer	 horário	 do	 dia. 
Análise	da	quantidade	méida	de	mínutos	caminhados	por	dia	sugeriu	que	a	gravidade	
das flutuações motoras não	estava	associada	a	mudanças	nos	padrões	da	quantidade	
caminhada por dia de pessoas que são leve a moderadamente afetadas pela DP. 
Conclusões:
1.  Sensores vestíveis e portáteis são uma ferramenta útil para responder 
questões relevantes para a prática clínica. 
2.  Qualidade da marcha, ao invés de quantidade, pode ser um campo mais 
promissor para investigar a influencia de flutuações motores na marcha. 
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Conclusão
Em conjunto, os resultados dos estudos incluídos nesta tese enfatizam a viabilidade 
do	uso	de	sensores	vestíveis	e	portáteis	para	monitorar	sintomas	relacionados	à	DP	na	
vida	diária. Dados coletados com sensores vestíveis podem melhorar o atendimento aos 
pacientes com DP e acelerar a pesquisa. 
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GENERAL DISCUSSION
Investigating the feasibility of an intervention or assessment method is an important step 
in establishing new methodologies [1]. The feasibility of technology is often associated 
with user experiences with system usability and compliance with usage, for example. 
Equally important is the fact that feasibility may also refer to technical feasibility, i.e. 
the implementation and performance of the technology. In this thesis, I describe a 
series of studies that investigated several feasibility aspects related to objectively and 
quantitatively assessing specific motor symptoms of Parkinson’s disease (PD). In this 
section, I elaborate on the results of those studies and discuss their possible implications.
Part I. Feasibility of  large-scale deployment of  wearable sensors in large Parkin-
son’s disease cohorts 
In the last decade, many research initiatives used technology to quantify specific motor 
symptoms of PD such as walking impairment and tremor [2-23]. Although these 
studies demonstrate the potential of objective measurements to quantify the symptoms, 
a systematic evaluation of their usability and the compliance of large patient cohorts 
remain unclear. Chapters 2 and 3 of this thesis aimed to address usability and compliance 
with a wearable device by describing the results of the Parkinson@Home study, a large 
observational study including a cohort of 953 patients with PD living in three countries: 
Canada and the United States in North America (NAM) and the Netherlands (NL). 
All the patients used the Fox Wearable Companion app on a smartwatch and their own 
smartphone for 6 weeks (NAM) or 13 weeks (NL).  The Fox Wearable Companion app 
on the smartphone collected accelerometer data from the smartwatch to estimate the 
participants’ daily movements, including walking and symptoms of PD such as tremor. 
The app presented these estimated quantities in graphs and summary reports of the data 
collected. Medication intake was collected via self-reports in the app. Compliance with 
technology use was high in both cohorts. The participants were compliant for 68% 
(16.3 hours/participant per day) of the study period in NL and for 62% (14.8 hours/
participant per day) in NAM. The attrition of participation was low: there was a loss of 
82 participants who contributed data in the NL cohort (27% of the participants) and 
89 in the NAM cohort (17% of the participants). Additionally, 13 participants (4% of 
all NL participants) and 135 (21% of all NAM participants) did not contribute any 
data during the study period. Daily accelerometer data collection decreased by 23% 
in NL after 13 weeks, and by 27% in NAM after 6 weeks. Data contribution was 
not affected by demographics, clinical characteristics, or attitude towards technology. 
With low attrition rates and high compliance, the results of this unique observational 
study showed that objective measurements taken from wearable sensors are feasible 
for deployment within large and diverse cohorts of people with PD. This was the first 
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initiative that systematically studied the feasibility of wearable sensors. 
Two other initiatives have investigated the potential of objective measurements by 
collecting data in large PD cohorts: mPower [24] and uMotif [22]. The largest initiative, 
mPower, deployed a smartphone application to a large cohort of 1087 people with 
PD and 5581 people without PD [24]. In this study, the participants were asked to 
complete a series of questionnaires and to do a set of scheduled motor tasks (that were 
quantified with the built-in sensors) through the app. Although the application was 
downloaded 48,104 times, the mPower study showed a low enrolment rate, with only 
35% (16,585) of those who downloaded the application confirming their participation 
in the study. Compliance with the application was also low: 50% of participants stopped 
using the app by day 20 of the follow-up [24]. Similar results have been reported in 
another smaller cohort study that used the uMotif approach. The uMotif study aimed 
to improve medication adherence by using a digital symptom tracker (i.e. a uMotif 
application). The application enabled participants to self-report ten PD-related 
symptoms, including mood, sleep pattern, energy, and exercise. Daily medication intake 
was also registered with the app and compliance was potentialised by reminders [22]. 
In this study, the attrition in the recruitment phase due to refusals was 9% (65 of 737 
participants) and attrition during study participation in the follow-up phase was 17% 
(18 of 104 participants). Information about compliance with application use during 
follow-up was not provided. 
Compared to mPower and uMotif, the Parkinson@Home study proved to be very 
successful. The high compliance with low attrition rates was attributed to several factors: 
(1) passive monitoring, i.e. minimum interaction with the system was needed to collect 
the data; (2) effective troubleshooting, such that persons who no longer contributed 
data were approached for technical support, and (3) the availability of a call centre 
during working hours.  I also argue that two other factors may have contributed to the 
success of the Parkinson@Home study. First, open recruitment facilitates inclusion of 
participants who are well motivated and willing to contribute to science. The sense of 
being a partner in research has already been listed as a key factor in improving patient 
compliance [25]. Second, monitoring systems that provide meaningful feedback to 
participants are more likely to receive active attention from people with PD, which also 
increases compliance [26]. In fact, the feedback about motor symptoms and physical 
activity provided by the Parkinson@Home app are among the preferred features that 
patients and clinicians monitor with such technology [27, 28]. 
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Certainly, the results of Part I of this thesis suggest that the feasibility of wearable sensors 
is well established, particularly because meaningful feedback is offered to participants. 
I strongly believe that the results from the Parkinson@Home indicate that, in the near 
future, objective measurements can be deployed by people with PD with different 
levels of education, socio-economic status, and literacy in technology. In Table 8.1., 
I summarise the lessons learned as a set of practical recommendations to facilitate the 
deployment of wearable sensors in large PD populations. These recommendations are 
likely to boost participant compliance, ultimately improve data collection, accelerate 
research, and – hopefully – improve clinical outcomes.
Table 8.1. Recommendations for large-scale sensor deployment in PD populations
Maximise system usability by including end-users in the design phase
Reduce the number of avoidable technology-related issues (e.g. app crashes, server downtimes, etc.)
Prepare a personalised troubleshooting model that includes a readily available support call centre
Aim at unobtrusive monitoring
Choose outcome measures that are meaningful to both patients and health professionals
Provide reliable feedback about the patient’s health-related outcomes 
Make participants with PD partners in the research evaluation of the new technical approach
Aim at sharing data with scientists worldwide
Part II. Applicability of  objective measurements for answering clinical and rese-
arch-relevant questions: wearable sensors for quantifying gait and falls
Validity of  wearable sensors for quantifying freezing of  gait and falls
Chapter 4 describes a systematic review that provides, as its main objective, an overview 
of the use of wearable systems to assess freezing of gait (FOG) and falls in PD. The 
results of this review showed that many studies have aimed at quantifying FOG by using 
accelerometer signals. In this approach, sensors can detect FOG with great sensitivity 
(73-100%) and specificity (67-100%). 
FOG is a complex phenomenon that is difficult to assess on the basis of physical assessments 
in the clinic alone. This emphasises the need to develop objective assessments that can be 
gathered for long periods while patients move about in their own natural environment. 
Having an unobtrusive way to objectively detect and monitor the presence and severity 
of FOG in the patient’s own home environment would have tremendous value and 
great potential for both diagnostic and therapeutic purposes [29, 30]. The results in 
Chapter 4 demonstrate that accelerometry is a well-validated instrument for detecting 
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FOG episodes under standardised conditions in the gait laboratory. However, different 
persons with PD show different manifestations of FOG (i.e. the specific phenotype of 
FOG can vary from person to person), which raises the complexity of assessing FOG 
with objective measurements. This is due to the fact that an algorithm that reliably 
detects FOG in person A may not function as well for person B or C. In addition to 
this inter-individual variation, a further challenge for algorithm performance lies in the 
difficulty of recognising ‘atypical’ or less severe FOG episodes, particularly very brief 
ones. Currently, algorithm performance during activities of daily living is sub-optimal 
because the signals of routine daily activities may present patterns similar to FOG 
episodes, which leads to decreased algorithm performance [31]. Nonetheless, as Chapter 
4 reports, a few initiatives have been somewhat more successful in detecting FOG in 
daily life. These initiatives improved algorithm performance by using more robust 
techniques, which often included data from multiple sensors collected from different 
body locations. However, the algorithms required substantially longer calculation times 
[32]. Currently, longer calculation times hamper the ability of sensors to detect FOG 
episodes in real time. Thus, FOG detection in daily life remains imperfect, and the 
calculation capability of the current systems need major improvements before they can 
be widely used. The challenge for future research now lies in dealing with the large 
diversity of behaviours that can be encountered in daily life without multiple sensors or 
long calculation times. 
Additionally, FOG detection for on-demand cueing is a promising and understudied 
application of objective measurements. Future research will have to improve algorithm 
performance to provide optimal levels of prediction because interventions for alleviating 
FOG are most effective when they are delivered before the actual onset of the walking 
block [33]. To this end, a few initiatives have combined different sensor signals to ‘predict’ 
the onset of a FOG episode [34-37]. However, improved performance and validation of 
this technique in larger PD cohorts remains necessary. Alternative approaches, such as 
new sensor types or characterising specific differences in gait patterns between freezers 
and non-freezers, instead of detecting FOG episodes, may partially address the pitfalls.
Although falls are a serious and burdensome problem in PD [38, 39], the number of 
studies in Chapter 4 that applied wearable sensors to quantify falls was surprisingly 
limited. Only one study reported on fall detection, and three others investigated the 
applicability of sensor signals for calculating fall risk. Not surprisingly, all the studies 
used accelerometry because detecting changes in acceleration and gait temporal 
characteristics are important features for fall detection and fall risk estimation. Perhaps 
investigating the risk of falls with wearable sensors instead of actual fall detection is more 
clinically relevant because that would open avenues for fall-prevention strategies. The use 
of wearable-sensor data to analyse gait quality parameters such as stride length, cadence, 
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and smoothness is a successful approach for identifying groups of participants at high 
risk of falling. Further, the classification performance of the wearable sensor is superior 
to conventional methods [21]. If we identify patients with PD at high risk of falling, 
prevention programs can be installed to intervene before the first fall occurs so that 
patients do not enter the vicious cycle of physical inactivity generated by fear of falling 
[40]. Early detection and actual prevention of falling would also reduce the costs of the 
avoided surgical procedures, hospital stays, and rehabilitation [41, 42]. Certainly, the 
results presented in Chapter 4 indicate the need for further research into the validity of 
objective measurements of falls. Although it is yet to be proven, objective measurements 
have advantages over classical fall-risk measurements. They could be taken remotely, 
continuously, and unobtrusively, signalling groups of vulnerable people with PD for 
whom fall-prevention programmes may be needed most. Another important challenge 
remaining for future research groups is further investigation of how specific gait quality 
measurements can help predict and detect falls in PD. 
Overall, Chapter 4 highlights the complexity of objectively measuring PD-related 
symptoms over long periods of time. Throughout the articles reviewed in Chapter 4, 
the term ‘wearable sensor’ was often used to refer to a range of new technologies with 
fundamental differences in number, type, and placement of sensors. This diversity does 
not come as a surprise because a single device containing only one sensor type placed 
in only one body location will likely fail to capture the spectrum of PD-related motor 
symptoms and their divergent characteristics. For example, a wearable sensor embedded 
in a smartwatch worn on the left wrist may show optimal performance for detecting 
tremor [43] in the person’s left arm, but this same device may not be effective in detecting 
dyskinesias, sleep patterns, FOG, or falls (and perhaps not even tremor in the right leg). 
Indeed, complex, generalised, and typically fluctuating events such as dyskinesias may 
well require placement of multiple sensors on multiple body parts [44, 45]. 
Chapter 4 provides examples of successfully used types of sensors and placements when 
a specific individual symptom is the object of study. Such a symptom might be FOG 
or falls. In general, we can  adequately assess FOG by analysing accelerometer and/or 
gyroscope signals. As Figures 8.1. and 8.2. (both extracted from Chapter 4) show, high 
system performance – as a measure of sensitivity and specificity – can be obtained with 
a single device placed on either the shin or the waist. A less clear pattern was observed 
for falls in this review, and further work will be necessary to establish which sensor 
type, how many sensors, and the optimal body location(s) that are necessary to reliably 
capture falls. In the same way, further research will also need to focus on determining 
these parameters for a wide range of other PD-related motor symptom.
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Fig. 3 Instrument performance (sensitivity) in FOG detection 
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Figure 8.1. Instrument performance (sensitivity) in freezing-of-gait detection
 
Fig. 4 Instrument performance (specificity) in FOG detection 
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Figure 8.2. Instrument performance (specificity) in freezing-of-gait detection
* Not reported
General discussion
175
Ch
ap
te
r 
8
Taken together, the results of Chapter 4 offer some initial guidance towards reaching 
consensus regarding appropriate methodologies for objectively assessing FOG and 
falls. A shift of measurements from standardised and lab-based settings to free-living 
environments is much needed in the field of FOG and falls. It would allow measurements 
and ultimately interventions during daily life, which is when participants experience the 
greatest difficulty with FOG and falls. 
Applicability of  objective measurements for answering research questions 
Objective measurements may help answer research questions. Indeed, Chapter 4 
presents an example of applying sensors to enhance epidemiological and clinical 
research. In this study, I used fall data collected during the movements in the daily life 
of a large cohort of 4126 people, with an average follow-up period of 1.1 years (from a 
window of 2.5 years of data). By using the data of 4126 elderly people prone to falling, 
of whom 2063 were people with self-reported PD, I determined that a person with 
PD is 1.8 times more likely to encounter a new fall after enrolment than an age- and 
gender-matched person who is prone to falls, but has not been diagnosed with PD. 
This study was unique in its kind, as all the participants used an emergency response 
programme including a wearable device (containing an accelerometer and a barometer) 
that automatically detected falls. The wearable device was worn around the neck, and all 
falls were confirmed by subsequent telephone calls from a call centre immediately after 
the fall had been automatically recorded.
Falls are a great example where the traditional measures – that are both burdensome and 
unreliable – can be replaced with sensors to collect meaningful data for both research 
and clinical purposes. Subjective diaries are prone to recall bias and reduced compliance; 
replacing them with objective measurements could improve the level of evidence 
presented in current epidemiological studies [46]. Similarly, objective measurements can 
enrich clinical trials by providing fine-grained and unbiased assessments of endpoints. 
Wearable sensors can now be worn for longer period of times, which makes them a likely 
alternative as a tool for obtaining a longitudinal and objective overview of fall episodes 
(Chapter 5). Furthermore, they have the advantage of collecting fall-related data without 
relying on the patient’s memory or willingness to keep diaries. Monitoring with sensors 
may also increase timely referral to fall-prevention programmes, which try to decrease 
the impact of falls in daily life and increase independence. Future research focusing on 
refining algorithms for fall detection, fall prediction, and fall risk analysis would allow 
researchers to objectively investigate and provide a more robust body of information 
about falls. More importantly, Chapter 5 establishes the fact that technology can aid 
research by objectively gathering large amounts of information over long follow-up 
periods.
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Applicability of  objective measurements for answering clinically relevant questions 
Motor fluctuations, an important complication, are associated with the long-term use of 
dopaminergic medication, in particular levodopa, but also dopamine agonists [47, 48]. 
They can limit gait performance [49], which may lead to greater inactivity. Identifying 
factors that can either hamper or promote a more active lifestyle among people with 
PD is crucial because physical activity has beneficial effects on PD symptoms [50-52]. 
I used the motor fluctuations as a targeted symptom to provide evidence (Chapter 6) of 
the applicability of objective measurements to answer clinically relevant questions. I also 
investigated whether the severity of motor fluctuations was associated with the total daily 
walking activity or with the change in walking activity after levodopa intake. For this 
purpose, I objectively quantified the walking activity of 304 people with PD who used a 
smartwatch with an accelerometer for 13 weeks. The results revealed that the severity of 
motor fluctuations was neither associated with the time spent walking per day nor with 
the change in time spent walking after levodopa intake. Physical inactivity in PD is a 
complex problem – many factors other than gait impairments are recognised as promoters 
of sedentary behaviours [40, 53, 54]. Disease progression also seems to play a role in the 
decrease of ambulatory activity among people with PD [55]. Therefore, gait quantity as 
measured with wearable sensors did not appear to be a sensitive and objective outcome 
for capturing motor fluctuations. Other studies have objectively classified changes in gait 
quality features related to levodopa intake [9, 17, 56, 57], and they have suggested that it 
may be possible to monitor motor fluctuations with these changes. Future research efforts 
should concentrate on investigating the usefulness potential of objective measurements 
for quantifying gait quality features such as stride length, stride velocity, gait cadence, and 
smoothness of gait [58]. These factors are known to respond to levodopa and are likely to 
provide more sensitive outcomes for monitoring motor fluctuations in clinical settings. 
More than feasibility: what still needs to be addressed?
A few main points still need to be addressed before objective measurements can be 
applied widely as part of routine healthcare in PD or as an accepted outcome measure in 
clinical trials (such as a ‘digital biomarker’). First, it is still uncertain whether the level of 
technology diffusion among people with PD offers fertile ground for openly deploying 
objective measurements for long-term monitoring. With reports of smartphone use 
among the elderly rising across the world [59, 60], it seems logical to expect that 
technology diffusion will only increase among our next generations [61]. Moreover, the 
Parkinson@Home study and other large initiatives [22, 24] did not face recruitment 
challenges, but indeed met with the widespread enthusiasm of potential participants, 
most of whom seem to embrace a future role for technology as part of healthcare. Long-
term compliance remains a concern, but the compliance in my study was certainly 
acceptable when certain requirements were met (Table 8.1). 
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Second, cognitively impaired patients have been excluded fairly systematically from 
prior research because this population’s reporting through diaries or scales is unreliable 
[62]. Due to the intrinsic nature of technology, cognitive impairment may also pose a 
threat to properly managing the new devices. Entirely passive monitoring, with little or 
no need for interaction to collect data, may be the way to address this limitation and to 
include this more vulnerable population in research. 
Third, even though wearable sensors hold great promise for addressing several 
shortcomings of current PD care, there is no single system at present that has been 
validated for long-term remote monitoring [31, 63]. The main reason is that systems 
struggle with underperformance in monitoring symptoms in daily life [31]. Further 
work is needed to address the feasibility and validity of objective measurements for real-
time monitoring in the daily life of unselected populations. 
Fourth, because objective measurements collect large amounts of data including personal 
data, future work should address issues such as privacy, data protection, data ownership, 
and data sharing before objective measurements are deployed on a large scale. Objective 
measurements can provide clinically meaningful insights that will help physicians, allied 
health personnel, and other healthcare professionals improve the clinical management 
of patients with PD. Objective measures may also improve clinical trial performance by 
minimizing intra- and inter-rater variability and simplifying performance of repetitive 
assessments [65, 66]. These promise now needs to be tested. Future work could address 
the impact of objective measurements in the shared decision-making of both clinicians 
and patients. All things considered, the challenge for researchers and clinicians is to find 
the best system for monitoring each motor symptom in PD, taking into account the 
specific research or clinical purpose.
Limitations
As presented in figure 1.1, there are multiple objective measurements that could be used 
for monitoring specific PD motor symptoms. Because of the wide range of options, 
I limited my work in this thesis to investigating the feasibility of a limited set of the 
objective measurements (shown in the red circle in Figure 8.3.).
Second, the encouraging results in Chapter 3 may be limited by the biased 
selection of mostly young and relatively mildly affected persons with PD who 
already owned smartphones. Additional strategies (that are perhaps more labour 
intensive) should be used to help the many people with PD whose technology 
literacy is an issue. A good example of this is the support model that I used in 
the Parkinson@Home study, which offered continuous access to troubleshooting 
for participants inexperienced with technology or for whom the troubleshooting
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technology was too time consuming. The support model functioned well in this 
particular study, but further research is necessary to establish whether the results 
are also valid for older and more severely affected people with PD. 
Limitations such as self-reported diagnosis and lack of information about 
the disease stage and severity in Chapter 5 introduced pitfalls into the study. 
However, I partially addressed these drawbacks by matching procedures and by 
using such a large sample. Furthermore, these biases are unlikely to affect the 
conclusion of the study because they were randomly spread across both groups. 
In Chapter 6, item 4.4 of the MDS-UPDRS part IV may not be the most 
sensitive assessment for motor fluctuations. Using alternative approaches to 
evaluate motor ﬂuctuations such as the Hauser dairy [90] might achieve a 
more accurate comparison of the activity between the OFF and ON periods. 
Although the gait detection algorithm was only validated in a lab-based setting, 
the outcomes of both the mean walking quantity and the daily pattern were 
similar to those in earlier reports [91, 92]. This suggests that the algorithm 
worked well in conditions of daily living. Although no data about the accuracy 
or compliance with medication reports were available through the app, I believe 
that the medication reminders and the excellent compliance of the participants 
with the system usage increased the accuracy of medication reports. 
Conclusion
Care in PD is largely based on clinical judgment and a set of standardised 
assessments of the severity of symptoms, the rate of disease progression, and 
the efficacy of therapeutic interventions. However, the high inter-rate variability 
and the ‘snapshot’ nature of standardised clinical assessments make it difficult 
to capture the large variability and non-linear decline of PD. A major challenge 
now lies in designing a detailed, objective, and reliable assessment that generates 
knowledge about real-life functioning. Objective measurements obtained 
with wearable sensors can address this limitation by continuously, and with 
great frequency, collecting objective and fine-grain health-related information. 
Previously, little structured evidence about the feasibility of using such a strategy 
in large populations at home was available. It was also unknown whether objective 
measurements in large cohorts could answer clinically relevant questions and 
collect data for research purposes. In this thesis, I began to address the pitfalls by 
presenting a series of studies where the feasibility of wearable sensors and their 
usefulness in clinical and research purposes were demonstrated. 
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THANK YOU WORD
“What would life be if we had no courage to attempt anything?”
Vincent van Gogh, 1853 – 1890 
During the past four years, I worked with pleasure on the research presented in this 
book. However, research never results from the effort of only one person. During my 
Ph.D., I collaborated with many people to make this thesis successful. It is now time to 
let them know the importance of their contribution in this journey. 
I would like to start by thanking the many people living with Parkinson’s who voluntarily 
put their time and effort in participating in the multiple projects presented in this book. 
Research is done by and for you. With you, I learned that the hope of better care for the 
generations to come is the fuel for research. To all the people living with Parkinson’s, 
who I personally visited in their homes during my Ph.D., and to the more than 1000 
people living with Parkinson’s who participated in all the projects shown in this thesis, 
my most sincere THANK YOU! 
Performing high-quality research without financial support is almost impossible. I 
would like to thank the CAPES foundation, under the Brazilian Ministry of Education, 
for my personal grant to follow a PhD trajectory in the Netherlands. I wish many more 
Brazilians could have the same opportunity that I had. In addition, I would like to 
thank The Michael J. Fox Foundation, Intel, The Stichting Parkinson Fonds, UCB 
pharma, Philips and The Movement Disorders Society for the financial support or in-
kind contributions that allowed our research group to conduct the studies reported here. 
To my promotor Prof. Dr. Bastiaan R. Bloem. Bas, you bet high. You dared to hire a 
Brazilian bachelor student, who did not speak English well, to be a part of your select 
group of PhDs. While I struggled to learn English, to get used to the Netherlands, and 
later to learn Dutch, you never lost faith that this day would come. And, here I am, 
defending my thesis as a proud member of the Radboudumc Center for Parkinson and 
Movement Disorders. Thank you for taking the risk and giving me this opportunity. 
Thank you even more for all the guidance, inspiration and motivation throughout those 
years. I hope that our partnership will last for many years to come. 
To my copromotor, and friend, Dr. Marjan J. Faber. What can I tell you? During these 
years, you have been much more than a supervisor. With you, I learned to critically 
conduct research and to never forget that each participant is a person with aspirations, 
dreams, and needs. Under your guidance, I am sure that I became not only a better 
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researcher, but also a better person. Thank you for encouraging me in the difficult 
moments and for cheering me up when I doubted my capabilities. 
To the Parkinson Thuis onderzoeksteam. Tim Hahn, Nienke de Vries-Farrouh, Pieter 
van de Haak, Luc Evers, and Jessica Hubbers. Throughout the years, you were the core 
team. Tim, thank you for all your assistance in the projects, especially with MatLab and 
designing the illustrations for some chapters of this thesis. Nienke, you are a brilliant 
researcher and physiotherapist. Thank you for all the advice and conversations. Pieter, 
I always find it so inspiring how relaxed you are at work. This is really a goal to strive 
for! Thank you for all the technical advice during these four years. Luc, thank you for 
the funny moments in the office and for the early drives to visit participants in our 
projects. From the scientific perspective, thank you for all the constructive criticisms 
you provided regarding all the studies we collaborated in. Jess, I had so much fun during 
these few months working with you. You showed how organized and dynamic you are. 
Thank you for all your help in the multiple research projects we worked together. Thank 
you also for lending a listening ear when needed. J To all the interns and research 
assistants who worked with us: Karliene Hoogeweg, Maarten van Else, Rebecca van 
Rijn, Erwin Koster, Jorike Colijn, Giel Eeuwes, and Julia Sleutes, thank you for your 
assistance. A special thanks to Jet Verheijen, whose good mood and similar taste in music 
made our early drives super gezellige. Thank you for the assistance with recruitment and 
data-collection of the multiple projects we worked on together. I’m sure you will be an 
outstanding doctor (and maybe also researcher J).
To all the researchers, developers and data scientists that I partnershiped with during 
those four years: Lauren Bataille, Daisy Daeschler, Lydia Herron, Efrat Muller, Eli 
Cohen, Michal Afek, Max Little, Kasper Claes, Babak Boroojerdi, Dolors Terricabras, 
Heribert Baldus, Giulio Valenti, Tine Smith and Dr. Bart van de Warrenburg. Thank 
you for all the constructive criticism and feedback provided in the chapters presented 
here. It was a very enriching experience (and a honor) to partnership with you all. 
Doing research at the Neurology department is not possible without the help of Angelique 
Arnoldussen, Eva Biemans, and Han Kruitwagen. Thank you for the much needed 
support with the administrative tasks. Marte van den Bosch and Daphne Nukoop, thank 
you for your help with scheduling meetings, rooms, and the recruitment of participants. 
To all colleagues from the Neurology department, Radboudumc Center for Parkinson 
and Movement Disorders and ParkinsonNet: thank you for the gezelligheid. Finally, 
thank you Violetta for always cleaning our offices with such good energy. 
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To my close colleagues and friends, Heidemarie Zach, Sigrid Dupan, Claudia Barthel, 
Sonal Sengupta, Tamine Capato, Janna Maas, Kasia Smilowska, Josefa Domingos and 
Esther Bekkers. Thank you for all the funny moments at the office, the BBQs, and 
dinners. Thank you also for the listening ear and advice throughout these years. You 
always lift my spirit, making the long days funnier. I am sure that you are and will all be 
successful researchers and/or health professionals.
Para os meus amigos brasileiros:
Gente! Muito obrigada pelo suporte durante esses anos. Mesmo distante, tenho certeza 
que a nossa amizada nunca mudou. Jéssica Leite, Pâmella Karolline e André Leal, vocês, 
além de amigos, são meus exemplos de profissionais competentes e dedicados. Cada 
história de vitória e desafios que compartilhamos por Whatsapp, me fortalece e me 
inspira a ser o melhor professional que eu posso ser. 
Jamine Vasconcelos, Ana Carolina Torres e Guillherme Andrade, nossa amizade nasceu 
na Espanha e perpetuou no Brasil, mesmo morando nos 4 cantos do Brasil e do mundo! 
Obrigada por me inspirarem a seguir em frente, a não desistir e a sempre dar o meu 
melhor. Me orgulha tê-los como amigos, e vê o quão bem sucedidos como profissionais 
e seres humanos vocês são. Continuem assim. 
Ao meu amigo caicoense Romualdo Santos; Mumu, muito obrigada por segurar minha 
mão quando eu precisei durante o processo de aprovação para o doutorado. Obrigada por 
ser sempre tão positivo e atencioso. Seu apoio foi fundamental para que eu conseguisse 
começar o meu doutorado. Me alegra vê-lo feliz com Ana e eu desejo para vocês um 
futuro cheio de felicidade e aventuras. 
À minha amiga caicoense Renata Cristina; amiga, obrigada por não desistir da nossa 
amizade. Mesmo morando distante e com pouco tempo para nos vermos, sempre que te 
vejo parece que nenhum dia passou e ainda somos aquelas adolescentes sonhando com a 
tão desejada aprovação no vestibular. Tenho orgulho de ver a profissional, esposa e mãe 
que você se tornou. Obrigada por me manter na sua vida. 
À minha amiga caicoense e de mais longa data, Georgia Kércia. Eu ainda me lembro 
quando tinhamos 17 anos, nenhum centavo no bolso, e sonhavamos em ter uma carreira 
bem sucedida e viajar o mundo. Tenho tanto orgulho de ver a mulher forte e determinada 
que você se tornou amiga! Muito obrigada pelo seu apoio durante todos esses anos. Te 
amo! Um agrecimento especial ao seu esposo Rudson Rummenigue, que junto com 
você, sempre são meu porto seguro em Natal. 
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À mis amigos de España: 
À mis amigos Coraline Gaspar y Ander Orbegozo Canton: muchas gracias por mantener 
nuestra amizade desde España. Mesmo que nos no hablemos muchos, me alegra saber 
que tengo vosotros en mí vida. Gracias por estares siempre dispuestos a celebrar los 
momento buenos y decirme para tener paciencia en los momentos difíciles. Muchas 
gracias por hacerem parte de mí vida!
Aos meus amigos brasileiros na Holanda:
Tainá Macherini, flor, você foi a primeira pessoa a me receber em Nijmegen. Com teu 
coração generoso, você me ajudou a me adaptar na Holanda. Até hoje, conversar com 
você me trás paz e me coloca na direção correta. Obrigada por todo teu (e do seu esposo 
Rodrigo Camargo!) durante esses anos. Já já estaremos celebrando tua conquista também. 
Angelica Lantyer, você é, como a gente diz lá no Nordeste, fogo! Nunca vi tanta energia e 
originalidade junta! Obrigada pelas festas doidas e pela energia positiva que você sempre 
transmite. 
To my international and Dutch friends:
To my Iranian friend Marzieh Ba, thank you for your friendship and encouragement 
during all these years. I am sure your journey as a successful research has just started. 
Believe in yourself and never give up!
Aan mijn relatief weinig, maar niet minder belangrijke Nederlandse vrienden Laurens 
Kauffeld en Renée Haan. Laurens, zoals een echte Nederlander betreft, ben jij er altijd 
zeker van dat er een oplossing is voor elk probleem. Ondanks dat ik deze zekerheid niet 
had, had jij altijd een advies klaar. Bedankt voor de vele adviezen die ik gratis van jou 
kreeg. J Renée, het was erg gezellig om een paar maanden met jou samen te wonen. 
Je bent ook een getalenteerde onderzoeker en ik weet zeker dat ik over een paar jaar bij 
jouw verdediging zal zijn.
To my paranymphs Danique Radder and Joames Kauffimann: 
Danique, you are my first Dutch friend. It has been a pleasure to see you growing and 
becoming a very knowledgeable researcher and doctor. Thank you for all the advice, the 
nice trips, and the friendship. Soon, it will be your day to defend your thesis and I hope 
to be there to see another one of your many victories! 
Joames, desde que dividimos apartamento a conexão foi tão boa que te rendeu o título 
de “marido”. Obrigada por todo amor e compreensão que você transmite quando 
conversamos. Obrigada também por ter aceitado ser meu paraninfo e compartilhar esse 
momento tão importante comigo. 
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Aan de familie Meekes
Annette, Wilfried, Kim, Michel en mijn net geboren nichtje. Jullie waren (en zijn nog 
steeds) mijn familie in Nederland. Bedankt voor de gezellige verjaardagen, kerst en 
weekendjes. Speciale dank aan Annette, voor alle moeite om mijn Nederlands te begrijpen. 
Ik ben echt trots om lid van jullie familie te zijn. Bedankt voor de ondersteuning! 
Para a minha família. 
Eu tenho muito sorte de ter duas família: uma de sangue e uma de coração. 
A minha família de coração: Vicente, Núbia, Ademar e Andrea. Desde 2003, vocês 
me adotaram como uma filha. Tivemos tantos momentos bons juntos. O suporte de 
vocês me ajudou a concluir a graduação e a estar hoje aqui. Mainha Núbia, seu cuidado 
maternal me devolve o sentido de estar em casa. Painho Vicente, sei que o senhor não 
gosta que eu more tão longe. Mas, mesmo assim, o senhor sempre esteve lá, pronto pra 
me ajudar. Ademar e Andrea, obrigada pelo carinho de irmão. 
Para minha família de sangue: Antônio (Sitonho), Ana Lúcia, Anistayne, Wellington, 
Miguel, Anyelle, Silvanildo (Nildo) e Lucas. 
Anystayne e Wellington, muito obrigada pela ajuda no processo de seleção do doutorado. 
Especialmente por me ajudar na entrevista em inglês. Miguel, Obrigada por todo amor 
nos seus dois primeiros anos de vida. Nossas memórias aquecem meu coração. Te amo! 
Anyelle, que orgulho de ver o quanto você cresceu como pessoa e como mãe. Agradeço 
a Deus a oportunidade de ter ficado mais próxima de você. Obrigada por trazer Nildo 
e meu sobrinho amado Lucas para nossas vidas. Obrigada por sempre ficar tão feliz 
quando eu vou pra casa, e por me mandar duzentas messagens toda semana. Mesmo da 
minha forma imperfeita, eu te amo muito! 
Painho (Sitonho J), o que eu posso te dizer? O senhor virou pai e mãe de repente. Ficou 
sozinho com 3 filhas e um mundo de problemas pra resolver. Nunca desistiu de fazer 
o seu melhor para que eu pudessse estudar. Me alegro de ter ficado mais próxima do 
senhor como filha. Obrigada por entender que eu tinha quer aceitar essa oportunidade 
e vir morar tão longe do senhor. Obrigada por me ouvir todo fim de semana, e obrigada 
por me contar como vai sua vida. Obrigada por ser meu pai. Te amo! 
Mainha (Ana Lúcia - in memorium), você se foi tão cedo da minha vida. Tem tantos 
moments que eu queria que a senhora tivesse visto. Não tem um dia que eu não sinta 
saudades da senhora. Queria muito mudar o passado, mas como eu não posso, me 
esforço para fazer um futuro melhor. Espero que onde a senhora esteja, esteja feliz e 
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orgulhosa de mim. Eu tentei e tento ser um profissinal e uma pessoa melhor todos os 
dias, para honrar todo seu sacrifício. Esta vitória também é sua, também vem do seu 
sacrifício. Então, em todas as línguas que eu sei: Obrigada por ser minha mãe, eu te amo! 
Muchas gracias por ser mí madre, te quiero! Thank you for being my mom, I love you! 
Dank je wel voor het zijn van mijn moeder, ik hou van jou!
 
Aan mijn verloofde Robin F. Meekes. Wij spreken Nederlands en Engels met elkaar. This 
thank you word could not be any different. Bedankt voor de ondersteuning en liefde die 
jij aan mij geeft. Thank you for all the encouragement through the hard times, and for 
your help during my Ph.D., even when that involved being a subject in my studies. J 
Loving you is a Ph.D. in itself; it is a continuous learning process while discovering all 
the possibilities. Ik kijk uit naar onze toekomst. Ik hou van jou!
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DISSERTATIONS OF THE DISORDERS OF MOVEMENT RESEARCH GROUP, 
NIJMEGEN 
Parkinson Center Nijmegen (ParC)
•   Jasper E. Visser. The basal ganglia and postural control. Radboud University Nijmegen, 
June 17th 2008
•   Maaike Bakker. Supraspinal control of walking: lessons from motor imagery. Radboud 
University Nijmegen, May 27th 2009
•   W. Farid Abdo. Parkinsonism: possible solutions to a diagnostic challenge. Radboud 
University Nijmegen, October 7th 2009
•   Samyra H.J. Keus. Physiotherapy in Parkinson’s disease. Towards evidence-based 
practice. Leiden University, April 29th 2010
•   Lars B. Oude Nijhuis. Modulation of human balance reactions. Radboud University 
Nijmegen, November 29th 2010
•   Maarten J. Nijkrake. Improving the quality of allied health care in Parkinson’s disease 
through community-based networks: the ParkinsonNet health care concept. Radboud 
University Nijmegen, November 29th 2010
•   Rick C.G. Helmich. Cerebral reorganization in Parkinson’s disease. Radboud 
University Nijmegen, May 24th 2011
•   I.B. Bruinsma. Amyloidogenic proteins in Alzheimer’s and Parkinson’s disease. 
Interaction with chaperones and inflammation. Radboud university Nijmegen. 
September21st 2011
•   Charlotte A. Haaxma. New perspectives on preclinical and early stage Parkinson’s 
disease. Radboud University Nijmegen, December 6th 2011
•   Johanna G. Kalf. Drooling and dysphagia in Parkinson’s disease. Radboud University 
Nijmegen, December 22nd 2011
•   Anke H. Snijders. Tackling freezing of gait in Parkinson’s disease. Radboud University 
Nijmegen, June 4th 2012
•   Bart F.L. van Nuenen. Cerebral reorganization in premotor parkinsonism. Radboud 
University Nijmegen, November 22nd 2012
•   Wandana Nanhoe-Mahabier. Freezing of physical activity in Parkinson’s disease, the 
challenge to change behavior. Radboud University Nijmegen, February 13th 2013
•   Marlies van Nimwegen. Promotion of physical activity in Parkinson’s disease, the 
challenge to change behavior. Radboud University Nijmegen, March 6th 2013
•   Arlène D. Speelman. Promotion of physical activity in Parkinson’s disease, feasibility 
and effectiveness. Radboud University Nijmegen, March 6th 2013
•   Tjitske Boonstra. The contribution of each leg to bipedal balance control. University 
Twente, June 6th 2013
•   Marjolein A van der Marck. The Many faces of Parkinson’s disease: towards a 
multifaceted approach? Radboud University Nijmegen, January 20th 2014
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•   Katrijn Smulders. Cognitive control of gait and balance in patients with chronic 
stroke and Parkinson’s disease. Radboud University Nijmegen, May 21st 2014
•   Marjolein B. Aerts. Improving diagnostic accuracy in parkinsonism. Radboud 
University Nijmegen, June 27th 2014 
•   Maartje Louter. Sleep in Parkinson’s disease. A focus on nocturnal movements. 
Radboud University Nijmegen, February 13th 2015
•   Frederick Anton Meijer. Clinical Application of Brain MRI in Parkinsonism: From 
Basic to Advanced Imaging, Radboud University Nijmegen, June 23th 2015
•   Jorik Nonnekes. Balance and gait in neurodegenerative disease: what startle tells us 
about motor control, Radboud University Nijmegen, September 25th 2015
•   Martijn van der Eijk. Patient-centered care in Parkinson’s disease. Radboud University 
Nijmegen, December 1st 2015
•   Ingrid Sturkenboom. Occupational therapy for people with Parkinson’s disease: 
towards evidence-informed care. Radboud University Nijmegen, February 11th 2016
•   Merel M. van Gilst. Sleep benefit in Parkinson’s disease. Radboud University Nijmegen, 
April 13th 2016
•   Arno M. Janssen. Transcranial magnetic stimulation - measuring and modeling in 
health and disease. Radboud University Nijmegen, June 2nd 2016
•   Annette Plouvier. De ziekte van Parkinson, een gezamenlijke reis van huisarts en 
patiënt. Radboud University Nijmegen, juni 15th 2017
•   Nico Weerkamp. Parkinson’s disease in long-term-care facilities. Radboud University 
Nijmegen, September 1st 2017
•   Digna de Kam. Postural instability in people with chronic stroke and Parkinson’s 
disease: dynamic perspectives Radboud University Nijmegen, October 4th 2017.
•   Freek Nieuwhof. The complexity of walking: Cognitive control of gait in aging and 
Parkinson’s disease Radboud University Nijmegen, October 27th 2017.
•   Koen Klemann. A molecular window into Parkinson’s disease. Radboud University 
Nijmegen, November 3th 2017.
•   Claudia Barthel. Moving beyond: freezing of gait in Parkinson’s disease. Radboud 
University Nijmegen, April 4th 2018.
•   Esther Bekkers. Freezing and postural control in Parkinson’s disease. Defense at KU 
Leuven, May 15th 2018. 
•   Erik te Woerd. “Feeling the beat: The neurophysiology of cueing in Parkinson’s disease. 
Radboud University Nijmegen, January 18th 2019.
Non-Parkinsonian disorders of  movement
•   Sacha Vermeer. Clinical and genetic characterization of autosomal recessive 
cerebellarataxias. Radboud University Nijmegen, April 5th 2012
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•   Susanne T. de Bot. Hereditary spastic paraplegias in the Netherlands. Radboud 
University Nijmegen, December 20th 2013
•   Catherine C.S. Delnooz. Unraveling primary focal dystonia. A treatment update and 
new pathophysiological insights. Radboud University Nijmegen, January 7th 2014
•   Ella M.R. Fonteyn. Falls, physiotherapy, and training in patients with degenerative 
ataxias. Radboud University Nijmegen, June 29th  2016.
•   B.S. Hoffland. Investigating the role of the cerebellum in idiopathic focal dystonia. 
Radboud University Nijmegen, March, 22nd 2017.
Vascular disorders of  movement – The Radboud Stroke centre
•   Liselore Snaphaan. Epidemiology of post stroke behavioral consequences. Radboud 
University Nijmegen, March 12th 2010
•   D. de Jong. Anti-inflammatory therapy and cerebrospinal fluid diagnosis in Alzheimer’s 
disease. Radboud University Nijmegen, September 21st  2010 
•   N.M. Timmer, The interaction of heparin sulfate proteoglycans with amyloid β 
protein. Radboud University Nijmegen. January 13th 2011.
•   Karlijn F. de Laat. Motor performance in individuals with cerebral small vessel disease: 
an MRI study. Radboud University Nijmegen, November 29th 2011
•   Anouk G.W. van Norden. Cognitive function in elderly individuals with cerebral 
small vessel disease. An MRI study. Radboud University Nijmegen, November 30th 
2011
•   P.E. Spies. The reflection of Alzheimer disease in CSF. Radboud University Nijmegen. 
March 15th 2012.
•   D. Slats. CSF biomarkers of Alzheimer’s disease; serial sampling analysis and the study 
of circadian rhythmicity. Radboud University Nijmegen. September 21st 2012.
•   Rob Gons. Vascular risk factors in cerebral small vessel disease. A diffusion tensor 
imaging study. Radboud University Nijmegen, December 10th 2012
•   Loes C.A. Rutten-Jacobs. Long-term prognosis after stroke in young adults. Radboud 
University Nijmegen, April 14th 2014 
•   M.K. Herbert. Facing uncertain diagnosis. The use of CSF biomarkers for the 
differential diagnosis of neurodegenerative disease. Radboud University Nijmegen 
July 8th 2014. 
•   Noortje A.M.M. Maaijwee. Long-term neuropsychological and social consequences 
after stroke in young adults. Radboud University Nijmegen, June 12th 2015
•   M. Müller. Foorprints of Alzheimer’s disease. Exploring proteins and microRNAs as 
biomarkers for differential diagnosis. Radboud University Nijmegen. April 18th 2016. 
•   K.A. Bruggink. Amloid-B and amyloid associated proteins in the pathology and 
diagnosis of Alzheimer’s Disease. Radboud University Nijmegen. April 25th 2016. 
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•   Anil M. Tuladhar. The disconnected brain: mechanisms of clinical symptoms in small 
vessel disease. Radboud University Nijmegen, October 4th 2016.
•   Pauline Schaapsmeerders. Long-term cognitive impairment after first-ever ischemic 
stroke in young adults: a neuroimaging study. Radboud Univesity Nijmegen, January 
24th 2017.
•   Inge W.M. Van Uden. Behavioral consequences of cerebral small vessel disease. An 
MRI approach. Radboud University Nijmegen, February 14th 2017.
•   Renate Arntz. Long-term risk of vascular disease and epilepsy after stroke in young 
adults. Radboud University Nijmegen, February 16th 2017. 
•   Helena Maria Van Der Holst. Mind the step in cerebral small vessel disease. Brain 
changes in motor performance. April 5th 2017.
•   E.M.C. van Leijsen. Unraveling the heterogeneity of cerebral small vessel disease; 
from local to remote effects. Radboud university Nijmegen. November 19th 2018. 
•   S.J. Ooms. Sleep well, age well. Assessing sleep disruption as a player in Alzheimer’s 
disease. Radboud University Nijmegen. November 30th 2018. 
Neuromuscular disorders of  movement
•   Mireille van Beekvelt. Quantitative near infrared spectroscopy (NIRS) in human 
skeletal muscle. Radboud University Nijmegen, April 24th 2002
•   Johan Hiel. Ataxia telangiectasia and Nijmegen Breakage syndrome, neurological, 
immunological and genetic aspects. Radboud University Nijmegen, April 23th 2004
•   Gerald JD Hengstman. Myositis specific autoantibodies, specificity and clinical 
applications. Radboud University Nijmegen, September 21st 2005
•   M. Schillings. Fatigue in neuromuscular disorders and chronic fatigue syndrome, a 
neurophysiological approach. Radboud University Nijmegen, November 23th 2005
•   Bert de Swart. Speech therapy in patients with neuromuscular disorders and Parkinson’s 
disease. Diagnosis and treatment of dysarthria and dysphagia. Radboud University 
Nijmegen, march 24th 2006
•   J. Kalkman. From prevalence to predictors of fatigue in neuromuscular disorders. The 
building of a model. Radboud University Nijmegen, October 31st 2006
•   Nens van Alfen. Neuralgicamyotrophy. Radboud University Nijmegen, November 
1st 2006
•   Gea Drost. High-density surface EMG, pathophysiological insights and clinical 
applications. Radboud University Nijmegen, March 9th 2007
•   Maria Helena van der Linden. Pertubations of gait and balance: a new experimental 
setup applied to patients with CMT type 1a. Radboud University Nijmegen, October 
6th 2009
•   Jeroen Trip. Redefining the non-dystrophic myotonic syndromes. Radboud University 
Nijmegen, January 22nd 2010
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•   Corinne G.C. Horlings. A weak balance: balance and falls in patients with 
neuromuscular disorders. Radboud University Nijmegen, April 1st 2010
•   E. Cup. Occupational therapy, physical therapy and speech therapy for persons 
with neuromuscular diseases, an evidence based orientation. Radboud University 
Nijmegen,  July 5th 2011
•   Alide Tieleman. Myotonic dystrophy type 2, a newly diagnosed disease in the 
Netherlands. Radboud University Nijmegen, July 15th  2011
•   Nicol Voermans. Neuromuscular features of Ehlers-Danlos syndrome and Marfan 
syndrome. Radboud University Nijmegen, September 2nd  2011
•   Allan Pieterse. Referral and indication for occupational therapy, physical therapy 
and speech- language therapy for persons with neuromuscular disorders. Radboud 
University Nijmegen, February 13th 2012
•   Bart Smits. Chronic Progressive External Ophthalmoplegia more than meets the eye. 
Radboud University Nijmegen, June 5th 2012
•   Ilse Arts. Muscle ultrasonography in ALS. Radboud University Nijmegen, October 
31st 2012
•   M. Minis. Sustainability of work for persons with neuromuscular diseases. Radboud 
University Nijmegen, 13 November 2013
•   Willemijn Leen. Glucose transporter – 1 deficiency syndrome. Radboud University 
Nijmegen, June 26th 2014
•   Femke Seesing. Shared Medical appointments for neuromuscular patients and their 
partners. Radboud University Nijmegen, September 2nd 2016
•   Nicole Voet. Aerobic exercise and cognitive behavioral therapy in fascioscapulohumeral 
dystrophy: a model based approach. Radboud University Nijmegen , October 14th 
2016. 
•   Barbara van der Sluijs. Oculopharyngeal muscular dystrophy (OPMD) in the 
Netherlands, beyond dysphagia and ptosis. Radboud University Nijmegen. December 
11th 2017. 
•   Simone Knuijs. Prevalence of dysarthria and dysphagia in neuromuscular diseases and 
an assessment tool for dysarthria in adults. Radboud University Nijmegen.  July 3th 
2018.
•   Marielle Wohlgemuth. A family based study of Facioscapulohumeral. Radboud 
University Nijmegen. November 7th  2018. 
•   Karlien Mul. The many faces of FSHD, opportunities and challenges on the road to 
therapies. Radboud University Nijmegen. 18 January 18th 2019.
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DONDERS GRADUATE SCHOOL FOR COGNITIVE NEUROSCIENCE
For a successful research Institute, it is vital to train the next generation of young 
scientists. To achieve this goal, the Donders Institute for Brain, Cognition and Behaviour 
established the Donders Graduate School for Cognitive Neuroscience (DGCN), which 
was officially recognised as a national graduate school in 2009. The Graduate School 
covers training at both Master’s and PhD level and provides an excellent educational 
context fully aligned with the research programme of the Donders Institute. 
The school successfully attracts highly talented national and international students in 
biology, physics, psycholinguistics, psychology, behavioral science, medicine and related 
disciplines. Selective admission and assessment centers guarantee the enrolment of the 
best and most motivated students.
The DGCN tracks the career of PhD graduates carefully. More than 50% of PhD alumni 
show a continuation in academia with postdoc positions at top institutes worldwide, 
e.g. Stanford University, University of Oxford, University of Cambridge, UCL London, 
MPI Leipzig, Hanyang University in South Korea, NTNU Norway, University of 
Illinois, North Western University, Northeastern University in Boston, ETH Zürich, 
University of Vienna etc.
Positions outside academia spread among the following sectors: 
-  specialists in a medical environment, mainly in genetics, geriatrics, psychiatry and 
neurology,
-  specialists in a psychological environment, e.g. as specialist in neuropsychology, 
psychological diagnostics or therapy, 
-  higher education as coordinators or lecturers. 
A smaller percentage enters business as research consultants, analysts or head of research 
and development. Fewer graduates stay in a research environment as lab coordinators, 
technical support or policy advisors. Upcoming possibilities are positions in the IT sector 
and management position in pharmaceutical industry. In general, the PhDs graduates 
almost invariably continue with high-quality positions that play an important role in 
our knowledge economy.
For more information on the DGCN as well as past and upcoming defenses please visit:
http://www.ru.nl/donders/graduate-school/phd/

